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ABSTRACT 
Background and aim: 
Implanon NXT® was introduced in South Africa (SA) in the public health sector in February 2014. 
There exist concerns with premature Implanon NXT® user discontinuation in SA however, the 
true extent remains unknown due to delayed monitoring systems and limited empirical data. This 
study aimed to evaluate the experiences of Implanon NXT® among users in the public health 
sector in SA. 
Methods: 
A retrospective study was conducted and entailed analysis of secondary data attained from the 
National Department of Health Pharmacovigilance Centre for Public Health Programmes using 
reports submitted from 1 April 2015 to 11 September 2017. A total of 3743 cases were extracted 
and analysed using SPSS®. Tests of association were performed using demographics, adverse 
drug reactions and discontinuation variables. Chi square test and Mann Whitney U-Test were 
performed to test differences between Gauteng and KwaZulu-Natal (KZN).  
Results: 
The 20-24-year olds were the most frequent Implanon NXT® users (25.70%; 962/3743). Of the 
36.57% (1369/3743) cases which reported adverse drug reactions (ADRs), menorrhagia 
(52.01%;712/1369), headache (20.45%;280/1369) and dizziness (11.18%;153/1369) were the 
most frequent ADRs. Discontinuation was reported by 63.56% (2379/3743) of case reports and 
premature discontinuation was reported by 81.1% (1210/1492). The common reasons for 
discontinuation were menorrhagia (34.27%;728/2124), expiry (29.57%;628/2124) and headache 
(10.26%;218/2124). Overall, ADRs were found to be the main reason for discontinuation 
(83.99%; 1784/2124). Pregnancies reported with Implanon NXT® occurred in 4.97% (68/1369) 
of case reports and efavirenz-based therapy was suspected to be associated with pregnancy in 
Implanon NXT® users (p<0.001). The common ADRs and reasons for discontinuation of 
Implanon NXT® reported in Gauteng was consistent with the national data while drug interaction 
and pregnancy were commonly reported in KZN. Premature discontinuation of Implanon NXT® 
was higher in Gauteng (82.6%, 252/305) than KZN (76.7%, 23/30).  
Conclusion: 
Young women were frequent users of Implanon NXT®. Menorrhagia was the predominantly 
reported ADR among all the users. A high frequency of discontinuation was identified, and ADRs 
were mainly responsible for discontinuation. The frequency of failure was small and efavirenz 
was suspected to be associated. The experiences of Implanon NXT® users differed between KZN 
and Gauteng which emphasizes tailored strategies need to be considered. Users’ counselling, 
xix 
adverse drug reaction treatment and management, monitoring and evaluation are recommended 
to address high discontinuation in SA.  
Keywords: Contraception, Implanon NXT®, Adverse drug reactions, Discontinuation, Failure, 
Pharmacovigilance. experiences, South Africa, Provinces 
 
 
1 
CHAPTER 1: INTRODUCTION 
1.1 Introduction 
This chapter provides a background to the study and contextualizes Implanon NXT® use in South 
Africa (SA). A description of the problem statement is provided, which includes the challenges 
with Implanon NXT® in the post-introductory phase in SA, particularly in KwaZulu-Natal (KZN) 
and Gauteng Provinces outlined. User discontinuation with Implanon® and Implanon NXT® is 
discussed in the background and problem statement, as it is relevant in both sections. The research 
questions, aims and objectives are stated, a brief description of the methodology is provided, 
followed by definition of terms, and the chapter concludes with an outline of the dissertation.  
 
1.2 Background and context 
Subdermal contraceptive implants are devices that provide a sustained release of sex steroids in 
vitro (Association of Reproductive Health Professionals, 2008), with the first implant being 
licensed in 1983 in Finland (Rowlands & Searle, 2014). There are two main types of implants 
currently on the market, levonorgestrel (e.g. Jadelle® and Sino-implant (II)®) and etonogestrel 
(e.g. Nexplanon® and Implanon NXT®) (2014). Implanon® is one of the etonogestrel 
contraceptive implants (2014), having been initially released in 1998 in Indonesia (Darney, Patel, 
Rosen, Shairo, & Kaunitz, 2009) and approved by the United States of America’s (USA) Food 
and Drug Administration in 2006 (Creinin et al. 2017). In Africa, Implanon® was introduced in 
Ethiopia in 2009 (Gebre-Egziabher, Medhanyie, Alemayehu, & Tesfay, 2017) and in Nigeria in 
2006 (Madugu, Abdul, Bawa, & Kolawole, 2015).  
The successor, Implanon NXT®, was approved by the European Medicines Agency as well as by 
the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency in 2010 
(Reproductive Health Supplies Coalition, 2013; Mansour, 2010). Implanon NXT® is reportedly 
bioequivalent to its predecessor Implanon® (Schnabel et al. 2012). The difference between 
Implanon® and Implanon NXT® is the addition of barium sulphate to make it radiopaque as well 
as changes to the applicator to facilitate one handed insertion of the implant (Schnabel et al. 2012; 
Mansour, 2010). The efficacy, pharmacokinetic characteristics and safety profile observed with 
Implanon® is comparable to Implanon NXT® (Schnabel et al. 2012).  
 
Nexplanon® is another brand of Implanon NXT® and the two products are equivalent (Park, Bae, 
Lee, Bae, & Park, 2017; Darney, 2015; Reproductive Health Supplies Coalition, 2013). 
Nexplanon® was launched in 2010 by Merck (Rowlands and Searle, 2014) and is available for 
use in several countries, including the USA. Implants (including Nexplanon®, Implanon® and 
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Implanon NXT®) have been registered for use in more than 100 countries and Implanon 
NXT®/Nexplanon® are registered in 80 countries (WHO, 2015; Rowlands & Searle, 2014). 
Implanon® or Implanon NXT® are registered in 44 of the world’s poorest countries, and in 2016, 
were registered in Egypt, Nepal and Sri Lanka (Merck Sharp & Dohme Corp., 2018). It appears 
that there is a phase-out process of Implanon®, as the Reproductive Health Supplies Coalition 
(2013:2) stated that “Implanon NXT® will progressively replace Implanon® in all countries in 
the next few years.” Lince-Deroche et al. (2016) remarked that the “introduction of the implant in 
South Africa in 2014 was relatively late compared with other countries on the continent” (Lince-
Deroche et al. 2016:102). Implanon NXT® and Jadelle® are registered in SA, “but only Implanon 
NXT was made available in public health clinics as part of the national contraception 
programme” (Pleaner et al. 2017:933; Republic of South Africa, National Department of Health, 
2015). The purpose of the Medicines Control Council in SA, now South African Health Products 
Regulatory Authority, is to “register every medicine before it may be sold/marketed” (Republic 
of South Africa, National Health Department, 2008:3), with Implanon NXT® being under review 
for registration by the Council in 2013 (Republic of South Africa, National Department of Health, 
2013c). Implanon NXT® was introduced into South African public health sector facilities in 
February 2014 (Mullick, Chersich, Pillay, & Rees, 2017).  
 
The London Summit on Family Planning in 2012 aimed to mobilize commitments to provide 
family planning services that are easily accessible, acceptable and affordable (Family Planning 
2020, 2012b). The Family Planning 2020 initiative was formed to address issues related to 
accessibility to contraceptives by the world’s poorest countries by 2020 (Scoggins & Bremner, 
2016). Of the 57 countries committed to this initiative, many were developing nationals, including 
Democratic Republic of Congo, India, Madagascar, Malawi, Mozambique, SA, Tanzania, Zambia 
and Zimbabwe, which pledged to strengthen its family planning services (Family Planning 2020, 
2012a). The commitment stipulated that a complete range of family planning methods must be 
made available at public health facilities (Family Planning 2020, 2012a), hence SA released 
contraception policies that added contraceptive implants to their existing methods (Republic of 
South Africa, National Department of Health, 2013a, 2013b).  
The public health sector in SA is government funded and provides health care services to all South 
Africans (Young, 2016). There are 4200 public health facilities in SA (Jobson, 2015) and they 
serve the majority of the SA population (Statistics South Africa, 2017b). The public health care 
system in SA runs as a district-based health system with a Primary Health Care (PHC) approach 
(Dookie & Singh, 2012). Family planning and contraception is an integral component of the PHC 
comprehensive services. The National Contraception and Fertility Planning Policy and Service 
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Delivery Guidelines 2013 state that implant services must be accessed at community health 
centers (CHC), district hospitals, tertiary hospital and academic and quaternary centers (Republic 
of South Africa, National Department of Health, 2013b). However, another report indicated that 
implants should be available at all service levels, including the PHC facilities (Lince-Deroche et 
al. 2016). Most implants insertions (76.2%) are performed at the main PHC facilities (Massyn et 
al. 2016).  
 
1.2.1 Prevalence of implant usage 
The prevalence of implant usage ranges from 0.1% to 18.1% among 113 countries worldwide, 
based on the latest available survey data for individual countries (United Nations, Department of 
Economic and Social Affairs, Population Division, 2018). The demographics of the women using 
the implants are those aged 15-49 years old and married (2018). The United Nations reported low 
implant prevalence in high income countries (range: 0.1%-5.6%), with an increase in several 
countries (2018). A notable increase in prevalence was observed in Australia from 0.8% in 2002 
to 4.3% in 2016, in France from 0.1% in 2008 to 2% in 2011, and in the USA from 0.6% in 2013 
to 1.3% in 2015. This document did not offer any explanation for the increase in prevalence, 
however, an Australian study identified younger age and those living outside major cities as 
factors influencing higher prescription of the etonogestrel implant (Bingham et al. 2016).  
 
Particularly for BRIC countries (Brazil, Russia, India and China), the implant prevalence was 
unchanged from 0.3% in China in 2001 to 2006 and from 0.1% in Brazil in 2006 to 2013 in 
married women aged 15-49 years old (United Nations, Department of Economic and Social 
Affairs, Population Division, 2018). No data was reported for India and Russia in the United 
Nations report (2018) in 2015/2016 despite it being in use (Scoggins & Bremner, 2016). 
Additionally, some studies have alluded that Implanon® is used in India (Bhatia, Nangia, 
Aggarwal, & Tewari, 2011; Singh, Gupta, Nigam, & Nigam, 2015). A trend of increased implant 
prevalence has been found in Sub-Saharan Africa (SSA) countries across almost all socio-
demographic categories (Jacobstein, 2018). The prevalence ranges from 0.4 % to 16.1% in 
married women aged 15-49 years old based on data from 2015 and 2016 (Tsui, Brown, & Li, 
2017). Jacobstein (2018:1) suggests the following key factors for increased prevalence rates in 
SSA: 
“sizeable reductions in commodity cost, much increased commodity supply, greater 
government commitment to expanded method choice, and wider adoption of high-
impact service delivery practices that broaden access and better reach underserved 
populations”  
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In SA, implant usage among currently married and sexually active unmarried women was 3.9% 
in 2016 (Statistics South Africa, 2017c). Implant usage varied across all provinces in SA, with a 
range of 2.6%-6.6%, the Western Cape and Northern Cape Provinces reporting the highest use, 
and Limpopo and North West provinces reporting the lowest (Statistics South Africa, 2017c). 
KZN’s implant users (4.1%) are reportedly higher than Gauteng (3.1%) among the currently 
married and sexually active unmarried women (2017c). However, the overall highest users (6.6%) 
were reported in the Western Cape. 
  
1.2.2 Implant discontinuation 
Although implant use is reportedly increasing in several countries worldwide, user 
discontinuation is simultaneously occurring. Hence, discontinuation and the reasons for 
discontinuation are briefly discussed in this section and a comprehensive overview of 
discontinuation in international and local studies is described in Chapter 2. 
 
1.2.2.1 Global studies on etonogestrel implant discontinuation  
Discontinuation is defined as “a breach or interruption of continuity” (Dictionary.com, 2018) 
and specifically refers to termination of etonogestrel implant use in this dissertation. 
Discontinuation is occurring, which ranges from 10.3% to 26.8% within 12 months of 
etonogestrel implant use internationally (Law, Liao, Lin, Yaldo, & Lynen, 2018; Apter et al. 2016; 
Grunloh, Casner, Secura, Peipert, & Madden, 2013). Discontinuation has also been reported in 
studies conducted in some BRIC countries (Bhatia et al. 2011; Singh et al. 2015; Shu-Rong, Huai-
Mei, Snao-Zhen, Guo-Wei, & Kaper, 1999) and in Egypt, Ethiopia and Nigeria (Asaye, Nigussie, 
& Ambaw, 2018; Ezegwui, Ikeako, Ishiekwene, & Oguanua, 2011; Aziz, El-Gazzar, & Elgibaly, 
2018). 
 
Adverse drug reactions (ADRs) were the main reason for Implanon® discontinuation in several 
global studies including in India and Africa (Teunissen, Grimm, & Roumen, 2014; Bahamondes 
et al. 2015; Asaye et al. 2018; Bhatia et al. 2011; Aziz et al. 2018; Ezegwui et al. 2011). ADRs 
are unintended noxious effects of a drug (Waller & Harrison-Woolrych, 2017) and in this 
dissertation specifically related to etonogestrel implants. Menstrual bleeding pattern changes is 
the most frequently reported ADR and reason for discontinuation, these changes being 
experienced by 11.5% to 26.7% of etonogestrel implant discontinuers (Harvey, Seib, & Lucke, 
2009; Apter et al. 2016; Asaye et al. 2018). To a lesser degree, non-menstrual ADRs such as 
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emotional lability (2.3%), weight increase (2.3%), headache 1.6%), acne (1.3%) and depression 
(1%) also led to discontinuation (Darney et al. 2009). 
 
1.2.2.2 South African studies on implant discontinuation 
The South African Health Review reported 820 implant discontinuations during the period 
February 2014 to  December 2014, and an estimated 0.1% implant discontinuation rate (Lince-
Deroche et al. 2016). In a short space of time, discontinuations increased with an estimated 5 000 
implant discontinuations recorded by April 2015 (Pillay et al. 2017b).  
In the Western Cape, a hospital recorded 239 Jadelle®/Implanon NXT® discontinuations in 2015 
(Western Cape Government, 2016) and 231 discontinuations in 2016, with the discontinuation 
frequency calculated at 11.03% in 2015 and 16.99% in 2016 using numbers from the report 
(2016). There were no reasons suggested for the discontinuations or increase in percentage of 
discontinuations from 2015 to 2016 in Western Cape. The KZN Annual report 2014/15 Vote 7 
reported 3884 discontinuations in 2014/15 (Province of KwaZulu-Natal, Department of Health, 
2015a), with the proportion of user discontinuations being calculated as 1.67%. The report went 
on to state that discontinuations were on the rise (2015a). Implanon NXT® associated menstrual 
bleeding and religious influences were some reasons for discontinuation offered by Ugu district 
in KZN (Province of KwaZulu-Natal, Department of Health, 2015b). Empirical data on Implanon 
NXT® discontinuation in governmental reports in Gauteng Province was unavailable, but an 
online 2015 newspaper article (Komane, 2015) suggested 250 Implanon NXT® discontinuations, 
with the proportion being calculated at 0.5%. Forty percent of participants discontinued Implanon 
NXT® in a study conducted in Gauteng and North West Province, with 90% discontinued due to 
intolerable ADRs across both provinces with menstrual pattern changes cited as a frequent reason 
(Pillay et al. 2017a). 
According to a study conducted in the Eastern Cape Province (Mrwebi et al. 2018), 67.3% 
discontinued within the first year of Implanon NXT® use. ADRs were reported to be the reason 
that over 70% of participants discontinued Implanon NXT® in the Eastern Cape and menorrhagia 
was the most reported ADR (Mrwebi et al. 2018). Pregnancy is a notable ADR associated with 
Implanon NXT® and reports of pregnancy while using Implanon NXT® have resulted in 
discontinuation of the device (Mrwebi et al. 2018). 
 
1.2.3 Adverse drug reactions due to drug interactions with etonogestrel implants 
Etonogestrel implants such as Implanon®, Implanon NXT® and Nexplanon® are the common 
therapeutic implants that are used as contraceptives. While these implants have been reported as 
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highly efficacious contraceptives (WHO, 2018), pregnancy is one of the serious ADRs 
particularly due to drug interactions with Implanon® (Creinin et al. 2017; Simon et al. 2016) and 
Nexplanon® (Simon et al. 2016). These studies that reported pregnancy during Implanon® and 
Nexplanon® are discussed further in Chapter 2 in addition to other studies such as method failure, 
untimely insertion and technique failure.  
 
A common reason for failure is due to drug interactions between Implanon® and concomitant 
enzyme-inducing drugs, such as antiretrovirals (ARV) (Patel et al. 2015), antituberculosis drugs 
(Gbolade, 2010) and antiepileptics (Schindlbeck et al. 2006).  Contextually, failure of Implanon 
NXT® due to drug interaction is problematic as a large portion of the SA population rely on 
efavirenz, rifampicin and carbamazepine, to treat Human Immunodeficiency Virus (HIV), 
Tuberculosis (TB) and Epilepsy respectively. According to Statistics South Africa (STATSSA), 
the estimated overall SA HIV prevalence rate is approximately 12,6%, and the number of people 
living with HIV is approximately 7.06 million as of 2017 (Statistics South Africa, 2017a). In 
adults of reproductive age (aged 15–49 years), approximately 18,0% of the population is HIV 
positive (2017a). SA is one of the top 20 countries with the highest estimated TB incidence, this 
being estimated to be 438 000 as of 2017 (WHO, 2017). Although there is limited data on the 
prevalence of Epilepsy in SA, one study reported the prevalence of active convulsive Epilepsy to 
be 7.0/1,000 in a rural SA population (Wagner et al. 2014). While the prevalence of Epilepsy in 
SA is lower than HIV and TB, women taking Antiepileptics will possibly be affected if they use 
Implanon NXT®.  
 
Policy changes have occurred in SA regarding the prescription of Implanon NXT® in patients 
using concomitant enzyme inducing drugs, such as efavirenz, rifampicin, carbamazepine, 
phenytoin and phenobarbital. In October 2014, the circular specified that these patients should 
not use Implanon NXT® and those already on Implanon NXT® should be offered discontinuation 
(Lince-Deroche et al. 2016). A recent commentary remarked that findings suggest implants could 
possibly be removed as a contraceptive option for HIV-positive women in SA (Patel et al. 2017). 
They also claimed that policy advising against the use of implants in women using efavirenz- 
based therapy was guided by limited evidence in SA (2017). Research on use of enzyme inducing 
drugs and implants continues, with new findings having influenced Implanon NXT® policy in the 
public health sector (Republic of South Africa, National Department of Health, 2014a; Republic 
of South Africa, National Department of Health, 2014b).  
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1.3 Problem statement  
Globally, it was reported that approximately a quarter of users discontinue their etonogestrel 
implant within 12 months (Law et al. 2018; Apter et al. 2016). While challenges with etonogestrel 
implants have been identified as premature discontinuation, drug interactions and failure, ADRs 
remain the primary reason for discontinuation among users (Apter et al. 2016; Teunissen et al. 
2014). There has been growing concern about the number of women returning for premature 
discontinuation of Implanon NXT® in SA. Studies from SA have reported the introduction of 
Implanon NXT® (Mullick et al. 2017), experiences of users (Mrwebi et al. 2018; Petro, 2017; 
Adeagbo et al. 2017; Pillay et al. 2017a), challenges of using Implanon NXT® (Pillay et al. 2017b; 
Mullick et al. 2017) as well as the way forward with the use of Implanon NXT® in SA (Mullick 
et al. 2017; Pleaner et al. 2017; Rees et al. 2017). A delayed monitoring system for Implanon 
NXT® has posed a challenge in determining the true extent of the discontinuation in SA (Lince-
Deroche et al. 2016). Furthermore, limited recording of user discontinuation, ADRs and other 
pharmacovigilance data (Pillay et al. 2017b), especially in patients using enzyme inducing drugs 
(Pleaner et al. 2017), were identified as challenges in SA.  
 
While experiences of Implanon NXT® users have been reported in the literature, there is limited 
publicably available national empirical data on Implanon NXT® in SA and uncertainty on its use 
in those also taking enzyme inducing drugs (Mullick et al. 2017). Additionally, at the initiation 
of the study, there was a lack of understanding of the experiences of Implanon NXT® users in the 
public health sector in under researched provinces such as KZN and in provinces with no available 
published discontinuation data such as Gauteng. The demographic profile of the provinces differs 
hence a provincial depiction of experiences of Implanon NXT® users in different provinces in SA 
is necessary to provide a comprehensive understanding. With few studies providing a 
comprehensive overview of the extent of Implanon NXT® discontinuation, ADR, frequency of 
failure as well as reasons for its discontinuation, this gap needs to be addressed as an evaluative 
exercise. An investigation on these factors will assist in identifying and quantifying problems of 
Implanon NXT®. This information will assist in policy making and have an impact on the practice 
and rational use of the device.  
 
1.4 Research questions  
The main research question was “what are the experiences of the Implanon NXT® users?” 
The secondary research questions are as follows: 
1.4.1 What are the demographics of Implanon NXT® users? 
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1.4.2 What ADRs of Implanon NXT® are reported among users? 
1.4.3 What is the frequency of discontinuation of Implanon NXT® and what are the reasons for 
discontinuation of Implanon NXT®? 
1.4.4 What is the frequency of failure with the use of Implanon NXT®? 
1.4.5 How do the experiences of Implanon NXT® compare between users from KZN and 
Gauteng Provinces? 
 
1.5 Aim and objectives of the study 
The study aimed to evaluate the experiences of Implanon NXT® among users in the public health 
sector in SA. 
The objectives of the study were: 
1.5.1 To identify the demographic profile of Implanon NXT® users  
1.5.2 To identify ADRs of Implanon NXT® reported among users 
1.5.3 To determine frequency of discontinuation of Implanon NXT® and reasons for 
discontinuation 
1.5.4 To determine frequency of failure of Implanon NXT® 
1.5.5 To compare experiences of Implanon NXT® between users in KZN and Gauteng 
Province. 
 
1.6 Research methodology 
This retrospective study entailed the analysis of secondary quantitative data from a national 
pharmacovigilance data set. Secondary analysis is when “the researcher takes previously 
collected and analyzed data from one study and reanalyzes the data or a subset of the data for a 
secondary purpose” (LoBiondo-Wood & Haber, 2018:516). This “secondary purpose” may be to 
answer “new research questions” (Polit-O’Hara & Beck, 2006:509). The advantages of secondary 
data analysis are the cost-effectiveness and volume and scale of available data that is a 
representative sample of the population (Boslaugh, 2007). Additionally, Boslaugh (2007) stated 
that data collected on a national scale are particularly important in epidemiology and public health 
fields that focus primarily on the health of populations. However, there are key disadvantages 
with secondary analysis such as deficient data sets and no control over variables collected (Polit-
O’Hara & Beck, 2006).  
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1.6.1 Process of data collection by the National Department of Health 
Pharmacovigilance Centre for Public Health Programmes 
Although there was delayed monitoring of Implanon NXT®, there is some monitoring data 
available. A closed data set containing monitoring information on Implanon NXT® in SA is 
housed by the National Department of Health Pharmacovigilance Centre for Public Health 
Programmes and is referred to as the National Pharmacovigilance Centre (NPC) in this 
dissertation. The purpose of the NPC is discussed in Chapter 2. The NPC is carrying out an 
ongoing surveillance reporting programme since 2015, where Implanon NXT® data reporting 
forms were completed by health practitioners across the country at public sector facilities where 
implant services were offered. It is within the scope of practice of professional nurses, midwives 
and doctors to provide implants to patients (Republic of South Africa, National Department of 
Health, 2013b). According to the Standard Operating Procedure (SOP) for Subdermal 
Contraceptive Implants Data Collection (Annexure 9), the form should be completed by any 
health practitioner prior to insertion, discontinuation and upon reporting ADRs of Implanon 
NXT® (Republic of South Africa, National Health Department. n.d.). The form collected some of 
the following categories of information: demographics, clinical data, ADRs, and discontinuation 
(Annexure 9). Once completed, provincial co-ordinators facilitated their collection and conducted 
data quality assurance. The successfully examined forms were forwarded to the Maternal Child 
and Women’s Health co-ordinator at the nine provinces various District Offices and were 
thereafter sent to the Provincial Health Departments, where they were finally transferred to the 
NPC.  
 
The data collection tool i.e. surveillance form, belongs to the NPC, and its validity and reliability 
was therefore not tested by the principal investigator of this study. The data was screened by the 
Department of Health at various stages, from data collection by the provincial coordinators to 
data capturing at the NPC for confirmability, validity and reliability. All nine provinces in SA 
provided data, with 36 of the country’s 52 districts submitting forms for analysis. 
 
1.6.2 Study area  
Over half (51%) of SA’s population were female in 2016 (Statistics South Africa, 2016), with the 
highest number of females in reproductive age range (15-49) being 20-24 years (Statistics South 
Africa, 2016). According to the Demographic and Health Survey of 2016, 58.3% of the married 
and sexually active unmarried women were contraception users of any method (Statistics South 
Africa, 2017c).  
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The demographic profiles of the provinces differ, with KZN and Gauteng Provinces being chosen 
as examples in the comparative analysis to represent different demographics in SA. Table 1-1 
illustrates the difference in demographics between KZN and Gauteng.  
 
Table 1-1: Demographics of KwaZulu-Natal and Gauteng Provinces 
 
Variable KZN % Gauteng % 
Number of women (Statistics South Africa, 2016) 52.0 49.6 
Females of reproductive age (Statistics South Africa, 
2016) 
50.9 56.5 
Currently married and sexually active unmarried 
contraception users (Statistics South Africa, 2017c) 
61.2 57.2 
Residing in urban areas (Housing Development 
Agency, 2013a, 2013b) 
47.0 97.0 
KZN=KwaZulu-Natal 
 
1.6.3 Cases  
All case reports from the nine provinces submitted to the surveillance programme at the NPC 
were included in the analysis of the study. The data date ranged from 1 April 2015 to 11 
September 2017. The following number of cases were reported per province: Eastern Cape 
(n=1011), Free State (n=792), Gauteng (n=717), KZN (n=84), Limpopo (n=547), Mpumalanga 
(n=31), North West (n=219), Northern Cape (n=264) and Western Cape (n=78). All variables 
related to counselling, laboratory test results and health practitioners on the case reports were 
excluded, as they fell beyond the scope of this study.  
 
1.6.4 Data extraction  
A Microsoft Excel® spreadsheet was designed to extract the quantitative data from the raw data 
provided by the NPC. The extraction sheet included the following additional variables that was 
not on the raw data set: health facility type, level of health care, level of urbanization and Body 
Mass Index (BMI). The name of the health facility, which appeared on the raw data set, was used 
to search for the health facility type, level of health care and level of urbanization using online 
governmental sources and STATSSA (National Department of Health, South Africa, 2018; 
Province of KwaZulu-Natal, Department of Health, 2014; Republic of South Africa, National 
Department of Health, 2016; Statistics South Africa, 2011). The weight and height data, which 
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appeared on the raw data set, was used to calculate BMI (Centers for Disease Control, 2017). The 
tool was designed to address the five objectives:  
Objective 1. Demographics: age, health facility visited, district and province.  
Objective 2. ADRs: specified ADR including additional information, date of onset of reaction and   
date of report of ADR.  
Objective 3. Discontinuation: Date of insertion, date of discontinuation, reason for 
discontinuation. Case reports with discontinuation date or a reason for discontinuation were 
considered to have discontinued, these variables being used to calculate the frequency of user 
discontinuations. Premature discontinuation was calculated using less than 36 months’ duration 
of treatment as an indicator.  
Objective 4. Failure: unwanted pregnancy was interpreted as failure of the product. 
Objective 5. Comparative experiences: Compared ADRs, discontinuation and failure between 
KZN and Gauteng 
 
It must be noted that the following clinical history variables were also included in the extraction 
tool: para, gravida, weight, height, concomitant conditions, concomitant drugs, name of drug, 
pregnancy test performed and results, previous contraception method and breastfeeding status. 
These were considered to be relevant in addition to the other variables and therefore extracted.  
The raw data set was received via email in the form of a Microsoft Excel® sheet from the NPC on 
11 September 2017. The principal researcher and a data extractor assistant extracted data from 
the raw data set from 12 September 2017 to 2 November 2017, which was thereafter cleaned by 
identifying and correcting incomplete and inaccurate data. Validation and accuracy of extracted 
data was performed by randomly selecting 10% of cases to cross-check with the raw data.  
 
1.6.5 Data analysis  
The 3743 case reports were entered into Microsoft Excel® from where they were exported to 
SPSS® (version 25) for analysis. As majority of the data was quantitative, descriptive analysis 
was performed for all relevant variables described in the data extraction section using the 
following methods: frequencies, percentages, measures of central tendency and variability. 
Inferential statistics were performed to relate the cases to the population for objective 1-5, with a 
95% Confidence Interval (CI) being used. Tests of association were performed using the Chi 
square test and Fischer’s Exact Test, and a p-value of less than 0.05 was considered statistically 
significant. Univariable and multivariable analysis using binary logistic regression was performed 
to identify factors associated with Implanon NXT®  discontinuation as an additional statistical 
test. Odds ratio was calculated to measure the association between variables and the 
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discontinuation of Implanon NXT® as an additional statistical test. In the comparative analysis of 
objective 5, Chi square test was performed using an online calculator to compare the ADRs, 
discontinuation and reasons for discontinuation between the Gauteng and KZN groups (Social 
Science Statistics, 2008), and the Mann Whitney U-test was performed to compare their users’ 
discontinuation. 
1.6.6 Data management  
The electronic data, including the original data set, will be deleted upon successful submission 
and completion of the degree, and all disseminations in the form of publications and reports to 
the Department of Health have been completed.  
 
1.6.7 Ethical considerations 
Full ethical approval was obtained from the University of KZN Biomedical Research Ethics 
Committee (BE266/17) (Annexure 1). Permission to use the raw data set was obtained from the 
NPC (Annexure 2).  
 
1.7 Definition of terms 
ADR: “a response to a medicine which is noxious and unintended, and which occurs at doses 
normally used in man” (WHO, 2002:5). 
 
Contraception: “a process or technique for preventing pregnancy by means of a medication, 
device, or method that blocks or alters one or more of the processes of reproduction in such a 
way that sexual union can occur without impregnation.” (Mosby's Medical Dictionary, 2009) 
 
Discontinuation: “a breach or interruption of continuity” (Dictionary.com, 2018). In this study, 
‘discontinuation’ was determined using case reports that reported a discontinuation date or a 
reason for discontinuation.  
 
Experience: “the fact or state of having been affected by or gained knowledge through direct 
observation or participation” (Merriam-Webster.com, 2018). In this study, experiences 
encompass ADRs, discontinuation experiences, reasons for discontinuation and failure of 
Implanon NXT®.  
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Failure: “the fact of not doing something that you must do or are expectedto do” (Cambridge 
Dictionary, 2018). In this study, failure was defined as unwanted pregnancy reported during 
Implanon NXT®  use.  
 
Implanon NXT®: is a subdermal progestin contraceptive implant which contains etonogestrel 
(Rowlands & Searle, 2014). 
 
Pharmacovigilance: “the science and activities relating to the detection, assessment, 
understanding and prevention of adverse effects or any other drug-related problem” (WHO, 
2004:1). 
 
Premature discontinuation: In this study, premature discontinuation is defined as the 
discontinuation of Implanon NXT® before 36 months post-insertion. 
 
Public health facilities: These include PHC clinics, CHCs, district hospitals, regional hospitals, 
provincial tertiary hospitals, specialised hospitals and central hospitals (Province of KwaZulu-
Natal, Department of Health, 2014). 
 
1.8 Outline of dissertation 
In addition to chapter one, the dissertation comprises of the following chapters: 
 
Chapter 2: Literature review. This chapter presents international and local literature available 
on pharmacovigilance, contraception practices and guidelines, description of etonogestrel 
implants, experiences of etonogestrel implants and challenges in the SA context. Experiences 
include: ADRs of etonogestrel implants, drug interactions, user discontinuation of etonogestrel 
implants, reasons for etonogestrel implant discontinuation and failure of etonogestrel implants.  
 
Chapter 3: Submitted Manuscript. This chapter consists of the first manuscript from the data 
extracted in this study and addressed objectives 1 - 4. The manuscript is titled: Adverse drug 
reactions and discontinuation of Implanon NXT® among users at public health facilities in 
South Africa and was submitted to The European Journal of Contraception & Reproductive 
Health Care on 29 June 2018. This article reported on the findings of ADRs amongst Implanon 
NXT® users, discontinuation and the associated reasons and factors.  
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Chapter 4: Manuscript for submission. This chapter presents the second manuscript from the 
data extracted in this study and addressed objective 5. The manuscript is titled: Comparisons of 
experiences of Implanon NXT® users between provinces in South Africa. The manuscript 
includes the demographic profile of the Implanon NXT® discontinuers and provides a descriptive 
overview of ADRs, discontinuation and reasons for discontinuation on a provincial level in SA 
and includes a comparative analysis of the experiences of Implanon NXT® among users from 
Gauteng and KZN Provinces. This manuscript is to be submitted to the South African Medical 
Journal. 
 
Chapter 5: Synthesis. This chapter concludes on the main objectives of the study, mentions the 
significance of findings and highlights the limitations of the study. Recommendation for policy, 
clinical practice and future research are also provided.  
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CHAPTER 2: LITERATURE REVIEW 
2.1  Introduction 
This chapter provides a background and the description of etonogestrel implants. This chapter 
expands on studies on discontinuation of etonogestrel implants, and other associated problems 
regrading the use. It must be noted that there are several published studies from the initial clinical 
trials of Implanon® that were retracted in 2004 (Rekers & Affandi, 2004), this being due to errors 
in data collection in Indonesia (Adams & Beal, 2009). The chapter highlights various sections 
including pharmacovigilance, contraception and experiences of etonogestrel implants. 
 
2.2  Background 
2.2.1 Pharmacovigilance  
The concept of pharmacovigilance emanated during the investigation of drug safety associated 
with Thalidomide at the World Health Assembly in 1963 (WHO, 2002a). Pharmacovigilance is a 
process of monitoring and evaluating ADRs (Jeetu & Anusha, 2010), which are considered 
detrimental to health, and rank among the top leading causes of mortality and morbidity in many 
countries (Najafi, 2018). There are numerous contributors to pharmacovigilance programmes, 
namely: international pharmacovigilance bodies, continental pharmacovigilance authorities, 
NPCs, pharmaceutical companies and manufacturers, health facilities, health practitioners and 
patients (Jeetu & Anusha, 2010). 
 
The World Health Organisation (WHO) Programme for International Drug Monitoring is 
responsible for the collection of global reports of ADRs from contributing countries (WHO, 
2004). Their collaborating centers are responsible for maintaining a global ADR database (2004). 
Some continents and countries also have local pharmacovigilance coordinators and regulatory 
bodies e.g. European Medicines Agency and USA Food and Drug Administration (FDA). There 
are 33 national pharmacovigilance centers in Africa that are full members of the WHO 
Programme for International Drug Monitoring (Dodoo & Ampadu, 2014). SA has been engaged 
in pharmacovigilance activities for 40 years and is the first country in Africa to become a member 
of the WHO International Drug Monitoring Programme in 1992 (Mehta et al. 2014; Mehta et al. 
2017) In particular, the Medicine Control Council in SA, now South African Health Products 
Regulatory Authority, is responsible for the safety, efficacy quality and post-marketing safety of 
drugs, the pharmacovigilance programme being coordinated by the NPC (Mehta, 2011).  
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The National Adverse Drug Event Monitoring Centre in the NPC is responsible for maintaining 
and managing the national ADR database (2011).  
 
The process for gaining pharmacovigilance data starts with health care practitioners, patients and 
the pharmaceutical industry reporting ADRs to the national pharmacovigilance centres (Delaney, 
2017). The national pharmacovigilance centres submit data to the WHO international database at 
the Uppsala Monitoring Centre (VigiBase) where they can analyse their data using VigiLyze 
(2017). Additionally, the Uppsala Monitoring Centre conducts analysis to detect signals which 
are reported to the national pharmacovigilance centre (2017).  
 
The success of a national post-marketing surveillance programme is therefore dependent on the 
active participation of health practitioners (WHO, 2002b). They are integral to drug monitoring 
programmes, as they are involved in conducting drug reviews, aid in drug and dosage selection, 
and are a part of developing therapeutic monitoring plans for patients (Karpa et al., 2015). They 
are the first point of contact with patients and are therefore in a position to recognize and report 
drug issues (Najafi, 2018; WHO, 2002b). According to the WHO, all healthcare practitioners 
should report ADRs as part of their professional responsibility, even if they are unsure of the 
direct relationship between the drug and a suspected ADR (WHO, 2002b). The degree to which 
health practitioners are informed about the principles of pharmacovigilance has an impacted on 
their quality of patient health care (WHO, 2002a). Patients also play a significant role in ADR 
reporting (Härmark & van Grootheest, 2008), with patient-reported concerns contributing to 
detecting drug safety issues (Härmark et al. 2016). They are provided with the opportunity to 
report ADRs to spontaneous reporting system in some regions e.g. European (Härmark & van 
Grootheest, 2008). Pharmacovigilance is conducted through surveillance methods. Surveillance 
is defined as a: 
“form of non-interventional public health research, consisting of a set of processes 
for the continued systematic collection, compilation, interrogation, analysis, and 
interpretation of data on benefits and harms (including relevant spontaneous 
reports, electronic medical records, and experimental data)” (Aronson, Hauben, & 
Bate, 2012:347).  
 
A spontaneous case reporting system is a “systematic collection, collation and analysis of 
reports of suspected ADRs” (WHO, 2015a:3). When an ADR is suspected, a case report 
form is completed. It contains patient information and a description of the ADR, or problem 
detected and drug information (WHO, 2002b). The completed forms are forwarded to the 
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relevant health authorities (2002b), the advantage of spontaneous reporting systems being 
that they detect signals of drug safety issues, which need to be confirmed by formal studies 
(van Grootheest, Harmark, & van Puijenbroek, 2011). 
 
Pharmacovigilance does not only involve spontaneous reporting but includes conducting various 
types of research using both quantitative and qualitative methods (Mehta et al., 2014). It is 
expanding to include quantifying event rates and the severity of known ADRs, identifying risk 
factors and their incidence (Mehta et al., 2017). The scope of pharmacovigilance includes: ADRs 
or adverse events, drug errors, counterfeit or substandard medicines, lack of efficacy of medicines, 
misuse and/or abuse of medicines, and the interaction between medicines (WHO, 2015a). The 
pharmacovigilance approaches adopted in SA are active surveillance, targeted spontaneous 
reporting for specific drugs or population groups and regulatory spontaneous reporting for all 
drugs (Mehta et al. 2017). The pharmacovigilance methods adopted link post-marketing research 
with pre-marketing data, and also include use cohort studies and registries (2017).  
 
An example of pharmacovigilance in hormonal contraception was the detection of thrombo-
embolism associated with the use of Yasmin (ethinylestradiol/drospirenone) (van Grootheest et 
al. 2011), and the association between Mirena (levonorgestrel containing intrauterine device) and 
uterine perforation (2011). International studies conducted on pharmacovigilance and post-
marketing research and data on etonogestrel implants has been released in the form of publications 
(Creinin et al. 2017; Simon et al. 2016; Harrison-Woolrych & Hill, 2005). These studies 
emphasize safety and efficacy issues reported with Implanon®  (Creinin et al. 2017; Simon et al. 
2016; Harrison-Woolrych & Hill, 2005) and Nexplanon® (Simon et al. 2016), as well as 
complications with insertion and discontinuation of the implants.  
 
2.2.2 Contraception 
The WHO maintains that: 
“Family planning allows people to attain their desired number of children and 
determine the spacing of pregnancies. It is achieved through use of contraceptive 
methods and the treatment of infertility” (WHO, 2018). 
Hence, contraception “prevents pregnancy by interfering with the normal process of ovulation, 
fertilization, and implantation” (Encyclopedia of Children's Health, n.d). Family 
planning/contraception prevents pregnancy related health risks, reduces infant mortality and the 
risk of unwanted pregnancy, empowers females and slows population growth (WHO, 2018). 
There are several modern contraception methods in use e.g. contraceptives pills, implants and 
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injectables, as well as traditional methods which includes the calender method and withdrawl 
technique (WHO, 2018).  Family planning/contraception methods vary in effectiveness to prevent 
pregnancy, with implants, sterilization and IUDs being some of the most effective forms of 
contraception (WHO, 2018).  
 
In 2015, 64% of married or in-union women of reproductive age were using some form of 
contraception method globally, with contraception use being 40% in the least developed 
countries, especially in Africa (33%) (United Nations, Department of Economic and Social 
Affairs, Population Division, 2015b). A modern contraceptive is “A product or medical procedure 
that interferes with reproduction from acts of sexual intercourse” (Hubacher & Trussell, 
2015:420). The United Nations Department of Economic and Social Affairs Population Division 
reported that modern contraception methods were used by most married and in-union women of 
reproductive age (57%) in 2015 (2015b). The 2015 United Nations Trends in Contraceptive Use 
Worldwide also found that more than one in three married or in-union women globally use long-
acting or permanent methods, namely sterilization, intrauterine device and implants (2015b). 
Short-term and non-hormonal methods i.e. the pill and male condom, are popular methods in 
Europe whereas the pill and sterilization are popular in North America (United Nations, 
Department of Economic and Social Affairs, Population Division, 2015a). In SSA, injectables 
and implants are frequently used methods (Tsui, Brown, & Li, 2017). In SA, the three monthly 
injectable is the most commonly used method (17.7%) in currently married and sexually active 
unmarried women (Statistics South Africa, 2017). As mentioned in Chapter 1, the implant is used 
in 3.9% of currently married and sexually active unmarried women in SA (2017), which is low 
compared to other SSA countries (Tsui et al. 2017).  
 
2.2.3 Accessibility and affordability of implants in developing countries 
The Implanon Access Initiative was launched in 2011 (Reproductive Health Supplies Coalition, 
2013), its aim being to improve affordability through public sector price agreements (2013). In 
2013, Merck and partners announced an agreement that will expand contraceptive access and 
options for millions of women in some of the world’s poorest countries. Merck will reduce the 
cost of Implanon® and Implanon NXT® or Nexplanon®  by approximately 50% for the next six 
years in specific countries (Merck, 2013). Merck has extended this initiative to these same 
targeted countries through till 2023 (IFPMA, 2012). Sixty four countries, including SA, are part 
of this initiative in the following regions: East Asia and Pacific, Europe and Central Asia, Latin 
America & Caribbean, Middle East & North Africa, South Asia and SSA (2012). The unit price 
of Implanon NXT® in SA is R 2 137.62 as of 1 April 2018, however, is it dispensed free of charge 
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by public health facilities (Republic of South Africa, National Department of Health, 2018a; 
Lince-Deroche et al. 2016). This section provides some insight for understanding the background 
to Implanon NXT® and this study. Implanon NXT® will hereafter be discussed in detail.  
 
2.3 Implanon NXT®  
2.3.1 Description of Implanon NXT®, 
Implanon NXT® is an etonogestrel subdermal implant, 4cm in length with a 2mm diameter, and 
is packaged inside a preloaded applicator (Kolawole et al. 2018; Mommers et al. 2012). The 
product contains “68 mg etonogestrel with 3% barium sulphate [37% ethylene vinyl acetate 
(EVA) copolymer;3% barium sulphate (15 mg); 60% ENG (68 mg)]” (Mansour, 2010:187). A 
summary of some of the Implanon NXT® product characteristics is provided in Table 2-1.  
 
There are several advantages of implants, including Implanon NXT®, which include: high 
efficacy, long-term effect, oestrogen-free, rapid return to fertility and is a non-user dependant 
contraceptive (Adams & Beal, 2009; Ladipo & Akinso, 2005). However, there exists some 
disadvantages which includes: ADRs, insertion and discontinuation complications, requires 
surgical procedure for insertion and discontinuation and practitioner dependence (Adams & Beal, 
2009; Grentzer, McNicholas, & Peipert, 2013). 
 
2.3.2 Timing of Implanon NXT® insertion and procedures for placement and 
discontinuation 
The appropriate timing of Implanon NXT® insertion depends on the previous contraception 
method used e.g if progestogen injectable was used then it can be inserted on the following due 
date (Palomba et al. 2012). If no previous contraception was used, Implanon NXT® can be inserted 
between day 1 and 5 of the cycle (2012). Insertion should be performed on the same day if it is 
post-first trimester abortion or between day 21 and 28 of the cycle if post-second trimester 
abortion (2012). Pregnancy must be ruled out prior to Implanon NXT® insertion, with the SA 
Standard Treatment Guidelines 2018, indicating that it can be inserted anytime in the menstrual 
cycle as long as pregnancy has been excluded (Republic of South Africa, National Department of 
Health, 2018b). Implanon NXT® is inserted subdermally on the non-dominent arm at 8-10cm 
above the medial epicondyle of the humerus (Palomba et al. 2012). The procedure is outlined in 
the product information leaflet (Merck Sharp & Dohme, Australia, 2010) as well as the SA 
Standard Treatment Guidelines (Republic of South Africa, National Department of Health, 
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2018b). Complications such as: pain, swelling, redness and wound infection are possible 
(Rowlands & Searle, 2014). 
 
Table 2-1: Summary of some Implanon NXT® characteristics  
 
Name Etonogestrel implant 
Brand/ manufacturer 
Implanon NXT® by Merck  (Reproductive Health Supplies Coalition, 
2013:2). 
Therapeutic category Contraceptive, etonogestrel implant (Mansour, 2010). 
Use Prevention of pregnancy for at least three years (Palomba et al. 2012).  
Mechanism of action 
Primary: Inhibition of ovulation (Kolawole et al. 2018). 
Secondary: Prevents sperm penetration and implantation (2018). 
Pharmacokinetic and 
pharmacodynamic 
properties  
Etonogestrel is the active metabolite of desorgestrel (Palomba et al. 2012). 
Etonogestrel is partially bound to sex hormone-binding proteins. Serum 
levels of etonogestrel >90pg/ml prevent ovulation (Hohmann, 2009). 
Serum etonogestrel concentraction levels increase to a mean of 265.9± 
80.9  pg/ml 8 hours post-insertion (Palomba et al. 2012). “Serum levels 
reach maximum values after about 4 days from the insertion of the device 
reaching a stady-state (200 pg/mL) after 4–6 months.” (2012:711).  
The serum concentrations decline from a mean of 196pg/ml after 1 year to 
a mean of 156 pg/ml after 3 years of use (Hohmann, 2009). The half-life 
elimination is approximately 25 hours (Palomba et al. 2012). 
Return of fertility  
The serum etonogestrel level is undetectable one week post- 
discontinuation (Hohmann, 2009). Ovulation has been reported 2-6 weeks 
post-discontinuation (Palomba et al. 2012).  
Dosage  68 mg of etonogestrel (Schnabel et al. 2012). 
Efficacy  The three-year Pearl Index is 0.00 (Mommers et al. 2012).  
 
Implanon NXT® must be located prior to discontinuation, and an X-ray or ultrasound may be 
performed if its presence cannot be verified (Palomba et al. 2012). Palomba et al. describes the 
discontinuation procedure as follows:  
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“Once the device has been located, it is necessary to press the proximal end in order 
to cause a lifting of the distal end. Identified the distal portion, after local anesthesia, 
a small skin incision is practiced on this zone.” (2012:713) 
The discontinuation procedure is also outlined in the product information leaflet (Merck Sharp & 
Dohme, Australia, 2010) as well as the SA Standard Treatment Guidelines (Republic of South 
Africa, National Department of Health, 2018b). The serum etonogestrel levels will decrease 
rapidly and be undetectable within four days post-discontinuation (Rowlands et al. 2017). 
Complications that arise from discontinuation include: implant breakage, implant attached to 
fibrous tissue and difficulty locating implants (Palomba et al. 2012). ADRs, which include 
complications arising from insertion and discontinuation, are reasons for discontinuation and the 
next section details their profile. 
 
2.4 Contextualization of experiences of etonogestrel implants 
2.4.1 Adverse drug reactions 
Adverse drug reactions (ADRs) associated with etonogestrel implants include menstrual-related 
ADRs as shown in Table 2-3 and non-menstrual related ADRs, such as headaches, weight gain 
and acne as displayed in Table 2-4.  
 
2.4.1.1 Menstrual-related adverse drug reactions 
Menstual bleeding patterns have been inconsistently defined across studies as highlighted in Table 
2-2, but most people have used or adapted the WHO assessment of bleeding patterns experienced 
while using progestin-only contraceptive methods (Belsey, Machin, & D’Arcangues, 1986). A 
90-day reference period (RP) is used to asses bleeding patterns (Belsey et al. 1986).  
 
Table 2-2: Summary of etonogestrel implant studies outlining definitions of menstrual 
bleeding patterns over a 90-day reference period  
 
Bleeding pattern 
 
Definition Reference 
Normal 3 to 5 bleeding/ spotting episodes  • Darney, Patel, Rosen, Shapiro, and 
Kaunitz (2009) 
Normal menstrual bleeding • Laban, Abd Alhamid, Ibrahim, 
Elyan, and Ibrahim (2012) 
Amenorrhoea No bleeding or spotting • Darney et al.(2009) 
• Guazzelli, De Queiroz, Barbieri, 
Torloni, and De Araujo (2010) 
• Laban et al.(2012) 
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• Singh, Gupta, Nigam, and Nigam 
(2015) 
No bleeding • Bitzer, Tschudin, Alder, and Group, 
S.I.S. (2004) 
• Zheng, Zheng, Qian, Sang, and 
Kaper  (1999) 
Absence of menstruation • Chaovisitsaree et al. (2005) 
• Gezginc, Balci, Karatayli, and 
Colakoglu (2007) 
 
Infrequent 
bleeding 
< 3 episodes of bleeding/spotting • Darney et al.(2009) 
• Chaovisitsaree et al. (2005) 
• Gezginc et al. (2007) 
• Singh et al. (2015) 
Bleedings that occurred at intervals 
were more than 6 weeks apart 
• Bitzer et al. (2004) 
1-2 bleeding episodes • Guazzelli et al. (2010) 
< 2 bleeding-spotting episodes • Zheng et al. (1999) 
1 or 2 bleeds or spotting episodes • Laban et al. (2012) 
Frequent bleeding > 5 episodes of bleeding • Darney et al. (2009) 
• Laban et al. (2012) 
• Singh et al. (2015) 
> 4 bleeding-spotting episodes • Guazzelli et al. (2010) 
• Zheng et al. (1999) 
> 5 bleeding or spotting episodes • Chaovisitsaree et al. (2005) 
• Gezginc et al. (2007) 
Prolonged bleeding ≥ 1 bleeding lasting > 14 consecutive 
days 
• Darney et al. (2009) 
• Laban et al. (2012) 
Bleeding longer than seven days • Bitzer et al. (2004) 
≥ 1 bleeding-spotting episode lasting > 
14 days 
• Guazzelli et al. (2010) 
• Chaovisitsaree et al. (2005) 
• Gezginc et al. (2007) 
• Singh et al. (2015) 
≥1 bleeding-spotting episode lasting ≥ 
10 days 
• Zheng et al. (1999) 
Irregular bleeding 3-5 bleeding episodes & < 3 bleeding-
free intervals of ≥ 14 days 
• Guazzelli et al. (2010) 
Experiencing frequent, infrequent, and 
prolonged bleeding 
• Chaovisitsaree et al. (2005) 
• Gezginc et al. (2007) 
Regular Periodic withdrawal bleeding within 28 
± 7 days 
• Chaovisitsaree et al. (2005) 
 
Recurring bleeding at 28 ± 7 days 
intervals 
• Gezginc et al. (2007) 
Acceptable None of the above • Guazzelli et al. (2010) 
 
Table 2-3 displays the frequency of bleeding patterns reported with etonogestrel implants 
globally. It must be noted that it may be difficult to compare findings across studies due to use of 
different definitions for bleeding patterns. The following quote from Adams and Beal (2009:144) 
explains the difference in interpretation of bleeding patterns using various definitions:  
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“Infrequent bleeding is the most common pattern under the older, more inclusive 
WHO standards …and is reported by 35% to 51% of users at 3 months, declining to 
approximately 25% to 34%at the end of year two. In studies using the stricter, 
revised WHO definition, the incidence generally drops to 10% or less for all time 
periods.” 
The interpretation of bleeding patterns in this section will include all studies in Table 2-3 
regardless of their definitions. It must be noted that Darney et al. (2009) provided proportions of 
bleeding patterns based on total RPs and not total women. Hence, they reported the following 
results: amenorrhoea (21.4% of RPs), infrequent bleeding (33.3% of RPs), frequent bleeding 
(6.1% of RPs) and prolonged bleeding (16.9% of RPs).   
 
Amenorrhoea ranges from 2.4% to 61.2% across studies with those from high income countries 
on the lower half of the scale i.e. 7.0% - 33%, however, 7.0% was an outlier. Amenorrhoea was 
considered a favourable bleeding pattern by users in international studies (Casey, Long, Marnach, 
& Bury, 2011; Beligotti, Mommers, & Marintcheva-Petrova, 2012; Flore et al. 2016; Inoue et al. 
2016). A study conducted in high income countries found that 77.7% of those who experienced 
amenorrhoea were very satisfied with their bleeding pattern, which could explain the lower 
proportion of reports (Apter et al. 2016). Additionally, a scoping review found that amenorrhoea 
was preferred in North America and Europe (Polis, Hussain, & Berry, 2018).  
 
Under half of the studies reported prolonged bleeding, which ranged from 2.2%-56.2%, with a 
review of Implanon® clinical trials reporting that this occurred in a small number of women 
(Mansour, Korver, Marintcheva-Petrova, & Fraser, 2008) and the Implanon® prescribing leaflet 
stating that 17.7% reported prolonged bleeding. Prolonged bleeding appears to be poorly tolerated 
in several studies (Polis et al. 2018), which potentially could explain the increased reporting. 
Unmet expectations of menstrual ADRs could have impacted on satisfaction levels as found in a 
study of Implanon NXT® users, prolonged bleeding occurred more often than expected (Beligotti 
et al. 2012), which could have increased the number of reports. 
 
In studies conducted in Africa, menorrhagia and amenorrhoea were more frequently reported than 
other bleeding patterns. One reason for frequent reporting of amenorrhoea was explored in a 
scoping review, which found that amenorrhoea was viewed negatively by some women, as they 
were suspicious of its occurrence and viewed menstruation as a natural process (Polis et al. 2018). 
Mrwebi et al. (2018) described that menorrhagia was the top ADR experienced by SA 
women.Although menorrhagia was frequently reported, the study also revealed higher 
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proportions of menorrhagia in the global literature i.e. 56.2% in Australia and 62% in the UK. 
Generally, users from Nigeria reported a low proportion of bleeding patterns (range: 1.2-14.8). 
Roberts, Morhason-Bello, Okunlola, and Adekunle (2015:51) argued that:  
“None of the clients manifested any complication of excessive bleeding clinically or 
through their haematological parameters. The amenorrhoea following Implanon® 
insertion has been associated with increased haematocrit level amongst clients; this 
is of clinical benefit in settings where maternal anaemia remains a public health 
concern”  
This quote suggests that menstrual ADRs were tolerable and beneficial, with the reporting of 
bleeding possibly having been low in Nigeria.  
 
Normal bleeding appears uncommon among users and ranged from 8%-11%. Infrequent bleeding 
was reported in 50% of studies (range: 3.2%-56.0%), while half reported frequent bleeding 
(range: 2.3%-36.4%). Mastor, Khaing, & Omar (2011) and Booranabunyat & Taneepanichskul. 
(2004) conveyed that infrequent bleeding was the most commonly reported bleeding pattern. 
Other bleeding patterns reported in studies included: regular (Mastor et al. 2011), vaginal 
haemorrhage (Mommers et al. 2012), prolonged spotting and polymennorhagia (Bhatia, Nangia, 
Aggarwal, and Tewari,  2011) as well as spotting and intermenstrual bleeding (Ojule, Oranu, and 
Enyindah, 2012; Roberts et al. 2015). Spotting, irregular and frequent bleeding were viewed as 
unfavourable bleeding patterns, which could explain the increased reports (Casey et al. 2011; 
Beligotti et al. 2012; Yonan, Borzutzky, Olson-Kennedy, Tanaka, & Iverson, 2018). 
 
It must be noted that menstrual bleeding appears to be varied across age groups, with age therefore 
probably not influencing bleeding patterns. López del Cerro et al. (2018) found no statistically 
significant differences for amenorrhoea, frequent, infrequent and prolonged bleeding according 
to age. Additional variables, such as BMI, postpartum and breastfeeding, were also not predictive 
of bleeding pattern (Casey et al. 2011). The range in bleeding patterns is extreme across studies 
and the reason for breakthrough bleeding in implants was proposed by Ramdhan et al. (2018:3) 
who observed that: 
“Women can experience a variety of bleeding patterns despite similar hormonal 
levels. For example, low estradiol levels and an absence of luteal activity can be 
associated with amenorrhea, frequent or prolonged bleeding” 
 
Summarizing the findings of various studies, bleeding patterns appear to be unpredictable and 
fluctuate over time (Guazzelli et al. 2010; Apter et al. 2016; Aisien & Enosolease, 2010). Women 
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have also experienced changes in bleeding pattern from their initial pattern (Darney et al. 2009; 
Bitzer et al. 2004). Studies suggest that there is no long-term trend in bleeding pattern associated 
with etonogestrel implants, these being patient specific.  
 
Table 2-3: Summary of studies reporting percentage of menstrual bleeding patterns with 
etonogestrel implants  
 
Bleeding 
pattern 
Percentage 
(%)1 
Region Reference 
Amenorrhoea 61.2 Ecuador Medina, Bahamonde, Endara, & 
Leon, (2015) 
41.3 Turkey Gezginc et al. (2007) 
40.2 Thailand Chaovisitsaree et al. (2005) 
38.9 Brazil, Chile, Zimbabwe, 
Dominican Republic, 
Hungary, Thailand 
Bahamondes et al. (2015) 
 
38.6 Brazil Guazzelli et al. (2010) 
10.1-35.3 Bangkok Thamkhantho, Jivasak-Apimas, 
Angsuwathana, Chiravacharadej, 
and Intawong (2008); 
Booranabunyat and 
Taneepanichsku (2004) 
33.0 Switzerland Bitzer et al. (2004) 
24.4-32.0 Turkey Șahİn et al. (2009): 
Duvan, Gözdemir, Kaygusuz, 
Kamalak, and Turhan (2010) 
27.9 Spain López del Cerro et al. (2018) 
 
11.8-24.0 India Singh et al. (2015); Bhatia et al.  
(2011) 
22.9 Malaysia Mastor et al. (2011) 
2.4-9.4 Nigeria Ojule et al. (2012); Balogun, 
Olaomo, Adeniran, and Fawole 
(2014); Roberts et al. (2015) 
7.0 Australia, Germany, France, 
UK, Norway and Sweden 
Mommers et al. (2012) 
Infrequent 
bleeding 
56.0 Spain López del Cerro et al. (2018) 
50.7 Malaysia Mastor et al. (2011) 
39.1 Thailand Chaovisitsaree et al. (2005) 
38.2 India Singh et al. (2015) 
28.0 Switzerland Bitzer et al. (2004) 
3.2-24.4 Turkey Duvan et al. (2010); Gezginc et 
al. (2007); Șahİn et al. (2009) 
23 Ecuador Medina et al. (2015) 
15.9 Brazil Guazzelli et al. (2010) 
Frequent 
bleeding 
36.4 India Singh et al. (2015) 
22.9 Malaysia Mastor et al. (2011) 
6.5-17.5 Turkey Duvan et al. (2010); Șahİn et al. 
(2009); Gezginc et al. (2007) 
16.4 Spain López del Cerro et al. (2018) 
9.8 Thailand Chaovisitsaree et al. (2005) 
2.3 Brazil Guazzelli et al. (2010) 
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Prolonged 
bleeding 
56.2 Brazil, Chile, Zimbabwe, 
Dominican Republic, 
Hungary, Thailand 
Bahamondes et al. (2015) 
10.0-21.0 Turkey Gezginc et al. (2007); Șahİn et al. 
(2009); Duvan et al. (2010) 
15.0 Switzerland Bitzer et al. (2004) 
13.6 India Singh et al. (2015) 
2.3 Brazil Guazzelli et al. (2010) 
2.2 Thailand Chaovisitsaree et al. (2005) 
Normal bleeding 11.0 Switzerland Bitzer et al. (2004) 
8.7 Thailand Chaovisitsaree et al. (2005) 
8.0 Egypt Laban et al. (2012) 
Menorrhagia 11-39.9 SA Pillay et al. (2017a); Mrwebi et al. 
(2018) 
35.4 Brazil, Chile, Zimbabwe, 
Dominican Republic, 
Hungary, Thailand 
Bahamondes et al. (2015) 
10.3 Australia, Germany, France, 
UK, Norway and Sweden 
Mommers et al. (2012) 
1.2-3.9 Nigeria Ojule et al.(2012); Roberts et al. 
(2015) 
Irregular 
bleeding 
86.0 Brazil, Chile, Zimbabwe, 
Dominican Republic, 
Hungary, Thailand 
Bahamondes et al. (2015) 
70 Maylasia Mastor et al. (2011) 
52.9 Bangkok Booranabunyat and 
Taneepanichsku (2004) 
29.3 Turkey Șahİn et al. (2009) 
27.0 India Bhatia et al. (2011) 
14.8 Nigeria Balogun et al. (2014) 
9.1 Brazil Guazzelli et al. (2010) 
SA=South Africa, UK=United Kingdom 
1 Calculated as bleeding pattern/total women. 
  
2.4.1.2 Non-menstrual adverse drug reactions  
The proportions of ADR per organ system differed between two international studies (Figure 2-
1). Darney et al. (2009) reported female reproductive disorders (excluding menstrual) as the most 
commonly occurring ADR per organ system. Some of the ADRs that constituted female 
reproductive disorders included: vaginitis (14.5%), breast pain (12.8%), leukorrhea (9.6%) and 
dysmenorrhea (7.2%). Simon et al. (2016) also noted reproductive ADRs as the most frequently 
affected system and included menstrual changes and pain or abnormalities in the breast or pelvis. 
Lower proportions of all ADRs per organ system, except reproductive disorder and complications 
at implant site, were reported by Simon et al. (2016) compared to Darney et al. (2009).  
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Figure 2-1: Adverse drug reaction reported per organ systems (Simon et al. 2016; Darney 
et al. 2009) 
 
A summary of etonogestrel implant studies that reported common non-menstrual ADRs are 
described in Table 2-4. It is necessary to be cognizant that more than one ADR could be reported 
in some cases. 
 
Headache: Headache is the most common non-menstrual ADR and is suggested to be steroid 
related (Brache, Faundes, Alvarez, & Cochon, 2002). There is a wide range in the proportion of 
headache reported across studies (range: 1.1-59.6%), the highest being mainly in upper-middle 
income countries, a possible reason being an increase in the incidence compared to prior to 
insertion (Șahİn et al. 2009). The proportion of headache reported in African studies was on the 
lower end of the scale, which could be due to changes in the incidence with time (Roberts et al. 
2015). An excerpt from Pillay et al. (2017a:819) reports “I experience a headache on early days 
when I inserted it, but now I’m ok and I would like to continue using it.”  
 
Weight increase: Weight increase is the second most common non-menstrual ADR, this being 
reported by over two-thirds of studies across regions, the range being 0.6%-23.6%. Weight 
increase was more frequently reported in high and upper middle-income countries, and in regions 
outside Africa. A recent multicenter randomized trial revealed that etonogestrel implant users 
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experienced a significant mean weight increase of three kilograms after 36 months of use 
(Bahamondes, Brache, Ali, & Habib, 2018). Brache et al. (2002:67) remarked that: 
“weight gain has been a consistent finding in all implant clinical trials, but it has 
also been reported among nonhormonal contraceptive users, suggesting that other 
factors may also be related, such as the natural increase in weight related to aging.”  
It is uncertain whether the weight gain expressed by users is Implanon® related or normal average 
weight gain for an adult (Bahamondes et al. 2018).  
 
Acne: Acne could be caused by the androgenic effect of progestogen (Brache et al. 2002), the 
majority reporting it is ranging from 1.2%-45.2% of users. It must be noted that only one study 
conducted in Africa reported acne implying that it may not be a common ADR in the region. It 
was argued by Funk et al. (2005) that 84.0% reported no change in acne and may therefore not 
have been a significant ADR for some users. The highest proportions of acne were reported by 
users in mainly upper-middle income countries. Yildizbas, Sahin, Kolusari, Zeteroglu, & Kamaci, 
(2007) reported that 26.8% of women experienced acne who did not have acne at baseline, this 
being higher than the percentage reported by Funk et al. (2005) of 16%.  
 
Loss/reduced libido: The loss of libido could possibly be related to implant use (Brache et al. 
2002), with changes having been reported by over a third of studies, the proportions ranging from 
1.0-21.7%. Al-Jefout et al. (2015) reported that 21.7% of changes in libido could be attributed to 
the high prevalence of menstrual disturbances, but that if this outlier is removed, small proportions 
of changes were reported. While there appears to be a considerable range of ADR proportions 
across studies, there is no definite trend based on age and region. In particular, studies from Africa 
have reported relatively fewer and lower proportions of ADRs. An important note is that some 
studies have revealed that not all ADRs were related to Implanon® (Darney et al. 2009; Funk et 
al., 2005) and Nexplanon® (Mommers et al. 2012). 
 
There were several other ADRs reported, some of which include: weight loss (Gezginc et al. 
2007), vomiting (Mastor et al. 2011), local arm irritation (Riney, O’Shea, and Forde 2009) and 
back pain (Mrwebi et al. 2018).  
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Table 2-4: Summary of etonogestrel implant studies showing common non-menstrual 
adverse drug reactions 
 
Non-menstrual 
ADRs 
Percentage 
(%)1 
Region Reference 
Headache 59.6 Brazil, Chile, Hungary, Thailand, Turkey, 
Zimbabwe, Dominican Republic 
Bahamondes et al. (2015) 
 
6.5-41.2 Turkey Duvan et al. (2010); Yildizbas et al. 
(2007); Șahİn et al. (2009) 
24.9 Mexico Flores,Balderas, Bonillaa and Vázuez 
Estrada, (2005) 
21.7 Jordan Al-Jefout et al. (2015) 
20.1 Ethiopia Birhane, Hagos, and Fantahun (2015) 
 
15.5 USA, Chile, Asia, Europe Darney et al. (2009) 
 
6.4-14.3 SA Mrwebi et al. (2018); Pillay et al. (2017a) 
 
1.1-13.3 Nigeria Balogun et al. (2014); Roberts et al. 
(2015)  
12.7 USA Funk et al. (2005) 
12.3 Australia, Finland, France,Norway, Sweden, 
UK 
Apter et al. (2016) 
9.0 Australia, Germany, France, UK, Norway, 
Sweden 
Mommers et al. (2012) 
8.6 Malaysia Mastor et al. (2011) 
4.0 Switzerland Bitzer et al. (2004) 
3.0 Ireland Riney et al. (2009) 
Dizziness 34.5-46.3 Turkey Șahİn et al. (2009); Yildizbas et al. 
(2007) 
44.5 Brazil, Chile, Hungary, Thailand, 
Turkey,Zimbabwe, Dominican Republic 
Bahamondes et al. (2015) 
 
1.0 Switzerland Bitzer et al. (2004) 
0.5 SA Mrwebi et al. (2018) 
Weight increase 23.6 Malaysia Mastor et al. (2011) 
23.2 Jordan Al-Jefout et al. (2015) 
16.0 Turkey Duvan et al. (2010) 
12.1 USA Funk et al. (2005) 
12.0 USA,Chile, Asia, Europe Darney et al. (2009) 
 
0.6-11.7 Nigeria Ojule et al. (2012); Balogun et al. (2014); 
Roberts et al. (2015) 
11.0 Australia,Germany, France,UK,Norway, 
Sweden 
Mommers et al. (2012) 
9.0 Switzerland Bitzer et al. (2004) 
8.0 Ireland Riney et al. (2009) 
7.5 India Bhatia et al. (2011) 
4.8 SA Mrwebi et al. (2018) 
2.8 Mexico Flores et al. (2005) 
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2.1 Ethiopia Birhane, Hagos, and Fantahun (2015) 
Pain at implant 
site 
15.2 Thailand Chaovisitsaree et al. (2005) 
 
9.6 SA Mrwebi et al. (2018) 
4.0 Australia, Germany, France, UK, Norway, 
Sweden 
Mommers et al. (2012) 
 
3.2 Turkey Duvan et al. (2010) 
2.9 USA, Chile, Asia, Europe Darney et al. (2009) 
Abdominal pain 50.4 Brazil, Chile, Hungary, Thailand, Turkey, 
Zimbabwe, Dominican Republic 
Bahamondes et al. (2015) 
 
23.9 Thailand Chaovisitsaree et al. (2005) 
 
15.0 Mexico Flores et al. (2005) 
 
5.2 USA, Chile, Asia, Europe Darney et al. (2009) 
 
3.0 Switzerland Bitzer et al. (2004) 
 
0.5 SA Mrwebi et al. (2018) 
 
Emotional 
lability 
14.2 USA Funk et al. (2005) 
5.8 USA, Chile, Asia, Europe Darney et al. (2009) 
 
Breast pain 8.6-12.2 Turkey Șahİn et al. (2009); Yildizbas et al. 
(2007) 
 
10.2 USA, Chile, Asia, Europe Darney et al. (2009) 
 
1.4 Mexico Flores et al. (2005) 
 
0.6-1.1 Nigeria Ojule et al. (2012); Balogun et al. (2014) 
Acne 45.2 Brazil, Chile, Hungary, Thailand, Turkey, 
Zimbabwe, Dominican Republic 
Bahamondes et al. (2015) 
 
1.6-26.8 Turkey Duvan et al. (2010);  
Gezginc et al. (2007); Șahİn et al. (2009); 
Yildizbas et al. (2007) 
16.3 Thailand Chaovisitsaree et al. (2005) 
 
15.5 Australia, Finland, France, Norway, Seden, 
UK 
Apter et al. (2016) 
 
14.5 USA Funk et al. (2005) 
12.3 Australia, Germany, France, UK, Norway, 
Sweden 
Mommers et al. (2012) 
 
12.0 Switzerland Bitzer et al. (2004) 
11.8 USA, Chile, Asia, Europe Darney et al. (2009) 
 
10.0 Malaysia  Mastor et al. (2011) 
 
6.3 Mexico Flores et al. (2005) 
 
5.8 Jordan Al-Jefout et al. (2015) 
1.2 Ethiopia Birhane et al.(2015) 
Breast tender-
ness 
6.5-18.8 Turkey Duvan et al. (2010); 
Gezginc et al. (2007) 
16.3 Thailand Chaovisitsaree et al. (2005) 
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11.0 Switzerland Bitzer et al. (2004) 
4.3 Mayalsia Mastor et al. (2011) 
Depressive 
mood 
2.5-17.1 Turkey Gezginc et al. (2007);  Șahİn et al. 
(2009); Yildizbas et al. (2007) 
7.3 USA Funk et al. (2005) 
 
2.0 Switzerland Bitzer et al. (2004) 
 
Loss of libido 4.3 Malaysia  Mastor et al. (2011) 
1.6-2.5 Turkey Duvan et al. (2010); 
Gezginc et al. (2007) 
1.1 SA Mrwebi et al. (2018) 
1.0 Switzerland Bitzer et al. (2004) 
Decreased 
libido 
21.7 Jordan Al-Jefout et al. (2015) 
7.6 Thailand Chaovisitsaree et al. (2005) 
 
5.9 Mexico Flores et al. (2005) 
 
Nausea 29.3-38.2 Turkey Yildizbas et al. (2007); Șahİn et al. 
(2009) 
 
13.4 Mexico Flores et al. (2005) 
5.0 Mayalsia Mastor et al. (2011) 
Dysmenorrhea 12.3 Australia, Finland, France, Norway, Sweden, 
UK 
Apter et al. (2016) 
9.7 USA Funk et al. (2005) 
2.4-5.7 Turkey Yildizbas et al. (2007); Șahİn et al. 
(2009) 
4.0 Ireland Riney et al.(2009) 
3.7 Australia, Germany, France, UK, Norway, 
Sweden 
Mommers et al. (2012) 
 
Mood changes/ 
swings 
21.7 Jordan Al-Jefout et al. (2015) 
17.4 Thailand Chaovisitsaree et al. (2005) 
9.5 Mexico Flores et al. (2005) 
5.0 Maylasia Mastor et al. (2011) 
3.0 Switzerland Bitzer et al. (2004) 
1.1 Nigeria Balogun et al. (2014) 
Hirsutism 3.2-5.7 Turkey Duvan et al. (2010); Șahİn et al. (2009) 
1.5 Jordan Al-Jefout et al. (2015) 
Hair loss 13.6 Malaysia Mastor et al. (2011) 
 
1.6 SA Mrwebi et al. (2018) 
ADRs=Adverse drug reactions, SA=South Africa, UK=United Kingdom, USA=United States of America 
1 Calculated as ADR/Total women. 
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There were 5.9% of participants who experienced 77 serious ADRs in the clinical trials (Darney 
et al., 2009). The most common serious ADRs were gastrointestinal conditions (1.1%), neoplasms 
(0.7%), and liver and biliary system disorders (0.6%) (Darney et al. 2009). Other serious ADRs 
included heart disorders, abdominal pain, and breast neoplasms (2009). Findings from a 
pharmacovigilance study reported 7% of serious ADRs cases (excluding pregnancy), the 
incidence of serious ADRs being estimated at 0.32 / 1000 patients for Implanon® and 0.09 / 1000 
for Nexplanon® (Simon et al. 2016). Migration/withdrawal problems, implant site reactions, 
neurological conditions and cardiovascular conditions were considered serious ADRs (2016). A 
Nexplanon® study reported several serious ADRs e.g. migraine, bipolar disorder and ovarian 
cysts, however, none were considered to have a definite relationship to the drug (Mommers et al. 
2012). Serious ADRs were reported by 2.4% of participants in a multicenter study, but only 
cerebral infarction was related to the implant (Apter et al. 2016). Funk et al. (2005) mentioned 
that 10 participants reported serious ADRs, but only a ruptured ovarian follicle and acute 
exacerbation of depression were deemed possibly related to Implanon®. Overall, under 10% of 
etonogestrel implant users experienced serious ADRs and only a few were related to Implanon® 
and Nexplanon®.  
 
2.4.1.3 Complications of etonogestrel implants 
Noteworthy ADRs are complications that relate to the implant site and device, with a case study 
reporting a red, swollen implant site with purulent discharge in a woman using Nexplanon® 
(Chaudhry, 2013). Skin infection post-Nexplanon® insertion (Partridge & Bush, 2013) and 
hypersensitivity reaction (Serati, Bogani, Kumar, Cromi, & Ghezzi, 2015; Niederhauser, Magann, 
& Hoffman, 2011) were also reported, while two cases reported allergic reactions to the barium 
in Nexplanon® (Pedroso, Martins, Palma, & Machado, 2015; Sullivan, 2012). Several case reports 
noted migrated (Baek, Kim, Seo, & Kim, 2012; Park, Bae, Lee, Bae, & Park, 2017; Kew, 
Senanayake, Djearaman, & Bishay, 2017), broken (Tomás-Tello & Hodgson, 2010; Myrick, 
Howell, & Ramakrishnan, 2012; Torres, Mendes, Machado, & Marques, 2013) and bent implants 
(Doshi, 2011). Cases testified the migration of Implanon® (O’Brien, O’Reilly, Sugrue, Lawler, & 
Farrelly, 2015) and Nexplanon® (Akhtar et al. 2018)  from the insertion site to a pulmonary artery, 
which resulted in embolism. Another study established that 30% reported migration of Implanon® 
devices from their insertion site (Vidin, Garbin, Rodriguez, Favre, & Bettahar-Lebugle, 2007). A 
case report on distal migration of Implanon NXT® found 10 other cases of distal migration 
reported (Park et al. 2017), while the results from a pharmacovigilance database revealed 38 cases 
of migration of etonogestrel implants (Kang, Niak, Gada, Brinker, & Jones, 2017). The 
etonogestrel implants migrated to various locations e.g. chest wall, lung, pulmonary artery, axilla
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and other body sites (2017). Some patients reported pain, discomfort, skin reactions, pulmonary 
fibrosis and dyspnea (2017). Location failures or migrations (24%), curved or broken etonogestrel 
implants (11%) and expulsions or absence of etonogestrel implants were noted in a 
pharmacovigilance study (Simon et al. 2016). A USA study reported 23 broken or cut implant 
rods, 15 bent and nine expelled rods to an etonogestrel implant monitoring programme (Creinin 
et al. 2017). Implant device fractures were found in 70% of Nexplanon® and 26% of Implanon® 
users in a recent study (Crouthamel, Schiff, Oelschlager, Prager, & Debiec, 2018). The implant 
fractures were due to patient manipulation (23%), unintentional trauma (11%), interpersonal 
violence (8%), lifting/carrying (6%) and fracture at discontinuation (6%) (2018). The bleeding 
pattern was not altered in majority of cases (78%), indicating no significant change in effects of 
Implanon® and Nexplanon® (2018). However, a case report specified that a patient had a change 
in bleeding pattern after Implanon® had broken (Pickard & Bacon, 2002). In SA, there were 14 
cases of discontinuation reported due to broken Implanon NXT® (Pillay et al. 2017b). Evidently, 
deformities of etonogestrel implants and migration of the implant is not a rare occurrence. Drug 
interactions with etonogestrel implants has also been described in several studies and is a notable 
ADR, which is explored in the next section.  
 
2.4.2 Drug interactions 
Drug interactions are changes in a drug effect that may result in ADR or therapeutic failure 
(Lynch, 2016). There are different types of drug interactions e.g. drug-drug interactions, drug-
disease interactions and drug-laboratory test interactions. Drug-drug interactions can occur due 
to recent or concurrent use of another drug/s, which may increase or decrease the effects of one 
or both drugs (2016). “A drug–disease interaction occurs when an administered drug exacerbates 
an underlying disease in a patient.” (Lindblad, 2007). Drugs can interfere with the analytics of 
laboratory tests due to the “potential for drugs and endogenous compounds to modify the 
concentrations of various analytes in body fluids” (Young, 1997:579). The in vivo ADR of the 
drugs can also result in abnormal test results (1997).  
 
2.4.2.1 Drug-drug interactions 
Evidence exists regarding drug interactions between etonogestrel implants and concomitant 
drugs. Phenytoin, carbamazepine and phenobarbital induce microsomal enzymes in the CYP450 
pathway and increase sex hormone binding globulin levels, thereby accelerating the metabolism 
process of etonogestrel and impacting on its effectiveness (Gaffield, Culwell, & Lee, 2011). In a 
prospective study, 10 women were analysed to determine the impact of carbamazepine in 
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Nexplanon® users (Lazorwitz, Davis, Swartz, & Guiahi, 2017). There was a median percent 
decrease of 61% in etonogestrel levels for most participants between pre-carbamazepine initiation 
and post-carbamazepine initiation (2017), with 80% of participants having below effective 
etonogestrel concentrations to prevent pregnancy (<90pg/ml) (2017). Less potent CYP450 
inducers, such as Topiramate and Oxcarbazepine, alter the plasma levels of contraceptive steroids 
to a small degree (Gaffield et al. 2011). A study revealed that progesterone only contraceptives 
did not affect the serum concentration of Lamotrigine (Reimers, Helde, & Brodtkorb, 2005). 
Despite evidence of reduced effectiveness with some anticonvulsants, the WHO and Centre for 
Disease Control (CDC) recommend that they may be used concurrently with implants, as the 
advantages of using the method generally outweigh the theoretical or proven risks (WHO, 2015b; 
Curtis et al. 2016). Nonetheless, it is recommended that other contraceptives must be promoted 
in long-term users of anticonvulsants (WHO, 2015b).  
 
Rifampicin is a potent inducer of CYP3A4 and other phase I and phase II enzyme systems in the 
liver, which lowers the plasma concentrations of etonogestrel (Commonwealth of Australia, 
2007). Maximum enzyme induction generally takes two to three weeks after initiation (2007). 
Rifampicin is known to cause a 55% reduction in the area under the concentration time curve in 
pharmacokinetic drug interaction studies (Gbolade, 2010). According to the WHO and CDC, the 
advantages of using implants with rifampicin generally outweigh the theoretical or proven risks 
(WHO, 2015b; Curtis et al. 2016). It must be noted that WHO encourages the use of alternate 
contraceptives for long-term rifampicin users due to reduced effectiveness (WHO, 2015b).  
 
St John’s wort (Hypericum perforatum L.) is a herbal drug that reduces the effectiveness of 
hormonal contraceptives (UK-MHRA, 2014), with the CDC having found the following 
evidence: 
“Although clinical data are limited, studies with pharmacokinetic and 
pharmacodynamics outcomes raise concern that St. John’s wort might decrease 
effectiveness of hormonal contraceptives, including increased risk for breakthrough 
bleeding and ovulation and increased metabolism of estrogen and progestin. Any 
interactions might be dependent on the dose of St John’s wort, and the concentration 
of active ingredients across types of St. John’s wort preparations may vary” (Curtis 
et al. 2016: 49).  
Therefore, the CDC states that implants may be used in women taking St John’s Wort as 
the advantages generally outweigh the theoretical or proven risks (Curtis et al. 2016). 
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Protease Inhibitors and NNRTIs are metabolized by CYP3A4 and inhibit or induce cytochrome 
P450, resulting in respective increases or decreases in the concentration of etonogestrel (Nanda 
et al. 2017). Protease Inhibitors primarily inhibit various CYP enzymes, with most NNRTIs being 
CYP inducers (Tseng & Hills-Nieminen, 2013). Lopinavir/Ritonavir based treatment, a Protease 
Inhibitor, was associated with an increase in etonogestrel bioavailability i.e. 52% increase in 
etonogestrel area under the curve, 60.6% increase in Cmax and 33.8% increase in Cmin (Vieira 
et al. 2014). Etonogestrel may be significantly reduced in the presence of efavirenz due to 
CYP3A4 induction (Tseng & Hills-Nieminen, 2013). An article by Shelton (2015) specified that 
efavirenz accelerates normal degradation of contraceptive progestin when using the implant and 
lowers the progestin blood levels by approximately half (2015). Progestin blood levels reduce 
over time, therefore continued concomitant use of efavirenz and the implant will result in some 
loss of effectiveness and an increased risk of pregnancy (2015). A Pharmacokinetic study 
demonstrated a reduction in etonogestrel bioavailability in efavirenz users, namely a 63.4% 
decrease in area under the curve, a 53.7% decrease in maximum concentration and a 70% decrease 
in minimum concentration (Vieira et al. 2014). While similar effects may occur with nevirapine, 
which is a moderate CYP3A4 inducers, etonogestrel concentrations were found to be 82% lower 
among those on efavirenz based therapy compared to those not on ART after 24 weeks of 
treatment, with nevirapine being found not to significantly affect etonogestrel concentration 
(Chappell et al. 2017). Updated prescription guidelines, released in December 2014 for SA 
recommends that patients on long-term drugs, which are strong enzyme inducers, such as 
efavirenz, should not use implants (Republic of South Africa, National Department of Health, 
2014). These guidelines continue that patients who already have the implant inserted and are on 
long-term strong enzyme-inducing drugs should be counselled on the increased risk of pregnancy 
and may continue with the device if acceptable by the user (2014). According to the WHO, the 
advantages of using implants in efavirenz, nevirapine and ritonavir users generally outweigh the 
theoretical or proven risks (WHO, 2015b). 
 
2.4.2.2 Drug-condition interaction 
The WHO recommends that implants should not be used in those with current breast cancer and 
those with past and no evidence of current disease for five years (WHO, 2015b). WHO states that 
“Breast cancer is a hormonally sensitive tumour, and the prognosis of women with current or 
recent breast cancer may worsen with POC use.” (2015b:174). However, studies on breast cancer 
risk in progestin contraceptives revealed no association between increased risk of breast cancer 
and progestin use (Marchbanks et al. 2002; Shapiro et al. 2000; Strom et al. 2004; Backman et al. 
2005). One study in particular suggested an association of increased risk of breast cancer in 
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prolonged progestogen use in users over the age of 40 (Fabre et al. 2007). Another study found 
the same level of breast cancer risk with combined oral contraceptives (COCs) and progestin-only 
pill (Kumle et al. 2002).  
 
The WHO recommends that implants should not be used in those with acute deep vein thrombosis 
and pulmonary embolism as the risk outweigh the advantages (WHO, 2015b).  WHO details that: 
“Although evidence on the risk of venous thrombosis with the use of POCs is 
inconsistent in otherwise healthy women, any small increased risk is substantially 
less than that with COCs (134–136).” (WHO, 2015b:161). 
Poulter, Chang, Farley, Marmot, & Meirik, (1998) maintain that there is little or no increased risk 
of stroke, venous thromboembolism or acute myocardial infarction associated with the use of 
progestogen-only contraceptives. Implants are not recommended in those with unexplained 
vaginal bleeding, severe cirrhosis, benign hepatocellular adenoma and hepatoma (WHO, 2015b).  
 
2.4.2.3 Drug-laboratory interaction 
A statistically significant increase in cholesterol and triglycerides levels was observed with 
Implanon® at the end of three years, but values were still within normal range (Inal et al. 2008). 
Dilbaz, Ozdegirmenci, Caliskan, Dilbaz, & Haberal, (2010) revealed that there was a significant 
decrease in total cholesterol (TC), high-density lipoprotein cholesterol (HDL) and triglycerides 
up to six months post insertion. Olumuyiwa, Adeyemi, Adeniran, Michael, & Olatubosun (2018) 
also established that TC rose, and serum triglycerides reduced, neither being significant 
throughout their use. Moreover, their study maintained that HDL levels were significantly higher, 
and that the lower Low-density lipoprotein (LDL) were not statistically significant. In addition, 
the HDL/TC and HDL/LDL ratios were significantly higher than those at baseline. There is 
contradicting evidence on the lipid profile effect, but it is recommended that: 
“Women who are being treated for hyperlipidemia should be followed closely if they 
elect to use Implanon NXT. Some progestagens may elevate LDL levels and may 
render the control of hyperlipidemia more difficult” (Merck Sharp & Dohme, 
Australia, 2010:5). 
 
A study evaluating the haematological indices in Implanon® users concluded that it has a safe 
profile in 36 months of use (Aisien & Enosolease, 2017). The study suggested that there were no 
statistically significant changes in white blood cell concentration and packed cell volume. The 
platelet concentration rose to a statistically significant value at 36 months, but remained within 
normal concentrations (Aisien & Enosolease, 2017; Henry, McPherson, & Pincus, 2011). A 
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significant increase in Haemoglobin was noted after six months, which could be due to 
amenorrhoea (Dilbaz et al. 2010).  
 
A statistically significant increase in mean Alanin aminotransferase (ALT) level at six months 
was found with Implanon® utilisation (Dilbaz et al. 2010), the study concluding that the above 
changes would not lead to clinical issues (2010). A study by Biswas, Biswas, & Viegas, (2004) 
established a significant increase in mean total and unconjugated bilirubin and the gamma-
glutaryl transferase levels after two years of Implanon® use but remained within the normal range. 
While the ALT levels were fairly unchanged in Implanon® users (2004), the aspartate 
aminotransferase and Lactate Dehydrogenase levels increased in the first year of utilisation and 
decreased towards initial reading in the second year (2004). Alkaline phosphate levels decreased, 
but not significantly, and no significant change was found in the serum albumin levels (2004).  
 
A study on carbohydrate metabolism in etonogestrel users indicated no difference in carbohydrate 
metabolism due to Implanon after 12 months of use (Biswas, Viegas, Bennink, Korver, & 
Ratnam, 2001). Meckstroth & Darney (2004) established that there were several studies where a 
significant effect in carbohydrate metabolism was noted, but that they were small. Additionally, 
a study on biochemical and metabolic parameters found no statistically significant differences in 
user levels of fasting blood glucose, blood urea nitrogen, serum glutamic oxaloacetic 
transaminase, serum glutamic pyruvic transaminase, serum low-density lipoprotein, high-density 
lipoprotein, free 3,5,3’-tri-iodothyronine, free thyroxine and thyroid stimulating hormone after 
three years of Implanon® use (Inal et al. 2008). Another study maintained that Implanon® had no 
significant effect on thyroid function, and that there were minimal changes in cortisol levels due 
to increased sex hormone binding globulin levels (Biswas et al. 2000) This study concluded that 
the changes would not be clinically significant in healthy individuals. 
These studies therefore suggest that while Implanon® does not have a significant clinical effect 
on laboratory parameters those using Implanon®  and Implanon NXT® should be cognizant of 
potential consequence on exiting conditions. 
 
2.4.3 Discontinuation of etonogestrel implants  
It is evident from the literature that a proportion of users choose to discontinue etonogestrel 
implants as highlighted in Table 2-5. Some studies define premature Implanon® discontinuation 
as ceasing to use it within the first two and a half years of its insertion (Birhane et al. 2015; Asaye, 
Nigussie, & Ambaw, 2018; Harvey, Seib, & Lucke, 2009) while others consider this to be three 
years (Burusie, 2015; Tadesse et al. 2017). The discontinuations across regions range from  
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0-80%, indicating a wide variability in study reports. High income countries reported 
approximately a quarter of women discontinued etonogestrel implants within 12 months, except 
in the study by Berlan, Mizraji & Bonny (2016). Nigerian studies reported lower discontinuation 
rates (4.5%-26.6%) compared to those in Ethiopia (16%-80%). In African studies, approximately 
21% discontinued in studies lasting 24 months if the two outliers are discounts. An unusually 
higher discontinuation incidence was reported in SA in 24 months (Pillay et al. 2017a).  
 
Table 2-5: Summary of studies reporting discontinuation of etonogestrel implants  
 
Percentage of 
discontinuation 
(%) 
Total 
number of 
women  
Approximate 
duration of 
use (months) 
Region Reference 
80.0 100 30 Ethiopia Burusie (2015) 
68.9 1397 48 UK Cea Soriano, Wallander, 
Andersson, Filonenko, and 
García Rodríguez (2015) 
65.0 4492 30 Ethiopia Asaye et al. (2018) 
47.0 149 36 Australian Weisberg, Bateson, 
McGeechan, and 
Mohapatra (2014) 
46.5 314 36 Ethiopia Siyoum, Mulaw, Abuhay, 
& Kebebe (2017) 
44.8 69 36 Jordan Al-Jefout et al. (2015) 
40.1 152 24 SA Pillay et al. (2017a) 
37.0 200 36 India Bhatia et al. (2011) 
35.0 942 24-48 USA, Chile, Asia, 
Europe 
Darney et al. (2009) 
35.0 116 36 USA Obijuru, Bumpus, Auinger, 
and Baldwin (2016) 
34.9 356 36 Spain Arribas-Mir et al. (2009) 
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27.2 110 12 India Singh et al. (2015) 
26.8 381 12 Australia, Finland, 
UK, France, Norway, 
Sweden 
Apter et al. (2016) 
26.6 121 48 Nigeria Madugu, Abdul, Bawa, and 
Kolawole (2015) 
24.0 14938 12 USA Law, Liao, Lin, Yaldo, and 
Lynen (2018) 
23.7 991 12 Switzerland Bitzer et al. (2004) 
23.0 140 36 Malaysia Mastor et al. (2011) 
22.6 190 12 UK Smith and Reuter (2002) 
21.7 304 24 Egypt Aziz, El-Gazzar, & 
Elgibaly, (2018) 
21.4 295 24 Nigeria Ezegwui, Ikeako, 
Ishiekwene, and Oguanua, 
(2011) 
16.0 244 30 Ethiopia Birhane et al. (2015) 
13.0 200 24 China Zheng et al. (1999) 
10.3 750 12 USA Berlan et al. (2016) 
7.0 1366 6 USA Grunloh, Casner, Secura, 
Peipert, and Madden (2013) 
5.4 168 48 Nigeria Ojule et al. (2012) 
4.5 669 24 Nigeria Muthir and Nyango (2010) 
0 44 12 Brazil Guazzelli et al. (2010) 
SA=South Africa, UK=United Kingdom, USA=United States of America 
 
The number of women discontinuing Implanon® increased over time, as noted in an Australian 
study, which described the following proportions: 26.3% at one year, 49.7% at two years and 
87.3% at three years (Harvey et al. 2009). A SA study reported higher proportions of Implanon 
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NXT® discontinuations over time, with 27.2% doing so within six months, 67.3% in 12 months 
and 94.4% after 24 months (Mrwebi et al. 2018).  
In an Ethiopian study (Siyoum et al. 2017) and Nigerian study (Muthir & Nyango, 2010), 
discontinuation of Implanon® commenced as early as two weeks post insertion. The average 
duration of use ranged from 6.6 months to 27 months across studies as shown in Table 2-6. The 
median duration of use was reported in the first year of use for half of the studies and in the second 
year for the rest of etonogestrel implant studies. Two SA studies reported that discontinuers used 
Implanon NXT® for a median of 8-10 months (Mrwebi et al. 2018; Pillay et al. 2017a). There is, 
therefore, a trend in the literature of premature discontinuation of etonogestrel implants.  
 
Table 2-6: Summary of studies reporting median and mean duration of etonogestrel 
implant use  
 
Median duration of use 
(months) 
Mean duration of use 
(months) 
References 
23.5  Obijuru et al. (2016) 
19.5  Burusie (2015) 
12.0  Siyoum et al. (2017) 
10.0  Mrwebi et al. (2018) 
8.0  Pillay et al. (2017a) 
 27.0 Pam et al. (2014) 
 Approximately 24.0 Darney et al. (2009) 
 24.0 Mastor et al. (2011) 
 21.5 Asaye et al. (2018) 
 Approximately 20.0 Law et al. (2018) 
 13.4 Muthir and Nyango (2010) 
 11.2 Mrwebi et al. (2018) 
 9.2 Bitzer et al. (2004) 
 7.5 Berlan et al. (2016) 
 6.6 Birhane et al. (2015) 
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Some factors that influence discontinuation are inconsistent in the literature such as past 
pregnancy as one study found that no previous pregnancy was associated with discontinuation 
(Siyoum et al. 2017) whereas another found that it was (Berlan et al. 2016). In the USA, 
participants who had a prior pregnancy/delivery were more likely to discontinue their implant 
compared to those who did not (p<0.001) (Law et al. 2018). Contradictory evidence was also 
found regarding the number of children (Asaye et al. 2018; Tadesse et al. 2017) and level of 
education (Siyoum et al. 2017; Tadesse et al. 2017) associated with discontinuation. It was clear 
that those who had no counselling or follow-up was associated with greater odds of 
discontinuation (Asaye et al. 2018; Siyoum et al. 2017; Birhane et al. 2015). Age appears to 
influence discontinuation, with young age at insertion being associated with greater odds of 
discontinuation (Tadesse et al. 2017). In a UK study, younger Implanon® users had a greater risk 
of discontinuation (Smith & Reuter, 2002). Conversely in a USA study, participants aged 20-24 
years old and 25-44 years old were more likely to discontinue the etonogestrel implant within one 
year of insertion compared to 15-19-years old (Berenson, Tan, & Hirth, 2015). In an Australian 
study, the clinic where Implanon® was inserted influenced discontinuation as those who attended 
regional clinics experienced significantly shorter time to discontinue than those who attended 
metropolitan clinics (Harvey et al. 2009). Additional factors found to be associated with greater 
odds of discontinuation include: medical care sought for implant concerns (Berlan et al. 2016), 
history of abortion (Tadesse et al. 2017) and perceived satisfaction (Siyoum et al. 2017; Birhane 
et al. 2015). Other factors, such as religion, counselling about benefit, counselling effectiveness, 
age, residence, parity, main decider, telephonic consultations and source of information, were 
tested for association but were not statistically significant.  
 
Those who experienced ADRs were established to have greater odds of discontinuation than those 
who did not (Asaye et al. 2018; Siyoum et al. 2017; Birhane et al. 2015). Contrary to the trend, 
Tadesse et al. (2017) found that ADRs were not significantly associated with discontinuation. 
Specific ADRs, such as headache, bleeding and weight gain, were not significant factors for 
discontinuation in one study (Birhane et al. 2015). Obese women were to be found 2.6 times less 
likely to discontinue etonogestrel implant for bleeding than overweight and normal weight women 
(Casey et al. 2013). However, Burusie (2015) offered that participants who complained of 
heavy/prolonged menstrual bleeding were significantly more likely to discontinue prematurely 
than for other reasons. Additionally, Berenson et al. (2015) reported that etonogestrel implant 
users were more likely to discontinue their devices within 30 days of visiting their doctor after 
reporting abnormal bleeding. Harvey et al. (2009) suggested that metropolitan women were 
significantly more likely to discontinue Implanon® use because of dissatisfaction with altered 
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bleeding patterns while, regional women cited multiple reasons for discontinuing. It appears that 
factors affecting discontinuation may be region or patient specific, as studies are not consistent. 
 
2.4.4 Reasons for discontinuation of etonogestrel implants 
The major reason for discontinuation of etonogestrel implants were due to ADRs as affirmed in 
both global and local studies (Lakha & Glasier, 2006; Asaye et al. 2018; Pillay et al. 2017a; 
Mrwebi et al. 2018). Possible reasons for discontinuation are offered in an international 
qualitative study, which proposed that some participants endured ADRs for a period of time but 
resorted to discontinuation due to their intolerability (Lunde et al. 2017). Multiple ADRs could 
have also played a role in discontinuation (Pillay et al. 2017a), another possible reason being that 
bleeding irregularities and reduced libido affected the participants sex life (Inoue et al., 2016, 
Pillay et al., 2017a). The negative experiences of ADRs on women’s relationships and finances 
led to discontinuation in some cases (Flore et al. 2016). The ADRs that led to etonogestrel implant 
discontinuation are summarized in Table 2-7. 
 
All studies displayed in Table 2-7, irrespective of region, reported bleeding changes, which led 
to discontinuation. A scoping review confirmed that contraceptive induced menstrual bleeding 
changes was the main cause, or one of the main causes, for discontinuation (Polis et al. 2018). 
The irregular bleeding pattern ranged from 0.3%-44.39%, and menorrhagia ranged from 3.7-
12.4%. A study conducted in the Netherlands endorsed that irregular bleeding was associated with 
the shortest duration of use of Implanon® (Teunissen et al. 2014), with amenorrhoea ranging from 
0.07-4.5%. There was a wide variability across regions, which was also acknowledged by Darney 
et al. (2009) who held that regional differences could be due to cultural and social factors. They 
also speculated that acceptability of ADRs plays a role in discontinuation, as those frequently 
reported may not be the same as those leading to discontinuation. Bleeding irregularities and 
weight gain were the main reasons for discontinuation in a French study, but other ADRs, though 
frequent, were not often a reason (Sergent, Clamageran, Bastard, Verspyck, & Marpeau, 2004).  
 
Weight increase was a commonly reported ADR, as shown in Table 2-4, with a low percentage 
of women discontinued due to weight increase. Some African studies reported a higher percentage 
of women who discontinued due to weight increase compared to regions outside Africa. Multiple 
ADR, as mentioned earlier in this section, in addition to weight gain, could have resulted in 
increased reports, as indicated by a participant in Pillay et al. (2017a:819). “At first it was fine, 
but now I’m experiencing headache, bleeding and I’m also gaining weight, so I want to remove 
it now”. It can be argued that perception of weight increase is patient specific, with Muthir and 
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Nyango (2010) reporting that an average weight increase of only 1.9 kg was observed from time 
of insertion to discontinuation.  
 
Almost all studies in Africa revealed headache as a reason for discontinuation, with a SA study 
reporting the highest percentage. The following quote from Pillay et al. (2017a:819) highlights 
that poor tolerability and severity of headaches was influential: 
“These were described as ‘constant headaches’ and ‘headaches every day’. One 
woman said: It was fine in the beginning, but then as the months went by it [the 
implant] started to cause me severe migraines.”  
 
Acne was a commonly reported reason for discontinuation in studies outside Africa, but the 
percentages were low (range 0.3-5.2). Low reporting of acne as a reason for discontinuation could 
be due to a small proportion of women reporting worsening of acne as expressed earlier in this 
chapter (Funk et al. 2005).  
 
Compared to other global studies, African studies reported pain at insertion site more frequently, 
particularly in Ethiopia. Counselling and management may be lacking in Ethiopia, as Burusie 
(2015) recommended reassurance and pain management for those experiencing pain. Another 
possible reason for pain being due to poor insertion techniques. Studies outside Africa reported 
emotional lability, depression and low sex drive, which were absent in the studies from Africa. 
Darney et al. (2009) implied that emotional lability, depression and abnormal sexual function 
were more frequently reported reasons for discontinuation in USA sites compared to non-USA 
sites, implying there may be a regional difference. A notable reason for discontinuation in SA 
was due to pregnancy, but the proportions were low, with pregnancy and causes of pregnancy 
being elaborated later in the chapter. There were several other ADR related reasons for 
discontinuation reported such as pelvic pain (Sznajder et al. 2017), back pain (Singh et al. 2015), 
breast tenderness (Ezegwui et al. 2011) and tiredness (Smith & Reuter, 2002).  
 
Desire to conceive was the most common non-ADR reason for discontinuation, being endorsed 
in all studies in Tables 2.8. A study conducted in the Netherlands reported that desire to conceive 
was associated with a short duration of Implanon® use (18.9 months) (Teunissen et al. 2014). 
Blumenthal, Gemzell-Danielsson, and Marintcheva-Petrova (2008) maintained that 
discontinuation due to desire to conceive was more frequent in the second and third year compared 
to the first year. There is a small range 0.2-12.4% for desire to conceive observed in studies 
outside Africa. Ezegwui et al. (2011) attested that desire to conceive was reported as prematurely 
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as between six months and one-year post insertion, and Aziz et al. (2018) explained that the desire 
to conceive was common after the first year of usage. The highest percentages for discontinuation 
due to desire to conceive was evident in Nigerian studies. It was suggested by Muthir and Nyango 
(2010) that Implanon® was viewed as a temporary method (73.3%), and that the average duration 
of use in these women was one year.  
 
In African studies, a prominent reason for discontinuation was husband opposition, which was 
absent in studies outside the continent. Nevertheless, an Implanon® qualitative study conducted 
in Australia proved that partner disapproval influenced decision to discontinue (Inoue et al. 2016). 
Another qualitative study conducted in Ethiopia validated that some women did not tell their 
husbands about using the implant due to pressure from husbands to continue having children 
(Zerihun et al. 2015). A quarter of women in a study conducted in Spain claimed full-term use of 
Implanon® (Arribas-Mir et al. 2009), whereas studies from Africa implied small percentages 
reaching expiry in Implanon® (Pam et al. 2014) and Implanon NXT® users (Mrwebi et al. 2018). 
Arribas-Mir et al. (2009) suggested that the low premature discontinuation rates in the study could 
be related to the high quality of pre-insertion counselling, which included information on possible 
ADRs and their high acceptability by the women.  
 
The health practitioner also plays an essential role in discontinuation, with two African studies 
indicating that provider advice was a reason for discontinuation, but with low percentages. Aziz 
et al. (2018) justified that practitioners advised discontinuation unnecessarily and due to 
complaints unrelated to Implanon®. There appears to be various reasons for discontinuation in 
Africa compared to outside the continent e.g. request by mother-in-law, religious opposition, 
rumors and on concomitant treatment. According to a qualitative Ethiopian study, additional 
reasons for discontinuation were: declined productivity, health problems, peer pressure, myths 
and interference with work/daily activity (Zerihun et al. 2015). Community members and 
religious leaders also influenced discontinuation decision, as myths about Implanon® led to hasty 
withdrawal and negative perceptions (2015).  
A study conducted on the influence of age on reasons for implant discontinuation revealed no 
statistically differences (López del Cerro et al. 2018). From the literature in Tables 2-7, there is 
no distinct trend in age as reasons for discontinuation due to ADR.  
Contraceptive method failure and pregnancy were notable reasons for discontinuation and will be 
discussed in detail in the next section.  
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Table 2-7: Summary of studies reporting adverse drug reactions as reasons for 
etonogestrel implant discontinuation  
 
ADR Percentage 
(%)1 
Region Reference 
Menstrual 
changes 
60.7 SA Pillay et al. (2017a)  
4.2-33.3 Nigeria Pam et al. (2014); Ezegwui 
et al. (2011);Muthir and 
Nyango (2010) 
4.5-26.7 Ethiopia Birhane et al. (2015); 
Siyoum et al. (2017); 
Asaye et al. (2018) 
21.6 Australia Harvey et al. (2009) 
14.4 Switzerland Bitzer et al. (2004) 
6.7-13.4 USA Berlan et al. (2016);  
Sznajder, Tomaszewski, 
Burke, and Trent (2017) 
7.4-13 UK Smith and Reuter 
(2002);Lakha and Glasier 
(2006) 
12.9 Malaysia Mastor et al. (2011)  
11.5 Australia, Finland, France, Norway, 
Sweden, UK 
Apter et al. (2016) 
 
11.1 USA, Chile, Asia,Europe Darney et al. (2009) 
11.0 Europe Short, Dallay, Omokanye, 
Stauch, & Inki (2014) 
Emotional 
lability 
2.3 USA, Chile, Asia, Euroupe Darney et al. (2009) 
0.9 USA Berlan et al. (2016) 
Weight increase 1.7-13.3 Nigeria Pam et al. (2014);Muthir 
and Nyango (2010) 
 
13.1 SA Pillay et al. (2017a)  
 
2.0-5.8 Ethiopia Birhane et al. (2015); 
Siyoum et al. (2017); 
Asaye et al. (2018) 
0.3-5 US Grunloh et al. (2013); 
Berlan et al. (2016); 
Sznajder et al. (2017) 
2.6-4.3 UK Smith and Reuter (2002); 
Lakha and Glasier (2006) 
2.3 Switzerland Bitzer et al. (2004) 
2.3 USA, Chile, Asia,Europe Darney et al. (2009) 
1.8 Australia, Finland,France,Norway, 
Sweden,UK 
Apter et al. (2016) 
 
1.7 Australia Harvey et al. (2009) 
1.3 Egypt Aziz et al. (2018) 
0.9 Europe Short et al. (2014) 
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Headache 39.9 SA Pillay et al. (2017a)  
1.9-10.5 Ethiopia Siyoum et al. 
(2017);Birhane et al. 
(2015); Burusie (2015); 
Asaye et al. (2018) 
0.5-6.7 Nigeria Pam et al. (2014); Muthir 
and Nyango (2010) 
3.7 UK Smith and Reuter (2002) 
1.6 USA, Chile,Asia, Europe Darney et al. (2009) 
1.0 Egypt Aziz et al. (2018) 
0.5-0.7 USA Grunloh et al. (2013); 
Berlan et al. (2016) 
Acne 5.2 Australia, 
Finland,France,Norway,Sweden,UK 
Apter et al. (2016)  
 
3.8 Switzerland Bitzer et al. (2004) 
3.3 Nigeria Muthir and Nyango 
(2010) 
2.6 Euopre Short et al. (2014) 
1.6 UK Smith and Reuter (2002) 
1.3 USA, Chile, Asia, Europe Darney et al. (2009) 
0.3-0.4 USA Grunloh et al. (2013); 
Berlan et al. (2016) 
Depression 1.7 Switzerland Bitzer et al. (2004) 
1.6 UK Smith and Reuter (2002) 
1.0 USA, Chile, Asia, Europe Darney et al. (2009) 
Changes in 
mood 
9.5 Nigeria Ezegwui et al. (2011) 
3.4 UK Lakha and Glasier (2006) 
2.9 Ethiopia Siyoum et al. (2017) 
2.5 Australia Harvey et al. (2009) 
0.3-2.5 USA Grunloh et al. (2013); 
Sznajder et al. (2017) 
1.6 Australia, 
Finland,France,Norway,Sweden,UK 
Apter et al. (2016) 
Irregular 
bleeding 
44.4 Nederlands Teunissen et al. (2014) 
10.0 India Bhatia et al. (2011);Singh 
et al. (2015) 
6.7 Nigeria Muthir and Nyango (2010) 
3.7 USA Grunloh et al. (2013) 
0.3 Australia, Finland, France, Norway, 
Sweden,UK 
Apter et al. (2016) 
Amenorrhoea 4.5 India Bhatia et al. (2011) 
1.1 Spain Arribas-Mir et al. (2009) 
0.1 USA Grunloh et al. (2013) 
Menorrhagia 12.4 Spain Arribas-Mir et al. (2009) 
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10.0 Nigeria Muthir and Nyango (2010) 
3.7 Australia, Finland, France, Norway, 
Sweden,UK 
Apter et al. (2016) 
3.4 India Singh et al. (2015) 
Heavy/prolonged 
bleeding 
60.7 SA Pillay et al. (2017a) 
36.0 Ethiopia Burusie (2015) 
Pain in arm 7.3-15.1 Ethiopia Siyoum et al. (2017); 
Burusie (2015);  
Asaye et al. (2018) 
6.3 Nigeria Ezegwui et al. (2011) 
3.0 Egypt Aziz et al. (2018) 
1.1 UK Smith and Reuter (2002) 
0.3 USA Grunloh et al. (2013) 
Abdominal pain 1.1 UK Smith and Reuter (2002) 
0.4 USA Berlan et al. (2016) 
Low sex drive 1.3 Australia, Finland, France, Norway, 
Sweden,UK 
Apter et al. (2016) 
 1.1 UK Smith and Reuter (2002) 
Prolonged 
bleeding 
16.7 Nigeria Muthir and Nyango (2010) 
9.9 Egypt Aziz et al. (2018) 
6.36 India Singh et al. (2015) 
Pregnancy 1.6-5.3 SA Pillay et al. (2017a); 
Mrwebi et al. (2018)  
ADR=Adverse drug reaction, SA=South Africa, UK=United Kingdom, USA=United States of America 
1 Calculated as reason for discontinuation/Total women  
 
Table 2-8: Summary of studies reporting common non-adverse drug reaction reasons for 
etonogestrel implant discontinuation  
 
Reason for 
discontinuation 
Percentage 
(%)1 
Region Reference 
Desire to conceive 16.0-42.9 Nigeria Pam et al. (2014); 
Muthir and Nyango (2010); 
Ezegwui et al. (2011) 
6.2-24 Ethiopia Tadesse et al. (2017); 
Birhane et al. (2015) ; 
Siyoum et al. (2017); Asaye 
et al. (2018); Burusie (2015)
  
12.4 Spain Arribas-Mir et al. (2009) 
 
7.1 Malaysia Mastor et al. (2011) 
7.0 Netherlands Teunissen et al. (2014). 
 
4.3-4.9 SA Mrwebi et al. (2018); Pillay 
et al. (2017a) 
3.6 Switzerland Bitzer et al. (2004) 
 
0.2-3.4 USA Sznajder et al. (2017) 
Grunloh et al. (2013) 
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3.4 Australia Harvey et al. (2009) 
 
3.0 Egypt Aziz et al. (2018) 
3.0 Europe Short et al. (2014) 
 
1.5-2.1 UK Lakha and Glasier (2006); 
Smith and Reuter (2002) 
1.0 Australia, Finland, 
France, Norway, 
Sweden,UK 
Apter et al. (2016)  
0.9-1.0 India Singh et al. (2015); Bhatia et 
al. (2011) 
Patient or partner 
sterilized 
2.9 Malaysia Mastor et al. (2011)  
1.1 UK Smith and Reuter (2002) 
Chose to switch to 
another 
contraceptive 
12.2 Netherlands Teunissen et al. (2014) 
11.9 Nigeria Pam et al. (2014)  
4.5 Ethiopia Birhane et al. (2015) 
3.0 Europe Short et al. (2014) 
1.4 Malaysia Mastor et al. (2011)  
Continuation with 
new implant 
39.3 Spain Arribas-Mir et al. (2009) 
25.2 Switzerland Bitzer et al. (2004) 
Contraception no 
longer required 
3.3 Nigeria Muthir and Nyango (2010)
  
2.1 Australia Harvey et al. (2009) 
2.0 Egypt Aziz et al. (2018) 
1.1 Spain Arribas-Mir et al. (2009) 
0.9 Nigeria Pam et al. (2014)  
0.1 US Grunloh et al. (2013) 
Partner opposition 2.5-9.2 Ethiopia Birhane et al. 
(2015);Tadesse et al. (2017); 
Asaye et al. (2018)  
1.8-6.7 Nigeria Pam et al. (2014); Muthir 
and Nyango (2010) 
Method failure 3.3 Nigeria Muthir and Nyango (2010)
  
0.8 Ethiopia Birhane et al. (2015) 
Inconvenience 1.2-8.8 Ethiopia Birhane et al. (2015); 
Tadesse et al. (2017) 
Religious 
opposition 
0.8-3.8 Ethiopia Birhane et al. (2015); 
Tadesse et al. (2017) 
Divorce/no longer 
in relationship 
3.3 Nigeria Muthir and Nyango (2010)
  
2.0 Ethiopia Asaye et al. (2018) 
0.3 UK Lakha and Glasier (2006) 
Husband travelling 1.6 Egypt Aziz et al. (2018) 
1.4 Ethiopia Asaye et al. (2018)  
Discontinued due to 
implant expiry 
25 Spain Arribas-Mir et al (2009) 
4.2 Nigeria Pam et al. (2014) 
1.1 SA Mrwebi et al. (2018) 
SA=South Africa, UK=United Kingdom, USA=United States of America 
1  Calculated as reason for discontinuation/total women
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2.4.5 Contraceptive method failure 
Contraceptive failure is defined as: 
“a conception that occurred during a month in which a woman (or her partner) was 
using a contraceptive method, as long as she did not report that she (or he) had 
stopped use before having become pregnant” (Fu, Darroch, Haas, & Ranjit, 
1999:57).  
In the developing world, 30% of the 74 million unwanted pregnancies that occur annually are due 
to failure of traditional or modern contraceptive methods (Polis et al. 2016), with Implanon® being 
a highly efficacious modern contraceptive, with a 0.05% failure rate in typical and perfect use 
(Trussell, 2011).  
 
The Pearl Index is used to report efficacy and is calculated using the “expected number of 
pregnancies per100 woman-years of exposure” (Darney et al. 2009:1648). A woman year is 
defined as “a period of 365.25 days and this is the equivalence of roughly 13 cycles” (Pam et al. 
2014:93).  A study by Darney et al. (2009) on an Implanon® clinical trial study reported that: six 
pregnancies occurred during the clinical trials, resulting in a 0.38 cumulative Pearl Index. The 
pregnancies occurred within two weeks of discontinuation of Implanon® and, according to the 
FDA, any pregnancy within this time of a hormonal method is considered contraceptive method 
failure. The manufacturing company recorded 1 688 spontaneous pregnancies over a nine-year 
period, therefore resulting in a post-marketing Pearl Index of 0.024, which was based on voluntary 
reports. Additionally, the clinical trial did not include participants who weighed more than 130% 
of their ideal body weight and who were using enzyme inducing drugs, these variables having 
been shown to affect Implanon® efficacy. The incidence of reported pregnancies in a study by 
Bensouda-Grimaldi, Jonville-Bera, Beau-Salinas, Llabres, and Autret-Leca (2005) is estimated to 
be 0.359/103 implants, and the estimated Pearl Index was 0.06. The approximate failure rate in 
the post-marketing phase in Australia is 0.1%, or 1 in 1000 insertions (Harrison-Woolrych & Hill, 
2005). Similarly, the contraceptive method failure rate in the USA monitoring program was 
0.17%  (Creinin et al. 2017). The incidence of pregnancy in studies from Africa was low as shown 
in Table 2-9 (Tadesse et al. 2017; Pam et al. 2014; Muthir & Nyango, 2010) with the exception 
of Patel et al. (2015) who reported a total of 86 pregnancies in their study. The average time of 
onset of pregnancy in a French post-marketing study (n= 104) was 13 months (median 10.7 
months) (Simon et al. 2016). Three pregnancies occurred in the first year of etonogestrel implant 
use and three in the second year in a USA monitoring program (Creinin et al. 2017).  
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Evidence from the literature in Table 2-9 indicates that pregnancies with etonogestrel implants 
can be due to reasons other than true contraceptive method failure. A notable reason for 
pregnancy, as established in several studies, was pregnancy prior to insertion. Practitioner-related 
reasons for pregnancy, such as insertion technique failure, and untimely insertion (Bensouda-
Grimaldi et al. 2005; Harrison-Woolrych & Hill, 2005), were also cited. User-dependent reasons 
for pregnancy were noted in only two cases and included improper use of implant (Creinin et al. 
2017) and unprotected sexual intercourse practiced in the first week of insertion (Obijuru et al. 
2016). In studies from Africa, pregnancy was due to drug interaction, contraceptive method 
failure and pregnancy prior to insertion as highlighted in Table 2-9 Tadesse et al. 2017; Pam et 
al. 2014; Muthir & Nyango, 2010; Patel 2015).  
One of the most common reasons for pregnancy was due to drug interaction with antiepileptics, 
ARVs, antituberculosis and St. John's wort (Simon et al. 2016, Harrison-Woolrych & Hill, 2005). 
While some studies have reported pregnancy in etonogestrel implant use (Olowu, Karunaratne, 
& Odejinmi, 2011; Rezai et al. 2018; Bouquier et al. 2012), others have particularly reported on 
failure of Implanon® in patients using efavirenz based therapy (Matiluko et al. 2007; Leticee, 
Viard, Yamgnane, Karmochkine, & Benachi, 2012; McCarty, Keane, Quinn, & Quah, 2011; 
Lakhi & Govind, 2010). Patel et al. (2015) revealed a three times higher risk of implant 
contraceptive failure in efavirenz than nevirapine users.  
 
Implanon NXT® efficacy may be affected by body mass index (BMI) however, there are 
contradicting arguments on this issue. The etonogestrel plasma levels is inversely related to body 
weight hence variations in serum concentration levels is possibly due to differences in body 
weight (Merck Sharp & Dohme, Australia, 2010). Creinin et al. (2017) suggested that BMI may 
influence failure and reported failure in one patient who was normal weight, two who were 
overweight and two who were obese. However, these results are insufficient to make a conclusion 
about possible effect of BMI on Implanon NXT® effectiveness. Xu et al. (2012) commented that 
one unwanted pregnancy over 1377 women-years resulted in an overall cumulative implant 
failure rate of 0.00 per 100-woman years, and 0.23 per 100-woman years in obese patients (2012). 
Mornar et al. (2012) also established that the estimated etonogestrel exposure for obese women 
in a three-year period was found to be 40% lower than in those of normal weight. Projected plasma 
concentrations at one, two and three years after device insertion in the obese women were 133, 
102, and 98 pg/mL respectively (2012). The projected etonogestrel concentrations for the third 
year was still above 90 pg/ml, which is an effective concentration to suppress ovulation. It is 
therefore evident that increased weight could be a factor in the contraceptive failure due to 
Implanon NXT®. 
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Table 2-9: Possible causes of pregnancy in etonogestrel implant use 
 
Possible cause Frequency (n) References  
 
Drug interaction 59 Simon et al. (2016) 
57 Patel et al. (2015) 
32 Australian Government (2010) 
32 Commonwealth of Australia 
(2007) 
8 Harrison-Woolrych and Hill 
(2005) 
4 UK-MHRA (2014) 
2 Bensouda-Grimaldi et al. (2005) 
2 Lakhi and Govind (2010) 
2 Leticee et al. (2012) 
1 Gbolade (2010) 
1 Lange, Teal, and Tocce ( 2014) 
1 Matiluko et al. (2007) 
1 McCarty et al. (2011) 
1 Patni, Ebden, Kevelighan, and 
Bibby (2006) 
1 Schindlbeck, Janni, and Friese 
(2006) 
Method failure 13 Harrison-Woolrych and Hill 
(2005) 
6 Creinin et al. (2017) 
6 Darney et al. (2009) 
2 Boucoiran, 
Trastour,Faraj,Delotte and 
Bongain (2011) 
2 Tadesse et al. (2017) 
1 Bensouda-Grimaldi et al. (2005) 
1 Muthir and Nyango (2010) 
1 Pam et al. (2014) 
Insertion technique failure 203 Simon et al. (2016) 
84 Harrison-Woolrych and Hill 
(2005) 
30 Bensouda--Grimaldi et al. (2005) 
Pregnant prior to insertion 71 Simon et al. (2016) 
46 Harrison-Woolrych and Hill 
(2005) 
6 Pam et al. (2014) 
4 Creinin et al. (2017) 
3 Robinson, Register, Ebner, and 
Orr (2015) 
2 Bahamondes et al. (2015) 
2 Muthir and Nyango (2010) 
2 Obijuru et al. (2016) 
2 Sznajder et al. (2017) 
1 Cooling and Pauli (2006) 
1 Devonald (2006) 
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2.5. Challenges reported with the use of Implanon NXT® in South Africa 
There are some specific challenges that have emerged regarding the use of Implanon NXT®  in 
SA. 
2.5.1 Training of health practitioners 
Insufficient training of health practitioners on Implanon NXT® has been emphasized in a SA 
study, with the following excerpts from Adeagbo et al. (2017:823) concisely capturing the 
severity of the lack of training:  
“We were only trained for two days. I feel like the training was not sufficient. I think 
I need intense trainings in order for me to deliver the service effectively.” 
(Professional nurse H, DKKD) 
“We had some trainings and we were shown how to insert and remove the implant and 
each clinic was expected to do that. It was like a once-off thing” (Professional nurse E, 
CoJ) “I was trained by another professional nurse, I would really not call it a proper 
training honestly”  
Health practitioners felt ill-equipped to provide the method to patients, which directly 
affected the quality of service due to insufficient knowledge, poor skills and lack of 
understanding of the insertion method (2017). Practitioners were weary to perform the 
procedure due to concerns about complications, concern about the time it would take, and 
the impact of these aspects on their daily duties (2017). Special training on insertion and 
discontinuation is suggested to ensure a steady release of etonogestrel and a smooth 
discontinuation (Lee, 2010). 
 
Training on drug interactions has also been identified as an added concern (Pleaner et al. 2017), 
while Lince-Deroche et al. (2016) reported the lack of understanding on drug-drug interactions 
and concerns about appropriateness of method for women. An ongoing qualitative study from the 
Western Cape Province revealed that health practitioners are concerned about inserting implants 
in all HIV positive patients, regardless of their treatment status (Patel et al. 2017). Additionally, 
a lack of understanding about and difficulty communicating information on drug interactions to 
patients, and the potential negative medical and legal outcomes from concomitant use, have been 
raised as practitioner concerns (2017). This has resulted in unnecessary discontinuation or 
practitioners not offering the method (Pleaner et al. 2017).  
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2.5.2 Counselling of implanon NXT® users 
A challenge for practitioners was counselling patients, which was found to be inadequate 
(Adeagbo, 2017). This was expressed by Potgieter et al. who provided evidence that: 
“Poor communication and reluctance from clinic staff to discuss ImplanonNXT® 
during antenatal visits contributed to poor knowledge about the implantable device 
and its side effects” ( 2018:174).  
 
According to the contraception counselling guidelines, method-specific counselling should 
include: common ADRs, how to use the method, when and why to return for follow-up, and when 
the use of dual protection was appropriate (Republic of South Africa, National Department of 
Health, 2013). Pillay et al. (2017a) noted that less than half of users and discontinuers were 
counselled on the effectiveness of Implanon NXT®, its safety, palpability and preventing STIs at 
the initial consult. Approximately half of the women in the same study were counselled on its 
ADRs and when to return for discontinuation, and approximately two thirds were counselled on 
duration of use (2017a). Similarly, in Ethiopia, not all women were counselled on ADR, the 
benefits of Implanon®, and the duration of its action and effectiveness (Siyoum et al. 2017; 
Birhane et al. 2015; Asaye et al. 2018). A study conducted in a Brazil investigated the effect of 
counselling styles on discontinuation rates and revealed that routine counselling is adequate to 
help reduce premature discontinuation rates (Modesto, Bahamondes, & Bahamondes, 2014). A 
study investigating different counselling styles found a majority in both groups felt they received 
enough information, and most were happy with their decision (Rubenstein, Rubenstein, Barter, & 
Pittrof, 2011). The “cautious” group had higher continuation rates at one year (96%) compared to 
the “just try it” group (80%) (2011). It appears that different counselling styles could be adopted 
in practice to achieve high continuation rates.  
 
An additional challenge is the health practitioners’ negative attitudes towards the method, which 
is concerning, as it could interfere with counselling patients (Adeagbo et al. 2017). The following 
excerpt from Adeagbo et al. sheds light on practitioner’s perception of Implanon NXT®: 
“To tell you the truth, lately, I hardly suggest Implanon unless a client wants it” 
(Professional nurse H, DKKD) “I wouldn’t go for it. I would stick to the known 
method – the pill or the injection. They’ve been around forever … I don’t think it’s 
[Implanon NXT] working, honestly, because of the removals we are doing and they 
[users] will tell you that they will never go for this method again” (Professional 
nurse B, DKKD)(2017:825) 
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Nurses plays a central role in contraceptive choice, provision and continuation in the public health 
sector in SA (Lince-Deroche et al. 2016) hence counselling of Implanon NXT® is a crucial gap in 
the implementation and success of Implanon NXT®.  
 
2.5.3 Management of adverse drug reactions  
Managing ADRs has been identified as a challenge for health practitioners in SA (Adeagbo et al. 
2017), with those experiencing ADRs having reportedly opted for discontinuation due to 
inefficient treatment options (2017). While there were no standardized guidelines for ADR 
management prior to 2018, the SA Standard Treatment Guideline 2018 recommends oral 
contraceptives for breakthrough bleeding (Republic of South Africa, National Health Department, 
2018b). However, Pillay et al. (2017a) identified that oral contraceptives to treat bleeding only 
provided short-term relief, therefore there may still be a gap in the management of menstrual 
ADRs. Other options to manage frequent and/or prolonged bleeding may be the use of 
mifepristone plus ethinyl estradiol and doxycycline alone (Weisberg et al. 2006). An algorithm 
for treating prolonged, frequent and/or menorrhagia with Implanon® was proposed by Adams and 
Beal (2009). It includes using bleeding diaries and treatment with COC or low dose oestrogen or 
doxycycline or non-steroidal anti-inflammatory drugs (2009). Another area of concern is that 
there is still no recommended management of non-menstrual ADR of Implanon NXT® in SA, 
except for pain after insertion (Republic of South Africa, National Department of Health, 2018b). 
The challenges and barriers related to usage of Implanon® are not well known (Prosad, 
Mashamba-Thompson, & Ojewole, 2018) hence S Prosad is undertaking a scoping review, which 
is aimed at mapping evidence on patients’ challenges and barriers linked to its use.  
 
2.6 Conclusion 
This chapter provided a detailed description of etonogestrel implants including Implanon NXT®, 
contextualized the experiences related to their use, and described the challenges reported in SA 
in particular. This literature review demonstrated that ADRs, discontinuation and failure with 
etonogestrel implants including Implanon NXT® are problematic globally. Although experiences 
are common, SA possesses contextually unique reasons for the use and discontinuation of 
Implanon NXT® related to disease profile and cultural factors. There is no definite trend about 
ADR profiles, specifically bleeding patterns. A significant proportion of etonogestrel implant 
failure is due to technique and prescribing issues. It was also acknowledged that there is a paucity 
of evidence on women’s experiences regarding Implanon NXT® in SA compared to etonogestrel 
implant studies globally. 
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CHAPTER 3: SUBMITTED MANUSCRIPT 
3.1 Introduction 
Chapter three highlights the following manuscript that was submitted to an international peer 
reviewed journal: 
Prosad S, Ojewole E, Dheda M & Tlou B 2018. Adverse drug reactions and discontinuation of 
Implanon NXT® among users at public health facilities in South Africa. The European Journal of 
Contraception and Reproductive Health Care. Submitted manuscript. Reference number: DEJC-
2018-0138.R1 
This chapter is presented in the format stipulated by the author guidelines of the journal and is the 
revised version. The copies of the manuscript  submission letters are attached as annexure 5.  
 
This is the first manuscript based on the data generated in this study and presents the significant 
findings.  
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Adverse drug reactions and discontinuation of Implanon NXT® among users at 
public health facilities in South Africa.  
Abstract  
Purpose: Discontinuation of Implanon NXT® in South Africa is concerning, 
however, national data on its surveillance is lacking. This study quantified adverse 
drug reactions and evaluated Implanon NXT® discontinuation.  
Methods: Secondary data analysis was performed using 3743 cases obtained from 
South African National Pharmacovigilance Centre for Public Health Programmes. 
Demographics, patient history, adverse drug reactions and discontinuation details 
were extracted and analysed using SPSS® version 25. Tests of association were 
performed and univariable and multivariable models were used to identify factors 
associated with Implanon NXT® discontinuation.  
Results: The frequently reported adverse drug reactions were menorrhagia 
(52.01%; 712/1369), headache (20.45%; 280/1369) and dizziness (11.18%; 
153/1369). Discontinuation of Implanon NXT® was reported by 63.56% 
(2379/3743) of cases and early discontinuation by 81.1% (1210/1492). Experience 
of adverse drug reactions was associated with Implanon NXT® discontinuation 
(AOR= 11.98, CI: 8.10-17.72, p<0.001). Discontinuation was mainly due to 
adverse drug reactions (83.99%; 1784/2124). Pregnancy was reported by 4.97% 
(68/1369) cases. Almost a third were on efavirenz and was suspected to be 
associated with pregnancy (p<0.001).  
Conclusion: Implanon NXT® discontinuation due to adverse drug reactions was identified 
in this study. efavirenz-based therapy could have resulted in pregnancy among Implanon 
NXT® users. Rigorous screening and monitoring should be applied to prevent user 
discontinuation.  
Keywords: Implanon NXT®, adverse drug reaction, user discontinuation, reasons for 
discontinuation, pregnancy 
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Introduction 
Studies conducted at various countries worldwide have reported that approximately a 
quarter of users remove their Implanon® within 12 months [1, 2, 3]. In Ethiopia, the 
overall proportion of early discontinuations ranged from 16% to 80% [4, 5, 6, 7]. The 
overall proportion of discontinuations ranged from 4.48% to 21.36% as reported in 
studies from Nigeria [8, 9]. Adverse drug reactions (ADRs) especially bleeding pattern 
changes have been reported globally [10, 11, 12, 13]. ADRs is the primary reason for 
Implanon® discontinuation among users [2, 14, 15, 16]. Experience of ADRs is a factor 
associated with early discontinuation of Implanon NXT® in Africa [5, 6, 7]. Recently, 
there were reports of early Implanon NXT® discontinuation among users in South Africa 
(SA) [17, 18, 19, 20]. There were 820 Implanon NXT® removed as at December 2014 
[21], however this figure has increased to about 5000 Implanon NXT® in April 2015 [19]. 
The demand for discontinuation of Implanon NXT® resulted in the public questioning the 
safety and efficacy of the product [21]. The efficacy of the use of Implanon NXT® in 
women on antiretroviral therapy has been raised as a concern in SA [21, 22]. The negative 
experiences highlighted in SA studies were ADRs, early Implanon NXT® discontinuation 
and Implanon NXT® failure. Moreover, one SA study reported that the use of concomitant 
drugs namely antiretroviral (ARV), antipsychotics and antituberculosis drugs 
necessitated the discontinuation of Implanon NXT® [20].  
 
Poor monitoring of Implanon NXT® discontinuations has resulted in the true extent of 
discontinuations being unknown [19, 21]. There is a lack of evidence on ADRs of 
Implanon NXT®, frequency and reasons for discontinuation in SA [19, 20, 21, 23]. 
Clearly, a need still exists to quantify the experiences of Implanon NXT® users in terms 
of ADR, discontinuation and reasons for discontinuation particularly at the national and 
provincial level.  
 
The aim of this study was therefore to quantify ADRs and evaluate discontinuation of 
Implanon NXT® among users in SA by analysing secondary data collected from a national 
pharmacovigilance database. The objectives included: quantifying ADRs of Implanon 
NXT®, determining the frequency of Implanon NXT® discontinuation,determining 
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factors associated with Implanon NXT® discontinuation and identifying reasons for 
Implanon NXT® discontinuation. 
 
Methods 
 
Study design  
Secondary data analysis was conducted using data obtained from the National 
Pharmacovigilance Centre (NPC) in SA. The NPC carried out surveillance where case 
forms were completed by clinicians prior to insertion and discontinuation of Implanon 
NXT® and report of ADR. The use of secondary data provided a large sample size and 
population-level data for the study [24, 25, 26].  
 
Data set 
The entire data set was analyzed in this study. A total of 3743 case reports that were 
submitted to the Subdermal Implant National Surveillance Programme from 1 April 2015 
to 11 September 2017 were included in the secondary analysis. All variables related to 
counselling, laboratory test results and clinicians on the case reports were excluded as it 
fell out of the scope of this study. Full ethical approval for the study was obtained from 
the University of KwaZulu-Natal Biomedical Research Ethics Committee (BE266/17), 
and permission to use the raw data set was obtained from the NPC.  
 
Data extraction, data processing and data validation 
Data was extracted from all the 3743 case reports. Variables describing demographics, 
patient history, ADR discontinuation and reasons for discontinuation were extracted from 
the raw data. The main outcomes measured and extracted from the dataset were ADR, 
discontinuation, premature discontinuation, reasons for discontinuation and pregnancy. 
Cases extracted per outcome included: ADR (36.57%; 1369/3743), discontinuation 
(63.56%; 2379/3743), premature discontinuation (81.1%; 1210/1492), reason for 
discontinuation (56.75%; 2124/3743) and pregnancy (4.97%;68/1369). Multiple ADRs 
and reasons for discontinuation could be reported per case resulting in total ADRs 
reported and total reasons for discontinuation calculated as n=2120 and n=2590 
respectively. Pregnancy, which is classified as an ADR in the raw data, was used to 
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evaluate Implanon NXT® failure. Premature discontinuation was defined in this study as 
discontinuation of Implanon NXT® less than 36 months’ post-insertion and was 
calculated using the difference between date of insertion and date of discontinuation. Not 
all cases reported insertion and discontinuation dates therefore the sample size used for 
premature discontinuation is n=1492. Case reports which reported a discontinuation date 
or a reason for discontinuation were used to calculate the frequency of user 
discontinuations regardless of early discontinuation. Data processing was conducted for 
the following additional variables using elements from the raw data and other sources 
[27, 28, 29, 30, 31]: Health facility type, level of health care, level of urbanisation and 
body mass index (BMI). Data was then cleaned by identifying and correcting incomplete 
and inaccurately captured extracted cases. The extracted data was checked for missing 
case reports and blank cells were identified for missing data. Validation of data extraction 
was performed by randomly selecting 10% of cases to cross-check with the raw data.  
 
Statistical Analysis 
Data was exported from Microsoft Excel 2016 to SPSS® version 25 for analysis. All 3743 
case reports were included in analysis. Descriptive analysis was performed, and results 
presented as frequencies, percentages, measure of central tendency and measure of 
variability. A 95% Confidence Interval (CI) was used to estimate the population values. 
CI limits of a proportion was calculated on an online calculator using the Wilson 
procedure without a correction for continuity [32]. The Pearson’s Chi square test and 
Fischer’s Exact Test were performed to test associations between demographics and 
ADR. A p-value of less than 0.05 was considered statistically significant. Univariable and 
multivariable binary logistic regression was conducted to identify factors associated with 
Implanon NXT® discontinuation. The odds ratios, 95% CI and p-values were calculated 
and a p<0.05 was used to identify independent variables that were significantly associated 
with Implanon NXT® discontinuation. The multivariable model eliminated the 
confounding variables and identified variables significantly associated with 
discontinuation of Implanon NXT®.  
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Results  
A total of 3743 case reports were analysed of which 22.26% reported insertion of 
Implanon NXT® and 63.56% reported discontinuation of Implanon NXT®. Cases which 
reported only ADRs were 6.06% (227/3743) and only reported demographic information 
were 8.12% (304/3743). Fifty percent of case reports reported age below 26 years 
(Interquartile range (IQR)=10 years; 95% CI: 27.09-27.58). Majority of the case reports 
were received from urban areas in SA (Table 1) [Table 1 near here]. Almost half of the 
cases were parity ≥1 (48.89%;1830/3743) and 47.58% (1781/3743) reported gravidity ≥1. 
Previous contraceptive use was reported in 44.30% (1658/3743) of cases and 1.3% 
(48/3743) reported no previous contraceptive use. The remaining case reports did not 
report on previous contraceptive use. A third (33.58%;1257/3743) reported previously 
using the injection. Fifty percent of the cases reported weight above 66kg (IQR=25.15kg; 
95% CI: 68.71-70.08) and the median BMI was calculated as 26.01 kg/m2 (IQR=9.67; 
95% CI: 27.05-28.85). The highest reported concomitant condition was HIV/AIDS 
(10.23%, 383/3743). The most reported concomitant drugs were: ARV (6.01%, 
225/3743), antihypertensives (0.0067%, 25/3743), antituberculosis drugs (0.0032%; 
12/3743) and antiepileptic drugs (0.0021%; 8/3743). efavirenz (4.62%,173/3743), 
tenofovir (4.35%, 163/3743) and emtricitabine (4.22%,158/3743) were the most 
frequently reported ARVs. There were 4.9% (185/3743) of the cases who reported 
breastfeeding while using Implanon NXT®.  
 
There were 457 cases which experienced two to four ADRs and 20 cases experienced five 
or more ADRs. The onset of ADR was higher in the first year of Implanon NXT® use 
than in the second and third year of use. The median and IQR for time between onset of 
ADR and the report of ADR was 91 days and 290 days respectively (95% CI: 191.30-
235.24). The commonly reported ADRs (n=1369) included: menorrhagia (52.01%), 
headache (20.45%), dizziness (11.18%) and irregular menstruation (8.11%) (Table 2) 
[Table 2 near here]. The Pearson Chi Square test was performed to associate age and 
commonly reported ADR. Headaches (p=0.039) and menorrhagia (p<0.001) were found 
to be associated with age. Reports of headache and menorrhagia increased with advancing 
age up to 44 years.  
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The median time between report of ADR and discontinuation of Implanon NXT® was 0 
days (IQR=29 days; 95% CI: 45.25-65.30). The median and IQR for the duration of 
Implanon NXT® use was reported as 573 days and 595 days respectively (95% CI: 
605.07-642.37). Implanon NXT® was discontinued prematurely in 81.1% (1210/1492) of 
cases. Implanon NXT® was removed more frequently in the 2nd year of use which 
accounted for 35.79% (534/1492) of cases. Parity, gravidity, age, BMI and cases who 
reported ADR were found to have a statistically significant association with Implanon 
NXT® discontinuation (Table 3) [Table 3 near here]. After adjusting for parity, gravidity, 
age and BMI, cases which reported ADR were 11.98 times more likely to remove 
Implanon NXT® than those who did not report ADR (p<0.001). Parity, gravidity, age and 
BMI were not associated with discontinuation of Implanon NXT® in the adjusted model. 
Age was marginally significantly associated with Implanon NXT® discontinuation 
(p=0.055). Those who were overweight (AOR= 0.83) and obese (AOR=1.19) were less 
likely to remove Implanon NXT® than those who were underweight (AOR=1.71) 
however this finding was not statistically significant (p=0.211).  
 
 Reasons for discontinuation due to ADR accounted for 83.99% (1784/2124) and other 
reasons accounted for 37.95% (806/2124) (Table 4) [Table 4 near here]. Not all ADR 
reported were reasons for discontinuation (2120 vs. 1784) e.g. 280 cases reported 
headache (Table 2) but only 218 cases reported headache as a reason for discontinuation 
(Table 4). There were 16.95% (360/2124) of cases who reported more than one reason 
for discontinuation. The most commonly reported reasons for discontinuation (n=2124) 
included: menorrhagia (34.27%), expiry after three years of use (29.57%), headache 
(10.26%) and desire to conceive (5.93%).  
 
There were 4.97% (68/1369) of pregnancy cases reported with concurrent Implanon 
NXT® use. Of these, two indicated that users may have been pregnant at the time of 
insertion and three indicated possible drug interaction with concurrent ARV use. The 
Fischer Exact Test was performed to associate pregnancy and age and a statistically 
significant association was found (p=0.011). Pregnancies were more frequently reported 
by 30-34-year olds (28.36%; 19/67) followed by 25-29-year olds (23.88%, 16/67) and 
35-39-year olds (20.90%, 14/67). An association between efavirenz users and non-users 
 93 
against cases reporting pregnancy was tested using the Fischer Exact Test. A statistically 
significant association between Implanon NXT® users on efavirenz-based therapy and 
pregnancy was found (p<0.001). There were 29.41% (20/68) of pregnancy cases using 
efavirenz-based therapy. Over a quarter (27.94%, 19/68) of pregnancy cases also reported 
greater than normal BMI, however, BMI and pregnancy was not statistically significant 
(p=0.468).  
 
Discussion 
 
Findings and Interpretation 
All age groups of women of reproductive age were represented in this study but 20-24-
year olds were the most frequent. Expected menstrual and non-menstrual ADR were 
commonly reported. Menorrhagia appears to be a distinctive ADR experienced in SA as 
menorrhagia was reported by more than half of the cases. Almost a tenth of ADRs 
(9.06%;124/1369) found in this study were not listed on the Implanon NXT® product 
leaflets [33, 34] and Implanon® prescribing leaflet [35]. Although unlisted, these ADRs 
may warrant further investigation to determine if they are associated with Implanon 
NXT® use. Older aged Implanon NXT® users were more prone to experience menorrhagia 
and headache suggesting that age of users influences experience of certain ADR. Fifty 
percent of users who reported ADRs to a clinician removed Implanon NXT® on the same 
day. This suggests that ADRs were intolerable and discontinuation was therefore 
requested. On the other hand, it also suggests that treatment and management of ADRs 
were not accepted by users or not encouraged by clinicians. Early discontinuation of 
Implanon NXT® has been highlighted in this study (81.1%; 1210/1492). Discontinuation 
of Implanon NXT® was mainly due to experience of ADR but independent factors such 
as expiry and desire to conceive were also reasons for discontinuation. The proportion of 
pregnancies reported while using Implanon NXT® was 4.97% (68/1369). The reason for 
pregnancy could not be determined in most cases due to limited details provided. Possible 
reasons for pregnancy could be due to conception before insertion of Implanon NXT® and 
drug-drug interactions. Efavirenz-based antiretroviral therapy was found to be associated 
with pregnancy. The concomitant use of these drugs is of concern as efavirenz is a widely 
used drug to treat HIV in SA.  
 94 
Strengths and Weaknesses of the Study  
A large sample size was included for analysis in this study. A national pharmacovigilance 
database was used as a source of data which provided ‘real-world’ evidence on 
experiences of Implanon NXT® users. A limitation of the study was missing data and 
incomplete case reports. A secondary data set was used as the source of data for this study 
therefore the principal investigator did not have control over the primary data collection. 
Underreporting on variables may have affected the outcome of study results. A small 
sample was used to associate pregnancy and ARV agents which could limit significance 
of result. There may have been gaps in the monitoring system as reporting was not 
rigorously monitored as is done in other study designs such as clinical trials. According 
to the standard operating procedure, serious adverse events were to be reported directly 
to the NPC and this may have resulted in exclusion of serious ADR from the study.  
 
Similarities and differences in relation to other studies  
The results from this study varied with results from SA and international literature but 
there were a few similar findings. The common ADR identified in this study were 
consistent with the ADR found in local [17, 18, 20] and international studies [10, 11, 36, 
37] but proportions of ADR differed. A SA study by Mrwebi et al. [20] reported lower 
proportions of the commonly reported ADR found in this study namely: menorrhagia, 
headache, back pain, weight gain, weight loss, dizziness and abdominal pain. In this 
study, menorrhagia was reported at a higher frequency compared to other studies [18, 36]. 
Irregular bleeding and amenorrhoea were more frequently reported in continental and 
international literature [10, 38, 39, 40]. Headache was reported at a lower proportion in 
several studies [10, 40][2] and weight gain was reported at higher proportions in studies 
[10, 11, 40]. Some of the unlisted ADR have been reported in research articles such as 
abdominal bloating [39], dyspareunia [41, 42], painful lower limbs [42], weakness [42], 
weakness in arm [11], swollen vagina [10], abdominal distention [7], anaemia [43], and 
varicose veins [42]. There is contradicting evidence on the effect of age on ADR 
experienced with Implanon NXT®. Berenson et al [41] found that older etonogestrel users 
were more likely to experience menorrhagia however, Casey et al [13] found no 
association between age and reported bleeding. There is limited research on the effect of 
age on non-menstrual ADR of Implanon NXT® but one study on contraceptive implants 
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found side effect incidence not significantly associated with age [44]. A higher percentage 
of premature discontinuations was reported in this study compared to Ethiopian studies 
which cited 65% [5] and 46.5% [6] of early discontinuers. Internationally, lower 
discontinuation rates were reported with 47% of discontinuers within three years [12], 
26.8% of discontinuers within 12 months [2] and 35% of discontinuers within 32 months 
in adolescents [45]. In the clinical trials of Implanon NXT®, 35% discontinued due to an 
ADR and more frequently due bleeding irregularities [46]. ADR is a factor associated 
with discontinuation of Implanon NXT® in Africa [5, 6, 7]. In addition, ADR is 
predominantly the reason for Implanon NXT® discontinuation [5, 6, 18, 20, 47]. 
Discontinuation due to menorrhagia was reported at comparable proportions in some 
studies [4, 18] and at a higher proportion in one studies [3]. Discontinuation due to 
irregular bleeding [48] discontinuation due to painful arm [4, 5, 6] and discontinuation 
due to headache and weight gain [5, 6, 18, 49] were reported at higher proportions in other 
studies. Geographic location and demographic profile are factors associated with 
Implanon NXT® discontinuation and this may be a reason for the difference in the above 
findings [3, 49]. While one study [50] reported lower number of pregnancies with 
Implanon® as compared to the present study, other studies have reported higher frequency 
of pregnancy [11, 51]. Similar to this study, a South African article reported a significant 
proportion of participants who fell pregnant while using Implanon NXT® (5.3%) [20]. 
Some reasons for pregnancy provided in studies included: inefficient etonogestrel levels, 
incorrect timing of insertion, non-insertion, pregnant at time of insertion and use of 
enzyme inducing medication [11, 50, 51] The study conducted in the United States found 
that 4 of the 6 cases reporting method failure had a BMI of above normal range [50]. The 
enzyme inducing drugs resulting in pregnancy included antiepileptics, ARVs, 
antituberculosis drugs and herbal medication [11, 51]. Efavirenz-based therapy has been 
associated with a reduction in etonogestrel bioavailability which impairs contraceptive 
efficacy in HIV patients [52, 53, 54]. A study in Kenya found that efavirenz-based therapy 
had a three times higher risk of implant failure than nevirapine-based therapy [55]. 
Similar to this study findings, pregnancy was found in Implanon NXT® users on efavirenz 
therapy [11, 55, 56, 57, 58]. However, some studies found no failures with concurrent 
Implanon NXT® and efavirenz use [56, 59]. The abovementioned studies show 
contradicting evidence on efavirenz use in Implanon NXT® users.  
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Relevance of the findings: Implications for clinicians and policymakers  
Interventions need to be applied in clinical practice to alleviate this problem and ensure 
higher continuation rates of Implanon NXT®. The initial counselling visit is crucial to 
assess if Implanon NXT® is a viable option for the patient. Additional counselling on 
increased risks need to be provided to patients using concomitant enzyme-inducing drugs. 
Additional non-hormonal contraception must be offered to these patients to prevent 
pregnancy. Clinicians can target their pre-insertion counselling includes expectations of 
ADR and inform patients on the procedure to address them. A regular follow-up schedule 
should be applied as onset of ADR were experienced in the first year of utilization and 
discontinuation was common in the second year of utilization. These follow-ups should 
include: report of any ADR, treatment of ADR and assessment of the insertion site for 
any abnormalities.  
 
Open questions and Future research 
True contraceptive method failure could not be established in this study due to insufficient 
information provided by cases reporting pregnancies. Additional information such as date 
of conception in relation to insertion date, timing of insertion, etonogestrel concentration 
levels must be provided to establish the reason for failure. An investigation study on ARV 
based therapy in Implanon NXT® users particularly in SA may be necessary to confirm 
an association between the drugs. It may be useful to identify differences between ADRs 
experienced among provinces and further explore differences in ADRs among age groups 
to provide interventions in needy demographics. It is unclear whether advice and 
treatment options for ADR management was not well received by users or whether it was 
not encouraged by clinicians. Further investigation needs to be conducted to identify the 
reason for those who removed their implanon NXT® rather undergo treatment for ADRs. 
Aspects related to counselling and clinicians were not included in this study, therefore 
interventional studies on counselling and management practices of Implanon NXT® may 
be conducted. The design of a follow-up protocol and a standardised algorithm for 
Implanon NXT® ADR management is necessary to ensure patients receive effective and 
high-quality care.  
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Conclusion 
This study determined a high frequency of early Implanon NXT® discontinuation at a 
national level. ADR was identified as the main factor associated with Implanon NXT® 
discontinuation. A possible association between efavirenz- based therapy and pregnancy 
in Implanon NXT® users was found. Interestingly, a small proportion reported pregnancy 
while on Implanon NXT®. Thorough screening and rigorous monitoring of users should 
be performed in practice to prevent user discontinuation. 
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Table 1: Demographics of Implanon NXT® cases reported in South Africa (N=3743).  
 Number of cases Percentage (%) Confidence Interval 
(95%) 
Age (years)    
<15 32 0.85 0.60-1.20 
15-19 469 12.53 11.51-13.63 
20-24 962 25.70 24.33-27.12 
25-29 886 23.67 22.34-25.06 
30-34 627 16.75 15.59-17.98 
35-39 354 9.46 8.56-10.44 
40-44 184 4.92 4.27-5.66 
45-49 63 1.68 1.32-2.14 
>49 12 0.32 0.18-0.56 
No data 154 4.11 ----- 
Province    
Eastern Cape 1011 27.01 25.61-28.46 
Free State 792 21.66 19.88-22.50 
Gauteng 717 19.16 17.93-20.45 
Limpopo 547 14.61 13.51-15.78 
Northern Cape 264 7.05 6.27-7.91 
North West Province 219 5.85 5.14-6.65 
KwaZulu-Natal 84 2.24 1.81-2.77 
Western Cape 78 2.08 1.67-2.59 
Mpumalanga 31 0.83 0.59-1.18 
Level of Urbanisation    
Urban 3168 84.64 83.45-85.76 
Tribal/Traditional 352 9.40 8.51-10.38 
Farm 3 0.08 0.03-0.24 
No data 220 5.88 ----- 
Health Care Facility Type    
PHC Clinic 1794 47.93 46.33-49.53 
CHC 600 16.03 14.89-17.24 
District Hospital 783 20.92 19.65-22.25 
Regional Hospital 241 6.44 5.70-7.27 
Provincial Tertiary Hospital 49 1.31 0.99-1.73 
National Central Hospital 55 1.47 1.13-1.91 
No data 221 5.90 ----- 
Level of Health Care    
Level 1 3177 84.88 83.70-85.99 
Level 2 241 6.44 5.70-7.27 
Level 3 49 1.31 0.99-1.73 
Level 4 55 1.47 1.13-1.91 
No data 221 5.90 ----- 
Body Mass Index Category (kg/m2)    
Underweight(below 18.5) 73 1.95 1.55-2.44 
Normal weight(18.5-24.9) 546 14.59 13.50-15.76 
Overweight(25.0-29.9) 341 9.11 8.23-10.07 
Obese(30.0 and above) 435 11.62 10.63-12.69 
No data 2348 62.73 ----- 
Note: PHC, Primary Health Care; CHC, Community Health Centre  
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Table 2: Adverse Drug Reactions with Implanon NXT® reported in South Africa 
(n=1369). 
Adverse Drug Reaction Number of Cases  Percentage (%) 
Menstrual -related ADR   
Menorrhagia 712 52,01 
Irregular menstrual period 111 8,11 
Amenorrhea 90 6,57 
Spotting 15 1,10 
Breakthrough bleeding 5 0,37 
Prolonged bleeding 3 0,22 
Menstrual bleedinga 2 0,15 
Total menstrual related ADR 938 68.52 
Non-menstrual related ADRb   
Central and peripheral system disorders 433 31,63 
Metabolism and nutrition disorders 169 12,34 
Application site related disorders 104 7.60 
Gastrointestinal system disorders 85 6,21 
Pregnancy 68 4,97 
General disorders  44 3.21 
Musculoskeletal and connective tissue disorders 42 3,07 
Skin and subcutaneous tissue disorders 30 2,19 
Psychiatric disorders 28 2,05 
Drug interaction 13 0,95 
Nervous system disorders 12 0,88 
Contraindication 9 0,66 
Reproductive system and breast disorders 9 0,66 
Complications related to product  6 0,44 
Immune system disorders 2 0,15 
Vascular disorders 2 0,15 
Infection 2 0.15 
Total non-menstrual related ADR 1056 77.14 
Unlisted ADRc   
Numbness in arm 53 3.87 
Epistaxis 10 0,73 
Eye related disordersd 4 0,29 
Numbness of lower limbse 4 0.29 
Swelling of lower limbsf 4 0,29 
Chest pain 3 0,22 
Implanon NXT® interferes with daily activity 3 0,22 
Loss of appetite 3 0,22 
Painful lower limbsg 3 0.22 
Varicose veins 3 0,22 
Weakness 2 0,15 
Neck pain 2 0,15 
Cramps on arm/s 2 0,15 
Other unlisted ADRh 28 2,05 
Total unlisted ADR 124 9.06 
Note: ADR, Adverse Drug Reaction 
 a  The type of bleeding pattern was not indicated in the case report. Menses/menstrual bleeding was indicated as an ADR. b  The non-menstrual ADRs include:  
Central and peripheral system disorders: dizziness (11.18%), headache (20.45%); Metabolism and nutrition disorders: weight gain (6.65%), weight loss (5.70%); Application 
site disorders: septic Implanon NXT® area (0.07%), painful insertion site (0.07%), itchy insertion site (0.07%), painful arm (7.01%), swollen arm (0.22%), Itchy arm (0.07%), 
bruising of arm (0.07%);Gastrointestinal system disorders: abdominal pain (3.87%), nausea (1.39%), vomiting (0.95%);Pregnancy: pregnancy; General disorders: fatigue 
(1.90%), general pain (1.10%), tiredness (0.07%), oedema (0.07%), influenza(0.07%); Musculoskeletal and connective tissue disorders: back pain (2.99%), painful joints 
(0.07%);Skin and subcutaneous tissue disorders: acne (0.15%), hair loss (0.80%), rash (1.10%), itchiness (0.15%);Psychiatric disorders: mood swings (0.29%), loss if libido 
(0.37%), mood changes (0.88%), depression (0.15%), low libido (0.29%), insomnia (0.07%);Drug interaction: adverse drug reaction; Nervous system disorders: drowsiness 
(0.80%), seizures (0.07%); Contraindication: contraindication; Reproductive system and breast disorders: dysmenorrhea (0.15%), enlarged breasts (0.07%), painful breasts 
(0.29%), itchy vulva (0.15%); Complications related to product: bent Implanon NXT® (0.07%), displaced Implanon NXT® (0.15%), broken Implanon NXT® (0.22%); 
Infections: Vaginal infection (0.15%); Immune system disorders: allergic reaction (0.15%); Vascular disorders: hot flushes (0.07%), hypertension (0.07%); Infections: Flu 
(0.07%). c Includes ADRs that were not listed in the Implanon NXT® product information and characteristics and Implanon NXT® prescribing information leaflet. [33,34,35] 
d Includes the following categories: painful eyes (0.07%), blurred vision (0.15%), vision changes (0.07%).e Included the following categories: numbness of lower limbs (0.15%) 
and numbness in leg (0.15%). f Included the following categories: swollen legs (0.07%) and swollen feet (0.22%). g Includes the following categories: painful feet (0.07%) and 
painful legs (0.15%). h Other unlisted ADRs includes the following categories with only reported 1 case: swollen face, anaemia, tender arm, abdominal distention, 
hypocalcaemia, skin disease, tremors, pale, swelling, bipolar-mood disorder, palpitation, painful hand, abscess, abdominal bloating, dyspareunia, loss of concentration,, swollen 
tongue, swollen vagina, tender nipples, burning sensation, weakness in arm, loss of balance, waist ache, painful face, swollen hand, malaise, memory loss, heartburn. 
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Table 3: Univariable and multivariable analysis of odds ratio (95% CI) for factors 
associated with discontinuation of Implanon NXT®  
 Univariable model Multivariable model 
Variable Odds Ratio Confidence 
Interval 
p-value Adjusted 
odds ratio 
Confidence 
interval 
p-value 
Level of Urbanisationa,b       
Tribal/Traditional 0.933 0.74-1.17 0.544  ----- g 
Urban 1 ----- ----- 
Parac       
≥1 1.49 1.16-1.92 0.002 1.07 0.52-2.17  0.860 
None 1 ----- ----- 1 ----- ----- 
Gravidad       
≥1 1.33 1.01-1.75 0.042  0.98 0.49-1.99 0.962 
None 1 ----- ----- 1 ----- ----- 
Age Group (years)e       
<15 0.022 0.02 -0.17 0.001 0.00 0.000  0.999 
15-19 0.408 0.12- 1.35 0.141 0.33 0.02-5.63 0.442 
20-24 0.84 0.25- 2.82 0.782 0.50 0.03-8.26 0.631 
25-29 0.94 0.28- 3.14 0.918 0.65 0.04-10.67 0.764 
30-34 1.20 0.36- 4.02 0.774 0.91 0.06-14.89 0.945 
35-39 1.22 0.36 -4.14 0.751 0.87 0.05-14.47 0.923 
40-44 1.17 0.34- 4.06 0.801 1.31 0.08-22.83 0.853 
45-49 0.76 0.21- 2.79 0.680 0.52 0.03-10.36 0.674 
>49 1 ----- ----- 1 ----- ----- 
Body Mass Index Category 
(kg/m2)f  
      
Underweight(below 18.5) 1.722 1.04-2.84 0.036 1.71 0.77-3.78 0.185 
Overweight(25.0-29.9) 1.54 1.17-2.02 0.0021 0.83 0.55-1.26 0.381 
Obese(30.0 and above) 1.67 1.29-2.15 0.000 1.19 0.81-1.74 0.379 
Normal weight(18.5-24.9) 1 ----- ----- 1 ------ ----- 
Cases reporting ADR/s       
Yes 4.62 3.93-5.45 <0.001 11.98 8.10-17.72 <0.001 
No 1 ----- ----- 1 ----- ----- 
ADR, Adverse drug reaction  
a Data on level of urbanisation is missing for 220 case reports therefore n= 3523 case reports. b Farm was excluded from analysis for association due to 
low frequency. c Data on para is missing for 1630 case reports therefore n= 2113 case reports. d Data on gravida is missing for 1729 case reports 
therefore n= 2014 case reports. e Data on age is missing for 154 case reports therefore n= 3589 case reports. f Data on body mass index is missing for 
2348 case reports therefore n= 1395 case reports. g Variable is not included in multivariable analysis as p< 0.05.  
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Table 4: Reasons for Implanon NXT® discontinuation reported in South Africa 
(n=2124). 
Reason for discontinuation Number of Cases Percentage (%) 
Frequently reported >25 cases   
Menorrhagia 728 34,27 
Expirya 628 29,57 
Headache 218 10,26 
Desire to conceive 126 5,93 
Dizziness 106 4,99 
Irregular menstruation 76 3,58 
Painful arm 72 3,39 
Weight gain 67 3,15 
Pregnancy 65 3,06 
Weight loss 63 2,97 
Risk of ADRb 46 2,17 
Abdominal pain 37 1,74 
Numbness in arm 37 1,74 
Amenorrhea 33 1,55 
Contraindication 31 1,46 
Patient request 30 1,41 
Less frequently reported ≥10 to ≤25 cases   
Back pain 24 1,13 
General pain 17 0,80 
Nausea 12 0,56 
Drug interaction 11 0,52 
Fatigue 11 0,52 
Rash 11 0,52 
Vomiting 11 0,52 
Few cases <10 cases   
Spotting 9 0,42 
Mood changes 8 0,38 
Broken Implanon NXT®  6 0,28 
Epistaxis 6 0,28 
Influenced by family/friends 6 0,28 
Change in contraception method 5 0,24 
Other reasonsc 90 4.24 
ADR, Adverse Drug Reaction 
a Cases were due for discontinuation of Implanon NXT® after three years of use. b Risk of ADR category includes cases reporting the following reasons 
for discontinuation: patient commencing ART, patient on ART but no drug interaction indicated and patients on antituberculosis medication, but no 
drug interaction indicated. c Includes the following categories and number of cases:  
4 cases: drowsiness, low/loss of libido, swollen lower limbs,syncope 
3 cases: dysmenorrhea, hair loss, inserted incorrectly,palpitation, varicose veins 
2 cases: seizures,allergic reaction, anaemia, chest pain,discolouration of Implanon NXT® site, displaced Implanon NXT®, feeling unwell with Implanon 
NXT®, painful breast, painful eyes,religious beliefs, swollen face 
1 case: acne, swollen arm, tender arm, skin condition, skin disease, insomnia, low Hb, itchy implant site, pale, swelling, poor vision, numbness in leg, 
vaginal infection, swollen hand, painful hand, hot flushes, abscesses, hormonal imbalance, blurred vision, abdominal bloating, dyspareunia, painful 
joints, numbness of the limbs, painful legs, neck pain, itchiness of vulva, recurrent VDS, itchiness, memory loss, menstrual bleeding, Polymenorrhea, 
hysterectomy, travelling, patient feels unsafe, cultural beliefs, desire to menstruate normally and interferes with daily activities. 
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CHAPTER 4: MANUSCRIPT FOR SUBMISSION 
4.1 Introduction 
This chapter presents the second manuscript based on the results from the comparisons of 
experiences of Implanon NXT® users in the provinces of SA.  
The manuscript: Prosad S, Ojewole E, Dheda M & Tlou B Comparisons of experiences of 
Implanon NXT® users between provinces in South Africa, was prepared and is to be submitted to 
the South African Medical Journal for publication. The guidelines for authors was followed and 
it is available from http://www.samj.org.za/index.php/samj/about/submissions#authorGuidelines. 
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4.2 Manuscript 
Comparisons of experiences of Implanon NXT® users between provinces in 
South Africa  
Shimona Prosad,1B. Pharm; Elizabeth Ojewole,2 PhD; Mukesh Dheda, PhD;3 
Boikhutso Tlou, PhD4 
 
1 Discipline of Pharmaceutical Sciences, School of Health Sciences, University of 
KwaZulu-Natal, Westville Campus, Durban, KwaZulu-Natal, South Africa, 
Private Bag X54001, Durban 4000, South Africa. Tel: +27 (0)31 566 3076; Fax: 
+27 (0)31 260 7792, prosadshimona@gmail.com 
2 Discipline of Pharmaceutical Sciences, School of Health Sciences, University of 
KwaZulu-Natal, Westville Campus, Durban, KwaZulu-Natal, South Africa, 
Private Bag X54001, Durban 4000, South Africa. Tel: +27 (0)31 566 3076; Fax: 
+27 (0)31 260 7792, ojewolee@ukzn.ac.za 
3 Pharmacovigilance Centre for Public Health Programmes, National Department 
of Health, South Africa; PBX 828, Pretoria; Tel: +27 (0)12 395 9506, 
mukesh.dheda@gmail.com 
4 Department of Public Health, School of Nursing & Public Health, University of 
KwaZulu-Natal, Durban, South Africa, P B X54001 Durban 4000; Tel: +27 
(0)31 260 4522, tlou@ukzn.ac.za 
 
*Corresponding author email: prosadshimona@gmail.com 
Contact number: Tel: +27 (0)31 260 7937; Cell: +27 (0)73 136 9751; Fax: +27 
(0)31 260 7792 
 
Word Count: Abstract: 380 
Main Text: 3472 
 110 
Abstract 
Background: While premature discontinuation of Implanon NXT® has been reported in 
South Africa, there is a lack of evidence about the frequency of this occurence. The 
concomitant use of Implanon NXT® and antiretroviral drugs has been suggested to result 
in reduced efficacy of the contraceptive, this being problematic in an Human 
Immunodeficiency Virus (HIV) rampant environment, such as KwaZulu-Natal Province. 
The study of Implanon NXT® in varying demographics (e.g. age and location) and 
different population groups (e.g. HIV positive women) is important to isolate areas that 
require individual intervention. KwaZulu-Natal and Gauteng Provinces are examples of 
under researched provinces with regard to  Implanon NXT® user experiences. These 
provinces were also chosen for this study to represent different contexts in SA in terms 
of demographic and disease profile, implant usage and discontinuation.  
Objectives: To compare the experiences of Implanon NXT® users between the provinces 
of  South Africa.  
Methods: A retrospective study was conducted utilizing secondary data obtained from 
the South African National Department of Health Pharmacovigilance Centre for Public 
Health Programmes. A total of 3743 national case reports were analysed, with patients’ 
demographics, history and discontinuation details being extracted and imported into 
SPSS® version 25 for analysis. The following outcomes were extracted: discontinuation, 
premature discontinuation, adverse drug reactions and reasons for discontinuation. 
Results were presented descriptively for demographic and discontinuation variables. A 
comparative analysis between Gauteng and KwaZulu-Natal province was performed 
using Chi square test and Mann-Whitney U-Test.  
Results: Discontinuation of Implanon NXT® was more frequent in under 30-year old, 
their most frequent reasons being desire to conceive, expiry, dizziness, headache and 
menorrhagia. The proportion of premature discontinuation was higher in Gauteng (82.6%, 
252/305) than KwaZulu-Natal (76.7%, 23/30); (p=0.01208). Significantly higher 
proportions of adverse drug reactions, apart from drug interaction, was reported in 
Gauteng compared to KwaZulu-Natal. Reasons for discontinuation, such as desire to 
conceive, bleeding patterns, headache, pain in arm, pregnancy and abdominal pain, were 
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significantly higher in Gauteng than KwaZulu-Natal. Notable reasons for discontinuation 
in KwaZulu-Natal were pregnancy and drug interactions. 
Conclusion: The users of Implanon NXT®  from Gauteng were more prone to discontinue 
than those from KwaZulu-Natal. A common reason for user discontinuation in KwaZulu-
Natal was due to possible drug interaction with the Implanon NXT®. Interestingly, users 
experiences, particularly reasons for discontinuation are different between the provinces, 
hence tailored interventions may be required.  
Keywords: Adverse drug reaction; Discontinuation; Implanon NXT®; South African 
provinces, drug interactions. 
Background 
Implanon NXT® is a single-rod etonogestrel contraceptive implant that lasts for three 
years.[1] The product was introduced in South Africa (SA) to provide a complete range of 
family planning methods at public health facilities,[2, 3] being made available in public 
health facilities in February 2014.[4] 
Contraceptive implants usage prevalence ranges from 0.1% to 18.1% among 113 
countries worldwide with growing acceptance globally, including sub-Saharan Africa.[5, 
6] However, user discontinuation of etonogestrel implants is also occurring 
simultaneously, ranging from 34.9% to 47% from 32 to 36 months post-insertion.[7-9] 
Studies indicate an increase in early discontinuation rate in the Netherlands,[10] 
Australia,[11] United Kingdom (UK),[12] India,[13] Ethiopia [14] and Nigeria.[15] These 
studies reported discontinuation from 3%-10.5% at six months, 8.1% to 28% at one year, 
and from 19.3% to 49.7% at 2 years. The prominent reason for discontinuation of 
etonogestrel implants globally are adverse drug reactions (ADRs).[10, 14, 16-18]  
Reports of early implant discontinuations emerged shortly after its introduction in SA,[19, 
20] with the South African Health Review reporting 820 discontinuations between 
February and December 2014, and estimated rate of 0.1%.[19] According to estimates, 5 
000 implant discontinuations have been recorded up till April 2015, this figure being 
expected to increase.[20] KwaZulu-Natal (KZN) Province reported 3884 discontinuations 
in 2014/15, this equating to a discontinuation frequency of 1.67%.[21] Empirical data on 
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Implanon NXT® discontinuation from departmental documents in Gauteng was 
inaccessible, but an online newspaper article published in 2015 alluded to discontinuation 
figures of 250, equating to 0.5%.[22] A study from the Eastern Cape Province indicated 
that 27.2% of participants discontinued Implanon NXT® within six months of use, 67.3% 
within the first year and 94.4% after the second year.[23] A study conducted in Gauteng 
and North West Provinces reported that 60% of discontinuations occurred less than a year 
post insertion.[24] 
Studies in SA have highlighted ADRs associated with Implanon NXT® 
discontinuation.[23-25] A study conducted in the Eastern Cape revealed that over 70% of 
participants discontinued Implanon NXT® due to the experience of ADRs,[23] while 
Gauteng and North West Provinces reported 90% discontinuation due to intolerable 
ADRs across both provinces, specifically bleeding pattern changes.[24] 
A particular area of concern in SA is the knowledge gap on discontinuation of Implanon 
NXT®,[20] with a lack of data on its frequency of and associated reasons.[4] In SA, where 
the incidence of Human Immunodeficiency Virus/Acquired Immune Deficiency 
Syndrome (HIV/AIDS) is very high, the concomitant use of Implanon NXT® and 
antiretroviral therapy (ART) is particularly concerning.[19, 26, 27] This is a concern in 
provinces where the HIV/AIDS prevalence is high, such as in KZN.[28] In 2014, the 
national prescription guidelines changed, the policy recommending discontinuation of 
Implanon NXT® in those using enzyme inducing drugs, such as efavirenz, rifampicin, 
carbamazepine, phenytoin and phenobarbital.[26] This could have had a direct effect on 
the increased early discontinuations in SA given the disease profile of the country. A SA 
study identified a need for implant surveillance data in young and adolescent women and 
in patients using enzyme inducing drugs.[29] The above knowledge gaps in SA are of 
concern, given that the product has been in use for four years.  
Recent publications provided some evidence on user discontinuation of Implanon NXT® 
and the associated reasons, but samples were limited to a few health facilities and focused 
only on those in the Eastern Cape, Gauteng and North West Provinces.[23-25] Geographic 
and clinic location is reported to be associated with Implanon® discontinuation.[11, 30] 
Hence, these findings may not necessarily be applicable to users in other provinces in the 
country. SA is a diverse country with varying demographics in terms of women’s 
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proportion of ages, level of urbanisation and health conditions. The study of Implanon 
NXT® in different demographics (e.g. age and location) and among various population 
groups (e.g. HIV positive women) is essential to identify areas that require tailored 
interventions, especially in undocumented province, such as KZN. This is essential to 
developing effective strategies and guidelines to address user discontinuation. This study  
compared the experiences of Implanon NXT® users among the provinces of  SA and 
focussed on a comparative analysis between Gauteng and KZN Implanon  NXT® users. 
Methods 
A total of 3743 case reports regarding the insertion, discontinuation and report of ADRs 
of Implanon NXT® from 01 April 2015 to 11 September 2017 were attained from the 
Pharmacovigilance Centre for Public Health Programmes, National Department of 
Health, SA.  
Design 
A retrospective study design was used, and secondary data analysed using comparative 
analysis techniques. Permission to use the raw data was obtained from the 
Pharmacovigilance Centre for Public Health Programmes, National Department of 
Health, South Africa and the study was approved by the University of KwaZulu-Natal 
Biomedical Research Ethics Committee (BE266/17). The analysis of secondary 
pharmacovigilance data provided a substantial volume of cases for analysis on a wide 
scale.[31]  
Setting 
Implants are available at all service levels in the public health care system, which includes 
primary, secondary and tertiary level facilities.[19] All nine provinces in SA, and 36 out of 
the 52 districts reported Implanon NXT® case reports to the national surveillance 
program. The main focus of this study was a comparative analysis between two provinces 
in SA, which were selected as examples to represent different contexts. This choice was 
based on the following criteria: demographic and disease profile, implant usage and 
discontinuation. The majority of Gauteng’s population resides in urban areas (97%),[32] 
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while KZN province has a 47% urban population.[33] In terms of disease profile, the HIV 
prevalence was higher (16.9%) in KZN than in Gauteng (12.4%) in 2012.[28] KZN was 
also one of the higher reporters of implant users among currently married and sexually 
active unmarried women (4.1%) and Gauteng was one of the lower reporters (3.1%).[34] 
As mentioned in the background, KZN also reported higher discontinuation figures than 
Gauteng, hence these factors provide a reflection of the spectrum of users across the 
country.  
Outcomes measured 
The outcome selection was informed by the available variables, which were 
discontinuation, premature discontinuation, ADRs and reasons for discontinuation. 
Discontinuation was defined as termination of using Implanon NXT® and was identified 
by report of a discontinuation date and/or a reason for discontinuation. Premature 
discontinuation was defined as the discontinuation of Implanon NXT® before 36 months 
post-insertion, and was created for analysis by calculating the difference between the 
insertion and discontinuation dates. The following variables were analysed from the raw 
data: province, age, para, gravida, concomitant conditions, concomitant drugs, insertion 
date, discontinuation date, ADRs and reasons for discontinuation. Level of urbanisation 
and health facility type were new variables processed for analysis. The health facility 
name, sub-district and district data was used to determine level of urbanisation from the 
Statistics SA website.[35] The health facility name was used together with the referal 
system guide,[36] health sites webpage [37] and EML Clinical Guide APP [38] to determine 
health facility type. The dataset for the comparative analysis was restricted to cases only 
from Gauteng(n=717) and KZN (n=84). A comparative analytical approach was used to 
measure the following outcomes: ADRs, premature discontinuation and reasons for 
discontinuation.  
Data analysis 
The extracted data was analysed using SPSS® (version 25), and descriptive analysis 
performed for all variables. Data was analysed using the median and interquartile range 
(IQR) for skewed continuous variables, and frequencies and percentages were generated 
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for categorical variables. A 95% confidence interval (CI) was used, and confidence limits 
generated. The Chi square test was used to determine significant differences for 
categorical data in the comparative analysis. This was done using SPSS to determine the 
p-value for all provinces an online calculator to determine the p-value for Gauteng and 
KZN.[39] A p value of <0.05 was considered statistically significant, and the proportions 
of significant variables were compared between Gauteng and KZN provinces. The Mann-
Whitney U-Test was used to compare continuous variables between Gauteng and KZN.  
Results 
Provincial demographics of discontinuers 
A total of 63.6% (2 379/3 743) of Implanon NXT® cases reported discontinuation, with 
the associated provincial demographics being presented in Table 1. The overall median 
age was 27 years (IQR=10, CI:27.84-28.43), and discontinuation was more frequent in 
under 30-year-olds. All health care facility types were accessed for discontinuation and 
most cases were reported from urban areas, with the exception of Limpopo, where 41.4% 
of cases were reported from tribal/traditional areas. Of those who reported, most 
discontinuation cases were para ≥1 (range: 26.4%-70.9%) and gravida ≥1 (range: 26.6%-
63.6%). Discontinuers who reported HIV&AIDS ranged from 1.8%-27.6% (n=283) 
(p<0.001) across all provinces. Those who reported using antiretrovirals (ARVs) ranged 
from 2.2%-32.6% (n=181) (p<0.001) across the provinces. Very few cases (≤10 cases) 
reported other concomitant conditions, such as Tuberculosis, Epilepsy and Psychiatric 
conditions.  
Table 1: Demographics of discontinuation cases in relation to provinces (n=2379) 
Variable EC 
n=459 
FS 
n=524 
Gt 
n=479 
KZN 
n=72 
Lmp 
n=481 
Mp 
n=29 
NW 
n=160 
NC 
n=120 
WC 
n=55 
% % % % % % % % % 
Age 
<15 0.2 0 0 0 0 0 0 0 0.0 
15-19 9.2 7.6 5.6 5.6 15.4 10.3 6.3 5 5.5 
20-24 20.5 28.2 25.1 26.4 25.8 24.1 28.8 26.7 25.5 
25-29 27.9 21.9 22.3 29.2 21.2 34.5 26.9 23.3 43.6 
30-34 19.0 16.2 20.5 25 18.1 17.2 16.3 21.7 18.2 
35-39 13.3 10.1 14.2 5.6 6.7 10.3 13.1 5 5.5 
40-44 6.3 4.6 4.8 1.4 6.7 0 4.4 10 1.8 
45-49 1.5 1.9 1.0 0 3.3 0 0 0 0.0 
>49 0.7 0.2 0 1.4 0.4 0 0 0.8 0.0 
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Missing data 1.5 9.2 6.5 5.6 2.5 3.4 4.4 7.5 0 
Level of urbanisation 
Urban 98.0 87.2 98.1 95.8 46.6 89.7 97.5 96.7 100 
Farm 0 0 0 0 0 10.3 0 0 0 
Tribal/traditional 0.4 2.7 0 4.2 41.4 0 0 0.8 0 
Missing data 1.5 10.1 1.9 0 12.1 0 2.5 2.5 0 
Health care facility type visited 
PHC 9.2 74.0 57.2 31.9 30.6 0.0 3.8 75 61.8 
CHC 29 10.1 29.4 47.2 5.4 10.3 0.6 21.7 38.2 
District hospital 60.3 5.7 0.0 0.0 41.4 0.0 13.8 0.0 0.0 
Regional Hospital 0.0 0.0 0.0 20.8 1.5 89.7 79.4 0.0 0.0 
Provincial tertiary 0.0 0.0 0.0 0.0 9.1 0.0 0.0 0.0 0.0 
National Central  0.0 0.0 11.5 0.0 0.0 0.0 0.0 0.0 0.0 
Unlistedf 1.5 9.9 0.6 0.0 11.0 0.0 2.5 2.5 0.0 
Missing data 0 0.2 1.3 0 1.0 0 0 0.8 0 
Para 
0 2.4 10.9 4.4 2.8 6.4 3.4 10.6 3.3 0 
≥1 47.1 50 56.8 41.7 26.4 55.2 51.3 55.8 70.9 
Missing data 50.5 39.1 38.8 55.6 67.2 41.4 38.1 40.8 29.1 
Gravida 
0 2.2 9.5 3.3 0 5.8 3.4 8.8 4.2 0 
≥1 45.8 51.1 49.9 33.3 26.6 55.2 53.8 55 63.6 
Missing data 52.1 39.3 46.8 66.7 67.6 41.4 37.5 40.8 36.4 
PHC = Primary Health Care facility; CHC = Community Health Centre; EC=Eastern Cape; FS=Free 
State; Gt=Gauteng; KZN=KwaZulu-Natal; Lmp=Limpopo; Mp=Mpumalanga; NW=North West; 
NC=Northern Cape; WC=Western Cape 
Provincial representation of Implanon NXT® discontinuation 
The median duration of Implanon NXT® use was 573 days (approximately 19 months) 
(IQR: 595, CI: 605.07-642.37). Figure 1 depicts cases discontinued Implanon NXT® per 
province, with the data to calculate duration of use being available for 39.9% of cases (1 
492/3 743). 
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Figure 1. Number of discontinuation cases from initiation until 36 months or longer in 
relation to provinces (n=1492) *  
*Cases based on the difference in number of months between insertion and discontinuation date.  
(EC=Eastern Cape; FS=Free State; Gt=Gauteng; KZN=KwaZulu-Natal; Lmp=Limpopo; 
Mp=Mpumalanga; NW=North West; NC=Northern Cape; WC=Western Cape) 
 
Discontinuation was frequently reported ≥12 - <24 months post-insertion apart from KZN 
and Northern Cape. Table 2 shows the frequently reported ADRs in relation to age and 
provinces of the users, with most being under 30 years. The three frequently reported 
ADRs were dizziness (4.09%; 153/3 743),  headache (7.48%; 280/3 743) and menorrhagia 
(19.02%; 712/3 743), and were also reported as reasons for discontinuation (Table 3). A 
small proportion (0-25.8%) reported discontinuation due to expiry (discontinuation after 
three years of use) across provinces. The highest proportion of full-term users were 
reported in Limpopo, Gauteng and Free State Provinces. Major reasons for 
discontinuation in the 20-34 year-olds were desire to conceive and expiry.  
Table 2: Frequently reported adverse drug reactions among Implanon NXT® users 
distributed by age and province 
 
 Dizziness Irregular 
menstruation 
Pain in arm Menorrhagia Headache 
 n (%) n (%) n (%) n (%) n (%) 
Age (years) * 
<15 0 (0) 0 (0) 0 (0) 1 (0.1) 1 (0.4) 
15-19 19 (12.7) 18 (17.0) 12 (12.6) 80 (11.6) 35 (12.8) 
20-24 36 (24.0) 29 (27.4) 28 (29.5) 214 (31.0) 65 (23.7) 
EC FS Gt KZN Lmp Mp NW NC WC
<6 months 28 49 32 5 53 2 12 12 7
>=6-<12 months 43 42 34 1 33 6 11 11 12
>=12-<24 months 138 116 137 5 69 11 36 10 12
>=24-<36 months 37 61 49 12 67 6 34 17 0
>=36 months 89 33 53 7 66 0 8 26 0
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25-29 57 (38.0) 29 (27.4) 25 (26.3) 172 (24.9) 89 (32.5) 
30-34 24 (16.0) 17 (16.0) 15 (15.8) 131 (19.0) 54 (19.7) 
35-39 8 (5.3) 11 (10.4) 9 (9.5) 54 (7.8) 21 (7.7) 
40-44 3 (2.0) 1 (0.9) 4 (4.2) 33 (4.8) 9 (3.3) 
45-49 3 (2.0) 1 (0.9) 2 (2.1) 5 (0.7) 0 (0) 
>49 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Total (n) 150 106 95 690 274 
Province  
EC 35 (22.9) 20 (18.0) 31 (32.3) 196 (27.5) 77 (27.5) 
FS  38 (24.8) 31 (27.9) 17 (17.7) 148 (20.8) 44 (15.7) 
Gt 40 (26.1) 19 (17.1) 22 (22.9) 184 (25.8) 77 (27.5) 
KZN 4 (2.6) 0 (0) 2 (2.1) 22 (3.1) 4 (1.4) 
Lmp 16 (10.5) 17 (15.3) 4 (4.2) 56 (7.9) 24 (8.6) 
Mp 5 (3.3) 0 (0) 4 (4.2) 13 (1.8) 7 (2.5) 
NW 10 (6.5) 18 (16.2) 7 (7.3) 42 (5.9) 27 (9.6) 
NC 4 (2.6) 6 (5.4) 1 (1.0) 38 (5.3) 10 (3.6) 
WC 1 (0.7) 0 (0) 8 (8.3) 13 (1.8) 10 (3.6) 
Total (n) 153 111 96 712 280 
ADR=Adverse drug reaction; EC=Eastern Cape; FS=Free State; Gt=Gauteng; KZN=KwaZulu-Natal; 
Lmp=Limpopo; Mp=Mpumalanga; NW=North West; NC=Northern Cape; WC=Western Cape 
*Data on dizziness missing for 3 cases therefore percentage based on n=150; data on irregular 
menstruation missing for 5 cases therefore percentage bases on n=106; data on pain in arm missing for 1 
case therefore percentage based on n=95; data on menorrhagia missing for 22 cases therefore percentage 
based on n=690 and on headache missing for 6 cases therefore percentage based on n=274. 
 
 
 
Table 3: Frequently reported reasons for Implanon NXT® discontinuation among users 
distributed by age and province  
 
Variables Expiry  
 
Dizziness 
 
 
Desire to 
conceive 
 
Menorrhagia 
 
Headache 
 
n (%) n (%) n (%) n (%) n (%) 
Age (years)*  
<15 0 (0) 0 (0) 0 (0) 1 (0.1) 0 (0) 
15-19 24 (4.2) 12 (11.4) 4 (3.3) 89 (12.7) 20 (9.5) 
20-24 106 (18.4) 33 (31.4) 32 (26.2) 228 (32.4) 61 (28.9) 
25-29 135 (23.4) 39 (37.1) 41 (33.6) 170 (24.2) 69 (32.7) 
30-34 127 (22.0) 14 (13.3) 32 (26.2) 127 (18.1) 37 (17.5) 
35-39 104 (18.1) 5 (4.8) 10 (8.2) 47 (6.7) 19 (9.0) 
40-44 53 (9.2) 1 (1.0) 3 (2.5) 34 (4.8) 5 (2.4) 
45-49 22 (3.8) 1 (1.0) 0 (0) 7 (1.0) 0 (0) 
>49 5 (0.9) 0 (0) 0 (0) 0 (0) 0 (0) 
Total (n) 576 105 122 703 211 
Province   
EC 110 (17.5) 19 (17.9) 16 (12.7) 143 (19.6) 47 (21.6) 
FS  123 (19.6) 27 (25.5) 31 (24.6) 162 (22.3) 33 (15.1) 
Gt 133 (21.2) 25 (23.6) 25 (19.8) 164 (22.5) 58 (26.6) 
KZN 23 (3.7) 2 (1.9) 1 (0.8) 22 (3.0) 7 (3.2) 
Lmp 162 (25.8) 23 (21.7) 22 (17.5) 135 (18.5) 23 (10.6) 
Mp 0 (0) 2 (1.9) 1 (0.8) 12 (1.6) 7 (3.2) 
NW 27 (4.3) 3 (2.8) 18 (14.3) 45 (6.2) 24 (11.0) 
NC 49 (7.8) 4 (3.8) 7 (5.6) 32 (4.4) 7 (3.2) 
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WC 1 (0.2) 1 (0.9) 5 (4.0) 13 (1.8) 12 (5.5) 
Total (n) 628 106 126 728 218 
EC=Eastern Cape; FS=Free State; Gt=Gauteng; KZN=KwaZulu-Natal; Lmp=Limpopo; 
Mp=Mpumalanga; NW=North West; NC=Northern Cape; WC=Western Cape 
*Data on expiry missing for 52 cases therefore percentage based on n=576; data on dizziness missing for 
1 case therefore percentage bases on n=105; data on desire to conceive missing for 4 cases therefore 
percentage based on n=122; data on menorrhagia missing for 25 cases therefore percentage based on 
n=703 and on headache missing for 7 cases therefore percentage based on n=211. 
 
Comparisons of Implanon NXT® users’ experiences in KZN and Gauteng  
The median duration of use in Gauteng was 573 days (approximately 19 months) (IQR: 
572, CI: 604.07-692.10) and 918 days (approximately 30 months) (IQR: 524, CI: 635.50-
919.74) in KZN, but the difference was not statistically significant (p=0.051). The 
proportion of premature discontinuation was higher in Gauteng (82.6%, 252/305) than 
KZN (76.7%, 23/30) (p=0.01208) (Figure 1). Table 4 presents the comparison of 
commonly reported ADRs in Gauteng and KZN. The most frequently reported ADRs in 
KZN were menorrhagia, drug interaction and pregnancy, whereas menorrhagia, headache 
and dizziness were more common in Gauteng. Comparatively significantly higher 
proportions of ADRs were reported in Gauteng, except for drug interaction (Table 4). It 
is important to note that if numbers are interpreted as a proportion of the total cases in 
each province, then pregnancy (7.1%; 6/84) was higher in KZN than Gauteng (2.5%, 
18/717). The drug interactions reported with Implanon NXT® could be due to the 
concomitant ARV use. The proportion of discontinuers with reported HIV&AIDS was 
higher in KZN (26.4%, 19/72) as compared to Gauteng (11.3%, 54/479) (p=0.00044). 
Proportionately, KZN reported higher ARV use (20.9%, 14/67) than Gauteng (6.6%, 
30/456) (p=0.01242).  
 
Table 4: Comparisons of commonly reported adverse drug reactions of Implanon NXT® 
users in Gauteng and KwaZulu-Natal Provinces  
 
ADR Gt  
 
KZN 
 
Overall p-value  P-value from calculating 
2 population proportions 
n (%)  n (%)  
Menorrhagia (n=712) 184 
(25.8) 
22 (3.1) <0.001* <0.0001 
* 
Headache (n=280) 77 (27.5) 4(1.4) <0.001* <0.0001 
* 
Dizziness (n=153) 40 (26.1) 4 (2.6) 0.001* <0.0001 
* 
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Irregular menstruation (n=111) 19 (17.1) 0 (0) 0.001* <0.0001 
* 
Pain in arm (n=96) 22 (22.9) 2 (2.1) <0.001* <0.0001 
* 
Weight gain (n=91) 24 (26.4) 0 (0) 0.031* <0.0001 
* 
Amenorrhoea (n=90) 26 (28.9) 0 (0) 0.018* <0.0001 
* 
Weight loss (n=78) 10 (12.8) 1 (1.3) 0.205**  
Pregnancy (n=68) 18 (26.5) 6 (8.8) 0.001* 0.00038* 
Abdominal pain (n=53) 17 (32.1) 1 (1.9) <0.001* <0.0001 
* 
Numbness in arm (n=53) 18 (34.0) 1 (1.9) 0.007* <0.0001 
* 
Back pain (n=41) 5 (12.2) 0 (0) 0.020* 0.0007* 
Spotting (n=15) 6 (40.0) 0 (0) 0.601**  
Drug interaction (n=13) 0 (0) 8 (61.5) <0.001* <0.0001 
* 
ADR=Adverse drug reaction; Gt=Gauteng; KZN= KwaZulu-Natal 
 *p<0.05 is significant. **No significant difference between distribution of ADR across all provinces 
therefore not included included for comparative testing. 
 
Table 5 illustrates the comparison of commonly reported reasons for discontinuation, the 
main three reasons being menorrhagia, expiry and headache in both provinces. 
Comparatively, the reasons for discontinuation, such as desire to conceive, bleeding 
pattern, headache, pain in arm and abdominal pain, were significantly higher in Gauteng 
than KZN. The experiences of dizziness, weight gain, amenorrhoea and numbness in arm 
as ADRs (as shown in table 4) were significantly different between the provinces, 
however as reasons for discontinuation were not significantly different (as in table 5). 
 
 
Table 5: Comparison of commonly reported reasons for Implanon NXT® 
discontinuation in Gauteng and KwaZulu-Natal Provinces 
 
Reason for discontinuation Gt  KZN p-value 
 
P-value from calculating 2 
population proportions  n (%)  n (%)  
Menorrhagia (n=728) 164 (22.5) 22 (3.0) <0.001* <0.0001 
* 
Expiry (n=628)***  133 (21.2) 23 (3.7) <0.001* 0.00012* 
Headache (n=218) 58 (26.6) 7 (3.2) <0.001* <0.0001 
* 
Desire to conceive (n=126) 25 (19.8) 1 (0.8) <0.001* <0.0001 
* 
Dizziness (n=106) 25 (23.6) 2 (1.9) 0.058**  
Irregular menstruation 
(n=76) 
12 (15.8) 0 (0) <0.001* 8E-05* 
Pain in arm (n=72) 14 (19.4) 2 (2.8) 0.002* 0.00016* 
 121 
Weight gain (n=67) 19 (28.4) 0 (0) 0.107**  
Pregnancy (n=65) 18 (27.7) 6 (9.2) 0.001* 0.00038* 
Weight loss (n=63) 7 (11.1) 1 (1.6) 0.057**  
Risk of ADR (n=46)****  3 (6.5) 5 (10.9) <0.001* 0.13362** 
Abdominal pain (n=37) 10 (27.0) 2 (5.4) 0.009* <0.0001 
* 
Numbness in arm (n=37) 13 (35.1) 1 (2.7) 0.232**  
Amenorrhoea (n=33) 5 (15.2) 0 (0) 0.423**  
Drug interaction (n=11) 1 (9.1) 6 (54.5) <0.001* <0.0001 
* 
ADR, Adverse drug reaction; Gt=Gauteng; KZN=KwaZulu-Natal 
*p<0.05 is significant. **No significant difference between distribution of reason for discontinuation 
across all provinces therefore not included included for comparative testing. ***Discontinuation after 
three years of use. ****Risk of ADR category includes cases reporting patient on ARV but no drug 
interaction indicated. 
 
Discussion  
More case reports were obtained from Gauteng (717 cases) than KZN (84 cases). The  
probable reasons could be due to the fact that discontinuation, associated reasons and 
ADRs were shown to be under-reported.[22] Another possible reason suggested by Mullick 
et al.[4] was that women of higher socioeconomic status were using implants, with 
Gauteng being the wealthier province.  
It appears that younger women (<30 years) were more frequent discontinuers of Implanon 
NXT® in all provinces in the present study. These findings corroborated with other studies 
on Implanon NXT® [23]  and Implanon®. [18, 40] However, a study conducted in Gauteng 
and North West Provinces reported mean ages of discontinuers as 30 and 31 years 
respectively, and only 15% ranged from 18-25 years.[24] Young women i.e. under 30-
year-old, mostly reported ADRs in the present study, which were common reasons for 
discontinuation in the same age group. Although the present study implies poor 
tolerability of ADR in young women, global studies investigating implants in the youth 
reported a higher tolerability.[41-43] A reason for discontinuation in the present study in 
20-34 year olds was the desire to conceive, with women in this age group being of 
marriageable and childbearing age. This reason is comparable to López del Cerro et al. in 
contraceptive implant users.[42] Overall, it appears that young women are frequent 
discontinuers of Implanon NXT®, which may be a significant finding, as the SA target 
population for implants are the youth.[44] 
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A clear majority of discontinuation case reports were obtained from urban health facilities 
in the present study, a possible reason being women’s perception of a higher quality of 
care provided in these facilities. Rural health care users indicated that their experiences 
in general are affected by staff shortages, poor staff attitudes, long travelling times, lack 
of medication, and a lack of monitoring and evaluation.[45] A study from Texas suggested 
that practitioners, especially those practicing in rural areas, are inadequately trained in 
long acting reversible contraceptives.[46] Another possible reason for increased reports is 
migration from rural areas to urban areas in SA,[47] this being relevant as Mlambo[47] 
reported that over 70% of SA population is estimated to be residing in urban areas by 
2030. Over 40% of discontinuation case reports were obtained from tribal/traditional 
health facilities in Limpopo Province, which has the highest rural population in the 
country (88-90%).[48] 
Primary and secondary level facilities i.e. primary health care facilities, community health 
centers and district hospitals were mainly accessed for discontinuation services in the 
present study. Higher level facilities were also used in Gauteng, KZN, Limpopo, 
Mpumalanga and North West Province, as all service levels are required to provide 
implant services.[19] A possible reason for reports from higher level facilities could be due 
to referrals from practitioners for discontinuation services as expressed in a study 
conducted in Gauteng, North West and Western Cape Provinces.[24, 49] 
The proportion of discontinuation of case reports across the provinces varied, ranging 
from 1.2% to 22.0% in the present study, this trend also being evident in Implanon® 
studies from Ethiopia (16% to 80%)[14, 18, 50, 51] and Nigeria (4.48%-21.36%).[15, 52-54] The 
proportion of premature discontinuation was only slightly higher in Gauteng (82.6%, 
252/305) than KZN (76.7%, 23/30), while the median duration of use was approximately 
19 months and 30 months in Gauteng and KZN respectively. These findings deviate from  
recent studies in Eastern Cape, [23] Gauteng and North West[24] which found that the 
median duration of etonogestrel implant use were ten and eight months respectively. One 
thought advanced is that health practitioners advised women to persevere through the 
symptoms and wait for the body to adjust to the hormones in the implant.[55, 56] 
The frequently reported ADRs in the present study i.e. menorrhagia, headache, dizziness, 
pain in arm and irregular menstruation, were also reported internationally[16, 57-59] and in 
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studies from Eastern Cape, Gauteng and North West Provinces.[23, 24] In a study from 
Gauteng and North West Provinces, 10.99% of users reported menorrhagia and 14.29% 
headaches, as ADRs of Implanon NXT®, however the present study reported higher 
proportion in Gauteng (25.8%).[24] Generally, it appears that while the same ADRs are 
reported throughout the country, the proportions differ across the provinces. In the present 
study, there were a significantly higher proportions of most ADRs in Gauteng as 
compared to  KZN.  It appears that the women from Gauteng are less tolerable of ADRs 
associated with Implanon NXT®.  
In the present study, ADRs were common reasons for Implanon NXT® discontinuation, 
which is in keeping with etonorgestrel implants reports.[10, 18, 23] The reasons for 
discontinuation in Gauteng i.e. menorrhagia, expiry, desire to conceive, dizziness and 
headache, were the same as for the entire country. Gauteng reported significantly higher 
proportions of discontinuation due to ADRs than KZN in the present study. In a study 
from Gauteng and North West Provinces, a majority of discontinuers (90%) stated that 
intolerable ADRs were the reason for user discontinuation,[24] with prolonged bleeding, 
menorrhagia, headache, weight gain, weight loss and pregnancy being the main 
reasons.[24] In that study, the ADRs, specifically bleeding, negatively affected patients’ 
sex life and led to implant discontinuation in some cases.[24] Global implant qualitative 
studies have found that unpredictable bleeding patterns, fear of embarrassment from 
unpredictable bleeding, difficulty managing irregular menstruation and increased 
financial cost could influence discontinuation.[56, 60-62] The health practitioner may also 
play a role in encouraging discontinuation as inadequate counselling and management of 
ADRs were notable challenges.[25] The quality of service may be poor due to insufficient 
knowledge, poor skills and lack of understanding of the method, as advanced by Adeagbo 
et al.[25] Treatment for bleeding associated with Implanon NXT® only provided short-term 
relief, and some women who experienced ADRs opted for discontinuation due to 
inefficient ADR treatment.[24, 25] 
In the present study, two main reasons for discontinuation in KZN were pregnancy and 
drug interaction, of which drug interaction was significantly higher in KZN than Gauteng 
possibly due to higher number of HIV positive patients. Discontinuation due to enzyme 
inducing drugs is shown in a study from the Eastern Cape, where 12.8% discontinued 
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Implanon NXT® due to concomitant medication.[23] A study from Gauteng and North 
West Provinces also reported that women were concerned about potential drug interaction 
with ARVs, which led to discontinuation.[24] Pregnancy in etonogestrel implant users 
could be due to concomitant ARV use,[59, 63, 64] as efavirenz causes increased metabolism 
of the hormone, leading to its lower levels and reduced efficacy.[1, 65] 
It appears that not all ADRs i.e. dizziness, numbness in arm, weight gain and 
amenorrhoea, warranted discontinuation in the present study. Possible reason for this 
were advanced in a study from Gauteng and North West Provinces,[24] which found that 
some ADRs disappeared over time, and that they changed over time and did not affect 
the women’s health negatively.[24] 
The second highest reason for discontinuation was expiry in the present study, although 
this only accounted for a quarter of total reasons. A smaller percentage (1.1%) reported 
discontinuation due to expiry in a study from the Eastern Cape.[23] In contrast, an 
Ethiopian study reported 35% of late Implanon® discontinuers,[18] while another noted 
that 53.5% of participants retained theirs for >35 months.[14] This may imply that SA has 
a lower frequency of full-term Implanon NXT® users’, which further provides evidence 
that early discontinuation is a problem in SA. Overall, findings from this study are in 
keeping with global patterns, which reiterates the point that the experiences with 
Implanon NXT® in SA are not unusual and mirror those globally.[29] 
This study provides empirical data on the discontinuation of Implanon NXT®, a gap 
having been identified in previous SA publications.[20, 29] To the best of our knowledge, a 
comparative analysis on Implanon NXT® discontinuation has not been conducted 
previously in the country. While the scale of the national data is a strength of the study, 
it has methodological limitations. Secondary data was used, with the primary data being 
collected by external personnel, which could have resulted in variable quality and 
completeness of the data, and the data available for KZN was less than for Gauteng. 
Despite this, cases from a variety of clinics from several districts in KZN were reported.  
The evidence from the present study can be used by policymakers in the provinces to 
support their Implanon NXT® prescription guidelines, counselling protocols and training 
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materials in public health facilities. The findings of this study may also be informative 
for health practitioners, as they are the first point of contact for patients. 
Conclusion 
Young women most frequently chose to discontinue Implanon NXT®, as ADRs and the 
desire to conceive were considered responsible across the provinces. The women from 
Gauteng discontinued more frequently than the women from KZN province. The  
common reasons for discontinuation were pregnancy and drug interaction in KZN. 
Interestingly, users’ experiences, particularly reasons for discontinuation are different 
between the provinces, hence tailored interventions may be required. It is important to 
discuss the risk of drug interaction during counseling with users of Implanon NXT®. 
Research on discontinuation using qualitative methods would be beneficial to gain an in-
depth understanding of the reasons, particularly in young women.  
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CHAPTER 5: SYNTHESIS 
5.1 Introduction 
While there are international studies on the use and discontinuation of etonogestrel implants, it 
must be acknowledged that in the SA context, there is a paucity of empirical data and literature 
on Implanon NXT® user discontinuation (Mullick, Chersich, Pillay, & Rees, 2017). In order to 
address this existent gap, this study presented and evaluated South African national 
pharmacovigilance data of Implanon NXT®. This chapter addresses the extent to which the aim 
was achieved by reviewing the main findings of each objective, and logically demonstrates the 
associated conclusions reached for each. This is followed by the recommendations for 
policymakers and practitioners, the study limitations, and an indication of the significance of the 
findings.  
 
5.2 Aim and objectives and conclusions reached  
The aim of the study was to evaluate the users’ experiences of Implanon NXT® in the public 
health sector in SA. The study had five objectives and two manuscripts have been written to 
address the objectives. The first manuscript addressed objectives one to four and reported a 
general overview of experiences using the national data for SA. The second manuscript provided 
an overview of ADRs and discontinuation in all other provinces, which was done to 
comprehensively understand the experiences of Implanon NXT® use in SA. The second 
manuscript also addressed objective five and focused on comparing the experiences between two 
provinces in SA to highlight regional differences.The study objectives, and the conclusions 
reached for each objective, based on the main study findings are outlined respectively: 
 
1. To identify the demographic profile of Implanon NXT® users  
 
Women of reproductive age and above used Implanon NXT®, and 20-24-year olds were the most 
frequent (25.70%; 962/3743). Almost half the women had a parity ≥1 (48.89%; 1830/3743) and 
gravida ≥ 1 (47.58%; 1781/3743). Most case reports were from urban area facilities (84.64%; 
3168/3743), and from all levels of health facilities. PHC (47.93%; 1794/3743), CHC (16.03%; 
600/3743) and district hospitals (20.92%; 783/3743) being mainly accessed. 
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2. To identify ADRs of Implanon NXT® reported among users 
  
The ADRs of Implanon NXT® users in SA were identified, with 36.57% (1369/3743) cases 
reported, being similar to international and local trends. The main ADRs reported in SA were 
menorrhagia (52.01%; 712/1369), headache (20.45%; 280/1369), dizziness (11.18%; 153/1369) 
and irregular menstruation (8.11%; 111/1369). Menorrhagia was the main reported ADR and may 
be a distinctive menstrual pattern experienced by SA users. 9.06% (124/1369) of reported ADRs 
were not on the product and prescribing leaflets e.g. numbness in arm (3.87%; 53/1369), epistaxis 
(0.73%; 10/1369), eye related disorders (0.29; 4/1369), numbness of lower limbs (0.29; 4/1369). 
 
3. To determine frequency of discontinuation of Implanon NXT® and reasons for 
discontinuation 
 
Younger women (<30 years) were more frequent discontinuers of Implanon NXT® (58.51%, 
1392/2379), most case reports being from urban health facilities (85.04%; 2023/2379) except in 
Limpopo Province (46.57%; 224/481). A high frequency of discontinuation (63.56%; 
2379/3743), particularly prematurely (81.1%; 1210/1492) was revealed. This indicated that the 
users in SA were not continuing Implanon NXT® to full term. There were various reasons for 
discontinuation, with ADRs being the main one (83.99%; 1784/2124) and other to a lesser degree 
(37.95%; 806/2124). Menorrhagia was the main reason for discontinuation among public health 
facility users (34.27%; 728/2124), with expiry being second (29.57%; 628/2124). Other common 
reasons for discontinuation included: desire to conceive (5.93%; 126/2124), headache (10.26%; 
218/2124), dizziness (4.99%; 106/2124) and irregular menstruation (3.58%; 76/2124). 
4. To determine frequency of failure of Implanon NXT® 
 
The frequency of pregnancy, interpreted as failure, was reported (4.97%; 68/1369). The finding 
was significant considering the reason behind unwanted pregnancies, with efavirenz-based 
therapy suspected to be associated with pregnancy in Implanon NXT® use (p<0.001). 
 
5. To compare experiences of Implanon NXT® between users in KZN and Gauteng Province 
 
More case reports were available from Gauteng (n=717) than KZN (n=84) and their differing 
profiles possibly being attributed to KZN’s high HIV prevalence. The top reported ADRs in KZN 
were menorrhagia (3.1%, 22/712), drug interaction (61.5%, 8/13) (possibly with ARVs) and 
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pregnancy (8.8%, 6/68), while Gauteng reported menorrhagia (25.8%, 184/712), headache 
(27.5%, 77/280) and dizziness (26.1%, 40/153). Premature discontinuation was higher in Gauteng 
(82.6%, 252/305) than KZN (76.7%, 23/30) (p=0.01208), the reasons for discontinuation in 
Gauteng being similar to the overall SA data, such as desire to conceive (19.8%, 25/126) and 
dizziness (23.6%, 25/106), whereas, in KZN it was due to pregnancy (9.2%, 6/65) and drug 
interaction (54.5%, 6/11) (possibly with ARVs). Implanon NXT® users’ experiences differed 
between provinces, therefore generalizations cannot be made for all users in SA. 
 
This research expands the reports on discontinuation of Implanon NXT® and capitalized on the 
use of secondary data to evaluate experiences of Implanon NXT® in the SA population. The 
findings of this study have contributed to knowledge of Implanon NXT® in SA which includes 
identification of ADRs, extent and magnitude of discontinuation, reasons for discontinuation 
and contributed evidence towards associating pregnancy and efavirenz based therapy. This 
study therefore highlighted the experiences of Implanon NXT users in SA hence the aim and 
objectives were achieved.  
 
5.3 Significance of the findings 
 
The evidence from the present study can be of significance in the following areas:  
• This study identified prevalent ADRs of Implanon NXT® and population groups prone to 
experiencing specific ADRs. The findings may be used to impact, and supplement policies 
such as ADR management, counselling guidelines, prescription of Implanon NXT® in those 
on enzyme-inducing drugs and Implanon NXT® monitoring systems. Enhanced guidelines 
and application of these guidelines may ultimately benefit users such as improved 
communication between health practitioners and patients and the provision of evidence-based 
knowledge during consultations. This could lead to better health outcomes and improved 
adherence to Implanon NXT®. 
• The findings from the study can assist in interventions such as educating users on ADRs of 
Implanon NXT® and providing awareness on failure of the product.  
• The evidence has highlighted that tailored interventions and guidelines may be necessary as 
problems pertaining to specific provinces in SA were identified. Individual needs should be 
addressed to assist women of different demographics such as in younger women where 
discontinuation is frequent and in KZN where drug interaction and pregnancy are common 
reasons for discontinuation.  
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• This research has sparked interest on conducting further monitoring and evaluation studies 
and interventional studies that will address and may reduce ADRs, discontinuation and failure 
with Implanon NXT®.  
 
5.4 Study Limitations 
The following limitations are acknowledged: 
• The study was limited by its study design. The use of a secondary data set meant that the 
principal investigator did not have control over the primary data collection.  
• The quality and completeness of the data varied, and missing data and incomplete case reports 
could have compromised the analysis of key variables. These inconsistencies may affect the 
reliability of the data. 
• Only public health facilities were included, as data for private health facilities have not been 
identified.  
• Small samples were used in some analyses, which provided some measure of association but 
with limited scope. 
 
5.5 Recommendations  
The following recommendations for South African Implanon NXT® users are detailed below. The 
recommendations are made collectively for all the objectives, with some addressing specific 
objectives. Although counselling and health practitioners were excluded from the study, the 
findings that emanated are influenced by these aspects. Hence, counselling and health 
practitioners are included as part of the recommendations.  
 
5.5.1 Counselling  
Routine counselling is recommended to assist in reducing premature discontinuation. The 
following suggestions are proposed to be included in counselling of Implanon NXT® users: 
• It is important for practitioners to thoroughly screen women at the pre-insertion 
counselling session to ensure that Implanon NXT® is an appropriate option for that 
particular woman. A comprehensive patient history and discussion of pregnancy 
planning is also recommended. Additional counselling on the increased risk of pregnancy 
needs to be provided to women using concomitant enzyme-inducing drugs. During the 
pre-insertion session, it is also essential to rule out pregnancy, as only 19.1% (714/3743) 
of case reports stated that a pregnancy test was performed.  
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• The practitioner is expected to discuss common ADRs during the method-specific 
counselling session. This discussion should also encourage women to report ADRs to 
avoid long-term effects and include the procedure for women to follow if they experience 
an ADR. Women on enzyme-inducing drugs who choose to use Implanon NXT® must 
be provided with counselling on using additional non-hormonal contraception to prevent 
pregnancy. It is also important to emphasize that Implanon NXT® is ideally used for 
three years and is not to be considered a short-term method. 
 
• A regular follow-up schedule should be enforced, as the data demonstrated that the onset 
of ADRs was experienced in the first year of utilization, with discontinuation being 
common in the second year. These essential follow-up sessions should include: 
discussion on satisfaction, any change in needs, report of any ADRs and their treatment, 
and assessing the insertion site for any abnormalities. The development of individualized 
counselling tools that address provinces’ individual uniqueness, and that utilizes 
available resources is recommended.  
 
Group counselling is a suitable option in the SA environment where communities and peers play 
a role in decision-making. Education and counselling should start at the ground level such as 
schools, community centers, and local clinics. Additionally, it is a time-saving way to create 
awareness, considering the heavy burden of patients on the public health care system. Moreover, 
group counselling as a modality of intervention, specifically in SA, maximizes on the number of 
women that can receive some form of supportive intervention at one time. Being cognizant of the 
realities of the South African public health environment, another option is the development of 
concise pre-insertion and method-specific counselling protocols. Alternatively, novel counselling 
tools e.g. using mobile phone apps or Digital Versatile Discs (DVDs), may be designed to ensure 
that women receive appropriate information. The use of alternative counselling styles such as 
cautious, comprehensive counselling and ‘just try it’ methods is also suggested. 
 
5.5.2 Health care practitioners 
Nurses in particular are usually the primary provider of contraceptives in the public health sector 
and counselling is a large component of Implanon NXT® provision and discontinuation, making 
comprehensive training essential. It is necessary to keep abreast with new developments, such as 
updated prescription guidelines and research regarding enzyme inducing drugs and implants. 
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Moreover, contextually within the public health care sector, the use of a multi-disciplinary 
approach to support Implanon NXT® users is recommended. Specifically, communication 
between practitioners within the same facility should be encouraged to effectively manage 
women. Pharmacy and Therapeutics Committee meetings may be an ideal point of contact of 
multiple disciplines to conduct evaluations of ADRs and Implanon NXT® discontinuations. A 
one-stop service delivery approach is also recommended to promote comprehensive care in other 
settings, such as HIV and TB clinics. In addition, training on the treatment of ADRs, and recording 
and reporting their occurrence should be on-going, which will be explained in the following 
sections. 
 
5.5.3 Adverse drug reaction management 
ADR treatment algorithms may be useful to reduce discontinuation due to ADRs. There is a SA 
guideline for short-term treatment for breakthrough bleeding associated with implants but not for 
long-term treatment. However, there is a need for a long-term treatment option that is safe and 
effective. Another area that necessitates intervention is treating non-menstrual ADRs, the 
percentage of total non- menstrual ADRs being greater than the total menstrual ones, as evident 
in the result of manuscript 1. An algorithm for treating options or referral protocols of common 
non-menstrual ADR, such as headache, pain in arm and dizziness is therefore recommended. 
 
5.5.4 Recording and reporting protocols 
Underreporting and missing data can result in skewed results, which may then not be truly 
representative of the realities that exist in public health facilities. These have an impact in under 
estimating the consequences, as the real extent and magnitude of the problem is unknown. An 
example of this is the recording of laboratory results, which was only completed for ≤2.6% of 
cases. This makes interpretation of the data difficult and limits its generalizability. Laboratory 
results were excluded from the analysis in the present study. Another example is that true 
contraceptive method failure could not be established in this study due to insufficient information 
provided by cases reporting pregnancies. Additional information, such as date of conception in 
relation to insertion date, timing of insertion and etonogestrel concentration levels, must be 
included to establish the reason for failure. The transfer of information has several steps, with 
multiple personnel being involved. It is recommended that health practitioners complete details 
fully on the surveillance form, and complete one for every Implanon NXT® user. In addition, it is 
recommended that data capturers correctly and completely transfer information from the source 
document to the database. The reason for incomplete data is unknown and may be worth 
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investigating, a possible explanation being the length of the form or the number of variables to be 
recorded. An evaluation may need to be conducted with health practitioners, and, should there be 
potential challenges, the form could be re-designed, or a revised collection tool considered.  
 
5.5.5 Monitoring and evaluations 
The NPC is conducting surveillance of sub-dermal implants, with robust monitoring systems 
being recommended to support areas where discontinuation is high. A multipronged approach to 
pharmacovigilance and ADR reporting is recommended. Various techniques for robust 
monitoring systems such as cohort studies and registries are encouraged. Ongoing monitoring and 
evaluation of Implanon NXT® is recommended, as this will comprehensively and continuously 
inform and strengthen clinical practice, which ultimately benefits Implanon NXT® users.  
 
5.5.6 Recommendations for future research  
A clinical trial investigating appropriate treatment to manage long-term bleeding with Implanon 
NXT® is also recommended, having long-term ramifications, as the treatment could be applied to 
other progestogen contraceptives where bleeding is problematic. An investigational study on 
ARV based therapy in Implanon NXT® users particularly in SA may be necessary to confirm an 
association between the drugs. The present study used a small sample to associate efavirenz and 
pregnancy, which limits the significance of the result. It will be beneficial to investigate the 
severity of ADRs and their relationship to discontinuation in future. The users’ role in 
discontinuation of Implanon NXT® must not be undermined therefore a qualitive study 
investigating accountability for discontinuation and decision-making needs to be conducted. The 
findings from qualitative research, in conjunction with empirical data, could guide future 
interventional research. The experiences were compared between KZN and Gauteng Province, 
and as the results cannot be generalized to other provinces in SA, a comparative analysis among 
other provinces, or groups of provinces (e.g. inland vs costal), may be valuable to highlight 
individual challenges and specific areas requiring intervention.  
 
5.6 Final Statement 
The study is a catalyst for future studies and motivates for expanding research within the public 
and private sector to deepen understanding of discontinuation of Implanon NXT®. Greater 
vigilance in the collection, monitoring and evaluation of data is suggested to continuously guide 
and strengthen Implanon NXT® service delivery and ultimately impact user adherence.  
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ANNEXURE 9: STANDARD OPERATING PROCEDURE FOR SUBDERMAL 
CONTRACEPTIVE IMPLANTS DATA COLLECTION (REPUBLIC OF 
SOUTH AFRICA, NATIONAL HEALTH DEPARTMENT, N.D)1 
 
 
 
                                                          
1 Republic of South Africa, National Health Department. n.d. Subdermal contraceptive implants 
data collection. Standard operating procedure. Pretoria: National Pharmacovigilance Centre.  
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